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1. Cell division  
Cell cycle or cell division includes a series of events that occur in a 
eukaryotic cell, involving its growth, division and replication and ending in the 
production of two identical daughter cells. Cell division is a tightly regulated 
process and is mainly characterized by DNA replication, chromosome 
condensation and segregation into two separate cells containing the same 
genetic information. This process was originally divided into two stages: i) mitosis 
or M phase and ii) interphase.  
Mitosis, when the nuclear division occurs, is sub-divided in well-defined 
stages based on the reversible physical state of the chromosomes and spindle: 
i) prophase; ii) prometaphase; iii) metaphase; iv) anaphase, and v) telophase. 
The first stage is prophase, when the chromatin condensation and microtubules 
polymerization from the duplicated centrosomes begins.  Prometaphase starts 
with the abrupt fragmentation of the nuclear envelope, exposing the 
chromosomes to the centrosome-radiating microtubules and ends with 
chromosomes correctly bi-orientated. In metaphase, chromosomes reach their 
most compacted state, lining-up in the equatorial plate of the mitotic spindle. A 
complex checkpoint mechanism – spindle assembly checkpoint (SAC) – 
determines whether the spindle is properly assembled and cells ready to divide. 
In  anaphase, the sister chromatids separate, and finally in telophase, the 
chromosomes reach the poles, the nuclear membrane is formed around each set 
of chromosomes and the chromosomal chromatin begin to decondense into 
interphase-like conformation. Cytokinesis, or the division of the cytoplasm 
between the two daughter cells, is the final physical division of the cell that follows 
telophase and is therefore sometimes considered the last phase of mitosis. An 
important feature that characterizes mitosis is the high level of chromatin 
condensation, in comparison to interphase, in which the chromatin is less 
condensed, to facilitate easy access of the transcriptional machinery to the 
chromatin.  
Chromatin condensation depends in part on the phosphorylation of the 
nucleosomal elements, histones, by protein kinases. A nucleosome is the 
fundamental subunit of chromatin and it is composed by around 147 DNA base 




histones H2A, H2B, H3, and H4. During mitosis, the highly condensed 
chromosomes become attached to the mitotic spindle through microtubules of 
tubulin radiating from the centrosomes. Microtubules attach to the chromosomes 
at their kinetochores and are able to pull the sister chromatids to opposite poles 
of the spindle. Here, SAC plays a key role determining whether the spindle is 
properly assembled and the cells ready to divide (Figure 1).  
In turn, interphase occupies a much larger fraction of the cell cycle and 
includes three different phases: i) G1, ii) S phase and iii) G2. DNA replication 
occurs in the S phase. At the end of this phase there is an important checkpoint 
– DNA synthesis checkpoint - controlling whether the DNA has been successfully 
replicated and allowing the entrance into mitosis. The S phase is preceded by a 
gap called G1 during which cells prepare for DNA synthesis and is followed by a 
second gap called G2 during which the cell prepares for mitosis. At the end of G1 
there is another important checkpoint – cell growth checkpoint – that regulates 
whether the cell is big enough and all the proteins necessary for replication were 
produced. At this point, cells can enter into the S phase or go to a resting state 
called G0 that accounts for the major part of the non-growing, non-proliferating 
ones (Figure 1) (Mitchison and Salmon, 2001; Paweletz, 2001). 
The transition between the different phases of the cell cycle occurs in an 
orderly fashion and is regulated by numerous and different cellular proteins. 
Consequently, errors and malfunctions in this well-regulated process can lead to 
the accumulation of mutations, improper cell proliferation and culminates in the 
initiation and development of cancer. The most well-known key regulatory 
proteins are the serine (Ser/S) – threonine (Thr/T) cyclin-dependent kinases 
(CDKs) that are activated at specific stages of the cell cycle. These protein 
kinases remain stable during the cell cycle, but in turn the levels of their activating 
proteins, the cyclins, vary in order to specifically and sequentially activate a 
particular CDK. Briefly, to enter in G1 the three cyclin D types (D1, D2 and D3) 
complexes to CDK4 and CDK6, and to regulate the progression from G1 to S 
phase, cyclin E associates with CDK2. Besides, during S phase, cyclin A, binds 
to CDK2, and in late G2 and early mitosis the same cyclin complexes with CDK1 
to promoter the entry into the M phase. Finally, the progression through mitosis 
is regulated by cyclin B in complex with CDK1 (Harashima et al., 2013; 




the control of cell cycle progression. In fact, several other proteins kinases (i.e. 
Auroras Kinases) and many transcriptional factors (i.e. p53) have been 
associated with the regulation of cell division by distinct mechanisms (Bolanos-
Garcia, 2005; Eastman, 2004; Lazo and Santos, 2011; Malumbres and Barbacid, 
2007). In this work, we explore the roles of Vaccinia-related kinase 1 (VRK1) in 
association with Aurora kinase B (AurKB) and with the reprogramming 
transcriptional factor SRY (Sex Determining Region Y)-Box 2 (Sox2) on the 
regulation of cell proliferation.  
 
Figure 1 – The cell cycle of animal cells was originally divided into mitosis and 
interphase. In pioneering studies Flemming observed that the nuclear material, which he 
named chromatin, appeared distinctly in the cells. Nowadays it is known that he had 
successfully distinguished cells in interphase from cells in mitosis.    
2. The protein kinases 
 The protein kinases are enzymes that catalyse the covalent ligation of a 
phosphate group to Ser, Thr or tyrosine (Tyr/Y) residues on specific cellular 
proteins. This process is called phosphorylation and it is a reversible 
posttranslational modification that mediates signal transduction in eukaryotic cells 
















stability and activity (Manning et al., 2002b; Pawson and Scott, 2005; Ubersax 
and Ferrell, 2007). Consequently, protein phosphorylation is a mechanism 
directly involved in the coordination of several biological processes such as 
angiogenesis, apoptosis, cell differentiation, DNA damage response (DDR), 
cellular growth, metabolism and migration (Shchemelinin et al., 2006). Any 
deregulation on these kinase proteins can lead to the development of a variety of 
diseases namely to cancer (Shchemelinin et al., 2006).  
In general, protein kinases show a great homology in a specific sequence 
of 250-300 amino acids, which forms the kinase domain or catalytic domain 
(Hanks and Hunter, 1995; Higgins, 2001). This is an important feature that 
preserves the main function of these proteins in cellular pathways, which is the 
ability to transfer a phosphate group from ATP to neutral hydroxyl groups on the 
Ser, Thr and tyrosine (Tyr/Y) residues (Taylor and Kornev, 2011). The 
phosphorylation is a reversible process that can be accurately modulated by 
phosphatases, which eliminate the phosphate group from the hydroxyl groups on 
phosphorylated amino acids (Hunter, 1995). However, despite the overall kinase 
domain homology, differences in the activating sequences and in the amino and 
carboxyl terminal regions are critical to regulate protein kinases activity, 
negatively or positively, in response to cellular signals (Nolen et al., 2004).  
The 518 genes, coding the respective proteins kinases, represent 2% of 
the human genome (Manning et al., 2002a; Manning et al., 2002b). Protein 
kinases are responsible for the phosphorylation of around 30% of the whole 
cellular proteins and, based in the specificity of the substrate, is sub-divided into 
three main sub-families:  
a) Ser-Thr kinases 
b) Tyr kinases 
c) Dual kinases (Ser-Thr-Tyr kinases). 
The phylogenetic of the human kinome was initially described in 2002 by Manning 
and colleagues, using public and proprietary genomic databases, complementary 
DNA (cDNA) and short sub-sequence of a cDNA sequence called Expressed 
Sequences Tags (EST) (Manning et al., 2002a; Manning et al., 2002b). This new 
classification follows another from 1995 by Hanks and Hunter, adding numerous 
new kinases to the kinase taxonomy (Hanks and Hunter, 1995). The kinases 




in turn subdivided in families. In 2002, four new groups were added by Manning, 
among them the casein kinase I (CK1) group of kinases, which included the family 
of Ser-Thr kinases VRK (Vaccinia-Related Kinase) (Figure 2) (Manning et al., 
2002b). 
 
Figure 2 - The human kinome following the classification of 2002, from Manning and 
colleagues. In evidence the CK1 group, which contains the VRK family and the AGC 
group that includes Aurora family. Adapted from (Manning et al., 2002b). 
3. The VRK family 
 The human VRK family belongs to the CK1 group of kinases and consists 
of three members: VRK1, VRK2 and VRK3. VRK1 and VRK2 have kinase activity, 
whereas VRK3 is a pseudo-kinase (without kinase activity), due to substitutions 
in key amino acids, present in its kinase domain, which disrupt invariant motifs 
essential to achieve a full catalytic activity (Nichols and Traktman, 2004). On the 
other hand, VRK2, due to alternative splicing of its mRNA, generates isoforms 
VRK2A and VRK2B, which mainly differ in their carboxyl-terminal (Blanco et al., 
2006). 
 In 1997, Nezu and colleagues, using a cDNA library enriched in foetal 




overexpressed in highly proliferating tissues, identified both VRK1 and VRK2 
(Nezu et al., 1997). Due to the high homology between the B1R kinase and the 
Vaccinia virus, important to viral replication, this group of kinases received the 
name of Vaccinia-related kinase (Nichols and Traktman, 2004). Curiously, since 
B1R and VRK1 share 39% of homology between them, VRK1 expression was 
shown to partial rescue the DNA replication of a Vaccinia virus-B1R negative 
mutant sensible to temperature (Boyle and Traktman, 2004). Later in 2003, using 
cDNA library databases, the third kinase from the VRK family, the pseudo-kinase 
VRK3, was identified (Vega et al., 2003). 
 From an evolutionary point of view, it has been suggested that a unique 
ancestral gene was duplicated twice in vertebrates, creating the three genes of 
the VRK family, in contrast to invertebrates presenting a single original gene 
(Klerkx et al., 2009). In yeast, orthologous genes had not been identified, being 
the only ones described isoforms of CK1, such as the Hrr25 gene of 
Saccharomyces cerevisiae or the hhp1 gene of Schizosaccharomyces pombe 
(Dhillon and Hoekstra, 1994). Interestingly, in Caenorhabditis elegans there is 
one orthologous gene to VRK1 codified by the VRK-1 gene. This VRK1 
orthologous gene is important to the proliferation of the germinal cells, through 
the direct regulation of CEP-1 (p53 orthologous gene) activity. The knockdown of 
VRK-1, using specific RNAi, is embryonic lethal due to defects in cell division 
(Kamath et al., 2003; Waters et al., 2010). Also, in nematodes, the importance of 
the VRK1 orthologous gene has been described regarding the phosphorylation 
of the barrier to autointegration factor (BAF), which regulates its localization and 
participation in the formation of the nuclear envelope (Gorjanacz et al., 2007). 
Moreover, in Drosophila melanogaster there is one orthologous gene of the VRK1 
protein, the nucleosomal histone kinase-1 or NHK1. NHK1 is responsible for the 
phosphorylation of histone H2A, in the Thr119 residue, during mitosis and could 
partially regulate the localization of the AurKB in the inner centromere chromatin 
and therefore its activity during the early phases of cell division (Aihara et al., 
2004; Brittle et al., 2007; van der Waal et al., 2012). NHK1 also phosphorylates 
BAF, regulating the affinity of this protein to the chromatin and to the nuclear 
membrane proteins, during the formation of the caryosome (Lancaster et al., 
2007). In Mus musculus, as in humans, there are three orthologous genes, being 




with high levels of auto-phosphorylation in Ser residues. All three kinases are 
expressed during embryonic development, reaching higher levels in highly 
proliferating organs such as liver, leucocytes, spleen and foetal thymus (Zelko et 
al., 1998). In adult rats, the levels of expression of each kinase depend on the 
cellular tissue (Vega et al., 2003). In general, we could assert that VRK proteins 
are present in all Holozoa. 
3.1 The structure of VRK protein kinases 
 All VRK family members present high homology in the amino terminal 
region, in contrast to the carboxyl terminal region where there are several 
differences between them (Figure 3). The VRK1 gene is located in the 
chromosomal region 14q32 and it codes a 396 amino acids protein. This protein 
presents in the N-terminus the catalytic domain (residues 35-275), containing not 
only the active Ser-Thr kinase domain (residues 175-185), but also the ATP 
binding domain (residues 43-71). In turn, the C-terminus of VRK1 contains a 
nuclear localization signal (NLS) (residues 356-360), a nuclear export signal 
(NES), and a basic-acid-basic domain (BAB) (residues 356-396), that is 
maintained between the orthologous genes (Aihara et al., 2004). Since the VRK1 
carboxyl terminal region is only characteristic of this VRK member, it is assumed 
that this region is the responsible for the regulation of this kinase protein (Lopez-
Borges and Lazo, 2000).   
 Regarding VRK2, this kinase protein has a 44% homology with VRK1, 
which can increase up to 53%, when comparing only the catalytic domain of both 
kinases. VRK2 gene is located in the chromosomal region 2p16 and codes two 
isoforms due to mechanisms of alternative splicing: VRK2A and VRK2B. VRK2A 
consists of 508 amino acids and VRK2B consists of 397 amino acids. Overall, 
both VRK2A and VRK2B show a similar sequence until the amino acid 394, 
where the new exon, produced by alternative splicing, introduces a premature 
stop codon, which swaps the amino acids between 395 and 508, by three VEA 
(valine-glutamate-alanine) residues (Blanco et al., 2006). The N-terminus, which 
is similar between the two isoforms, comprises the ATP binding domain (residues 
35-61) and the active kinase domain (residues 162-174). On the other hand, the 
C-terminus of VRK2A contains a hydrophobic transmembrane region (residues 




the BAB motifs absent in the truncated isoform VRK2B (Blanco et al., 2006; 
Nichols and Traktman, 2004). VRK1 and VRK2 are active kinases that have the 
ability to phosphorylate basic or acid proteins and present high 
autophosphorylation activity (Barcia et al., 2002; Lopez-Borges and Lazo, 2000). 
  At last, the 474 amino acid pseudo-kinase VRK3 is coded by the VRK3 
gene in the chromosomal region 19q13, and shows minor homology with VRK1 
(33%) and VRK2 (23%). The amino terminal region of VRK3 contains the NLS 
whereas the carboxyl terminal region contains a degenerative kinase domain, 
due to alterations in key amino acids that lead to a null catalytic activity (Kang 
and Kim, 2006).   
 
Figure 3 – Schematic representation of the structure of VRK family of protein 
kinases and the main domains and motifs of each kinase. The percentages relate to the 
level of homology between the three different members of the family.  
 Concerning the tri-dimensional structure of the VRK family members, they 
show an additional α-helix (αC4) in the activation domain that makes the kinases 
constitutively active (Scheeff et al., 2009). This is important since the members 
of the VRK family lack a conserved phosphorylation site in the activation loop in 
order to regulate the kinase activity, being equally active due to this extra helix. 
Nevertheless, in VRK3, several glycine residues in the G-loop (GxGxFG) are 
degraded and replaced by larger amino acids. These substitutions prevents the 
binding of ATP, as well as other modifications outside the G-loop and turn the 






































3.2 Subcellular localization of VRK protein kinases 
 VRK1 is typically a nuclear kinase, since it contains a NLS in the protein 
structure. In the nucleus, VRK1 was described to be in the nucleoplasm, 
nucleolus and was also associated with the chromatin (Andersen et al., 2005; 
Kang et al., 2007b; Valbuena et al., 2011b). However, it is important to notice that 
VRK1 subcellular localization depends on the cell type and cell growth conditions, 
as it can also be observed in the cytoplasm of a few cell lines.  
 
Figure 4 – Subcellular localization of VRK family of protein kinases. VRK1 is 
predominantly a nuclear kinase, being detected on the nucleoplasm, nucleolus and 
associated with the chromatin. In the cytosol, a smaller fraction is observed in the 
cytoplasm and associated with the Golgi apparatus. 
 Additionally, a subpopulation of VRK1 was also detected in the Golgi 
apparatus and VRK1 was described as being part of transcription complexes 
associated with the chromatin, alongside with histones and transcriptional factors 
(Figure 4) (Guermah et al., 2006; Valbuena et al., 2007a). VRK2 has two isoforms 
due to alternative splicing. The first isoform, VRK2A, is located anchored to the 
membranes of Golgi apparatus, endoplasmic reticulum (ER) and nuclear 
envelope, through the transmembrane domain. This domain is present in the 
carboxyl terminus region and has a hydrophobic nature. On the other hand, due 
to the absence of a transmembrane domain in its protein structure, VRK2B can 




has a nuclear localization, due to the NLS located in the amino terminal region of 
the protein kinase structure (Figure 3).     
3.3 The human VRK1 kinase 
 The human VRK1 is the first member of the VRK family and it is the best 
characterized protein kinase of the group. VRK1 is ubiquitously expressed in all 
tissues, with particular high expression in highly proliferating tissues, such as liver 
and thymus or cancer cell lines (Nezu et al., 1997; Vega et al., 2003). Thus, based 
on VRK1 features and expression, this kinase has been related to cell cycle 
regulation and proliferation. Nowadays, new updates on this kinase have 
emerged, and several others functions have been associated with VRK1 
(Valbuena et al., 2011b). In summary, VRK1 was described to participate in a 
broad group of processes such as: i) the correct progression of the cell cycle 
through transcriptional factors regulation; ii) DDR pathways; iii) modulation of p53 
levels; iv) nuclear envelope breakdown; v) histone phosphorylation; vi) formation 
and maintenance of Cajal body (CB); vii) chromatin condensation and viii) 
fragmentation of the Golgi apparatus. VRK1 protein functions are described in 
detail in the following chapters and are summarized in the Table I.    
3.3.1 Role of VRK1 in cell proliferation and cell cycle progression 
 VRK1 is an important regulator of proliferation and cell cycle progression. 
The majority of these observations were obtained from studies related with VRK1 
expression. It was described that in normal squamous epithelium VRK1 is highly 
expressed near the highly proliferative basal layer, decreasing as the epithelial 
cells differentiate, and correlating positively with the proliferation marker Ki67. 
Moreover, in head and neck squamous cells tumours, VRK1 expression was 
described to correlate positively with proliferations markers, such as CDK2, 
CDK6, cyclin A, Ki67 and topoisomerase II and, negatively with cell cycle 
inhibitors such for example p16 and p27. Likewise, VRK1 was also described to 
positively correlate with the expression of proliferation marker p63 in pharynx 
squamous epithelium. Altogether, these results suggest that VRK1 behaves as a 
proliferation marker (Santos et al., 2006; Valbuena et al., 2008b; Valbuena et al., 
2007a). Accordingly, it was also observed that the inhibition of VRK1 gene 




A, cyclin D1, PCDNA, among other proliferation markers, leading to a cell cycle 
arrest in the G1 phase (Valbuena et al., 2008b; Valbuena et al., 2011b). 
Moreover, it was also observed the dependence of Ewing sarcoma (ES) cell lines 
on human VRK1. Here, knockdown of VRK1 with small hairpin RNA (shRNA) 
induced low proliferation and rapid onset of apoptosis on ES cell lines. A result 
supported by in vivo studies, demonstrated the clear reduction in tumour 
development after injection of VRK1-depleted SKNMC-ES cells. These results 
confirmed that VRK1 is critical for ES proliferation and survival, displaying the 
tumoral cells a marked higher sensitivity to the suppression of the kinase (Riggi 
et al., 2014).       







53BP1 Ser25; Ser29 DNA damage repair 
ATF2 Ser62; Thr73 Transcriptional activation 
BAF Thr2; Thr3; Ser4 Nuclear envelope break-down 
c-Jun Ser63; Ser73 Transcriptional activation 
Coilin Ser184 Cajal bodies assembly 
CREB Ser133 Cell cycle progression in G1/ S phase transition 
Histone H2A.X Ser139 DNA damage repair 
Histone H2B Unknown Unknown 
Histone H3 Thr3; Ser10 Chromatin condensation during mitosis 
Histone H4 Unknown Unknown 
NBS1 Ser343 DNA damage repair 
p53 Thr18 p53 activation and cell cycle arrest 
    In the table are represented the major VRK1 substrates described in the literature.  
 However, not all the tumours express the same levels of VRK1. As an 
example, lung carcinomas express variable levels of VRK1 depending on the 




of VRK1, when compared to adenocarcinomas. Curiously, squamous cell lung 
carcinomas present p53 mutations, which could indicate a tendency for tumours 
positive with p53 mutations to accumulate VRK1 (Valbuena et al., 2007b). 
Besides, in breast cancer, the levels of VRK1 expression diverge depending on 
tumour type. High levels of VRK1 could indicate poor prognosis in breast cancer, 
whereas low levels of VRK1 expression and other mitotic markers could indicate 
good prognosis in breast cancer (Fournier et al., 2006). The same conclusion 
was obtained in an independent study, in which it was shown that high expression 
of sixteen cell cycle-related kinases, including VRK1, correlated with poor 
prognosis in breast cancer (Finetti et al., 2008). Nevertheless, VRK1 is also 
involved in several other mechanisms associated with cell proliferation as 
explained in the next sections.  
3.3.2 The implication of VRK1 on chromatin remodelling 
 The chromatin is the state in which the DNA is packed inside the cell, being 
the nucleosome the fundamental component of chromatin. The nucleosome 
contains approximately 147 base pairs of DNA, wrapped around of an octamer 
composed by two copies of the four core histones: H3, H4, H2A and H2B 
(Kouzarides, 2007; Smith and Shilatifard, 2010). The core histones are globular 
except for their amino-terminal ‘‘tails,’’ which are unstructured and vastly modified 
on their residues. These tails can be submitted to different posttranslational 
modifications, such as phosphorylation, acetylation, ADP ribosylation, 
deamination, (mono-; di-; tri-) methylation, proline isomerization, sumoylation or 
ubiquitination (Kouzarides, 2007). Histone modifications can change the active or 
repressive state of the chromatin, modulating the activity of histone chaperones, 
nucleosome remodelers, transcription factors and other histone modifiers (Baek, 
2011) and, ultimately regulating chromatin condensation during mitosis, 
apoptosis, DDR, genome stability, replication and transcription (Berger, 2007; 
Costelloe et al., 2006; Hans and Dimitrov, 2001; Hurd et al., 2009; Kang et al., 
2007b; Luijsterburg and van Attikum, 2011; Smith and Shilatifard, 2010; 
Valbuena et al., 2011b).  
VRK1 directly participates on chromatin remodelling mostly through 
histone H3 phosphorylation on the residues Thr3 (H3T3ph) and Ser10 




progression and are also phosphorylation targets of two other relevant mitotic 
kinases: Haspin, that phosphorylates H3T3, and AurKB, which phosphorylates 
H3S10 (Kang et al., 2007b; Valbuena et al., 2011b; Vazquez-Cedeira et al., 
2011). Curiously, H3S10ph was also reported to be important for chromatin 
relaxation and transcription (Prigent and Dimitrov, 2003). Besides histone H3, 
VRK1 is also able to phosphorylate, in a smaller scale, H2A, H2B and H4. 
Altogether, it seems that VRK1, besides its involvement in the cell cycle 
progression during interphase, also contributes to chromatin condensation, and 
consequently to the G2/M transition, through histone phosphorylation (Kang et 
al., 2007b; Valbuena et al., 2011b). Lately, the potential role of VRK1 on histone 
acetylation and methylation has been also studied, and it appears that the kinase 
has an active role on the regulation of other histone modifications besides 
phosphorylation (Salzano et al., 2015).  
3.3.3 Regulation of transcription factors by VRK1 
 VRK1 is a kinase with high autophosphorylation capacity, capable of 
phosphorylating both acidic and basic proteins. Interestingly, this particular 
characteristic is not shared with other kinases from the casein kinase 1 group. 
(Lopez-Borges and Lazo, 2000).  
 Among the numerous substrates of VRK1, several transcription factors are 
regulated by VRK1-phosphorylation, namely p53. The tumour suppressor p53 is 
important to maintain cell homeostasis, as it mediates cell cycle arrest in order to 
correct the detected ‘’errors’’ on the DNA. Otherwise, the cell undergoes 
apoptosis. The accumulation, stabilization and activation of p53, in response to 
cellular ‘’stress’’ is perfectly regulated, and this regulation occurs mostly due p53 
phosphorylation and acetylation. VRK1 phosphorylates p53 on the Thr18 residue, 
blocking the binding of p53 to the negative modulator Mouse double minute 2 
(Mdm2) and promoting the binding to p300 (Barcia et al., 2002; Dumaz and Meek, 
1999). Thus, VRK1 avoids p53 degradation through the Mdm2-dependent 
ubiquitin proteasome pathway (UPP) and it increases the acetylation of lysine 
(Lys/K) 373 and Lys382 by the co-factor p300. This leads to the stabilization of 
the transcription factor (Vega et al., 2004a). On the other hand, VRK1 and p53 
form an autoregulation loop, since VRK1 is tightly regulated by p53. The 




expression, which in turn promotes the degradation of VRK1 through lysosomal 
degradation in the autophagic pathway (Valbuena et al., 2011a; Valbuena et al., 
2006b). In addition, p300 affects the specificity of p53 towards particular 
transcription targets while protecting VRK1 from degradation (Valbuena et al., 
2008a).  
 Moreover, VRK1 phosphorylates c-Jun and the activating transcription 
factor 2 (ATF2). Both c-Jun and ATF2 are activating protein-1 (AP-1) transcription 
factors. The c-Jun protein regulates genetic expression, in response to stress, of 
cytokines and grow factors, controlling in turn several cellular mechanisms such 
as apoptosis, differentiation or proliferation. The activation of c-Jun occurs 
through direct phosphorylation by kinases belonging to the mitogen-activated 
protein (MAPK) kinase family, like the ERK1/2 (extracellular signal-regulated 
kinases) and JNK (c-Jun N-Terminal kinase) kinases (Chang and Karin, 2001). 
Additionally, VRK1 phosphorylates c-Jun in the Ser63 and Ser73 residues, which 
stabilizes and activates the transcriptional activity of c-Jun (Sevilla et al., 2004a). 
Regarding ATF2, the transcription factor belongs to the ATF/ CREB (cAMP 
response element-binding) family and, through the activation of genes involved 
in cell growth, differentiation and immune response,  promotes proliferation and 
oncogenesis (van Dam and Castellazzi, 2001). ATF2 is phosphorylated by 
MAPKs as ERK, JNK and p38 (Bhoumik and Ronai, 2008), and as described 
recently, it is also phosphorylated by VRK1 on the Ser62 and Thr73 residues, 
which are phosphorylation targets of protein kinase A (PKA) and calmodulin-
dependent kinase IV (CAMK-IV). Both Ser62 and Thr73 phosphorylation lead to 
the accumulation and transcriptional activation of ATF2 (Sevilla et al., 2004b). 
Furthermore, VRK1 is capable of phosphorylating the Ser133 residue of 
transcription factor CREB. This parallel VRK1-dependent activation of CREB and 
ATF2 increases the binding of both transcriptional factors to the promoter 
CCND1, enhancing the expression of cyclin D1 protein and promoting G1/ S 
phase transition (Sevilla et al., 2004b).  
3.3.4 Role of VRK1 on the Golgi apparatus fragmentation 
 The fragmentation of the Golgi apparatus is a common feature that occurs 
during mitosis. More precisely, at the end of the cell cycle the redistribution of the 




and assembly of the Golgi apparatus, in a process dependent on 
phosphorylation. Normally, this phosphorylation process leads to the 
fragmentation of the Golgi apparatus and it is attributed to MEK1 (mitogen-
activated protein kinase 1) and Plk3 (polo-like kinase 3) (Ruan et al., 2004; Xie 
et al., 2004). Recently, also VRK1 has been described to actively participate in 
this fragmentation mechanisms. In short, VRK1 interacts with Plk3, forming a 
stable complex, co-localizing in the Golgi apparatus. Plk3 phosphorylates the 
Ser342 residue localized in the ‘’regulatory-carboxyl-terminal-region’’ of VRK1. 
Besides, it was observed that the down-regulation of VRK1, using small 
interfering RNA (siRNA), partially blocks MEK1 and Plk3 induced fragmentation 
of the Golgi apparatus. This was also observed when a VRK1 mutant without 
kinase activity was expressed. In summary, VRK1 is essential for the correct 
fragmentation of the Golgi apparatus at the G2/ M transition, playing a role 
downstream of the MEK1/ Plk3 pathway (Lopez-Sanchez et al., 2009).      
3.3.5 VRK1 importance on the assembly of nuclear envelope  
 The nuclear envelope breakdown and assembly is a well-regulated 
mechanism that begins at early stages of mitosis and ends during telophase. 
Among the proteins involved in this breakdown-assembly process one of the most 
important is BAF. BAF is a small protein involved in the maintenance of the 
nuclear architecture. BAF binds the DNA and proteins with LEM motifs, namely 
emerin, lamina-associated polypeptide 2 (Lap2) and LEM domain-containing 
protein 3 (MAN1) that are localized in the internal nuclear membrane. 
Furthermore, BAF changes its sub-cellular location depending on the phase of 
the cell cycle. So, during interphase BAF is located in the internal nuclear 
membrane, playing a role on the anchorage of chromatin to the nuclear envelope 
while during the early stages of mitosis it is released from the chromatin and 
nuclear membrane proteins, playing a role in the chromatin condensation and 
nuclear envelope breakdown. On anaphase, BAF is located near the telomeres, 
enhancing the recruitment of proteins necessary for the nuclear envelope 
assembly (Haraguchi et al., 2001).  
 VRK1 phosphorylates BAF in three residues in the amino-terminal region: 
i) Thr2, ii) Thr3 and iii) Ser4. These phosphorylations, while slightly affected the 




chromatin and the subcellular localization of the protein. Thus, VRK1 
phosphorylates BAF, releasing the protein from the DNA, facilitating chromatin 
condensation and nuclear envelope breakdown. In conclusion, VRK1 plays an 
important role in the nuclear envelope breakdown-assembly dynamics. (Molitor 
and Traktman, 2014; Nichols et al., 2006b; Zhuang et al., 2014).  
3.3.6 Implication of VRK1 on DNA-damage response (DDR) 
 Cell homeostasis is regulated by several mechanisms like: proliferation, 
cell senescence and cell death, representing a fundamental balance for cell 
survival and maintenance of the DNA integrity the DDR. The DDR system has as 
fundamental functions the detection, signalling and repair of DNA breaks and 
mutations, induced by either endogenous cellular processes or by exogenous 
agents. When a break/mutation is detected, the cell cycle arrests in order to 
prevent the replication and propagation of damaged DNA to the daughter cells. 
DDR then activates the correct DNA damage repair pathway as a way to repair 
the DNA and maintain the DNA integrity. When the damage is efficiently repaired, 
cell re-enters the proliferative state, but if the damage is too severe, the cell 
undergoes apoptosis. Errors in the repair of DNA damage or non-repaired lesions 
can lead to tumorogenesis. Concerning the different types of DDR, these can be 
related to single-strand breaks (SSBs) such as BER (base excision repair), in situ 
repair, MMR (mismatch repair) and NER (nucleotide excision repair), or related 
to double-strand breaks (DSBs) like HR (homologous recombination) and NHEJR 
(non-homologous end-joining repair). Focusing only on DBSs, the most lethal 
form of DNA damage, numerous proteins are involved DNA repair. For instance 
the sensor proteins H2A.X, MRN (Mre11-Rad50-NBS1) complex and PIKKs 
(phosphoinositide 3-kinase-related protein kinase: ATM (ataxia telangiectasia 
mutated), ATR (ataxia telangiectasia and Rad3-related protein) and DNA-PKcs) 
that detect the lesions, the scaffold proteins breast cancer associated 1 (BRAC1) 
and mediator of DNA damage checkpoint protein 1 (MDC1), which recruit other 
proteins important for the repair, the transducing proteins checkpoint kinase 1 
and 2 (Chk1 and Chk2) and PIKKS responsible for amplify the detection signal 
and the effector proteins cdc25 and p53 in control of the cell cycle arrest, 
reparation, senescence or apoptosis. Recently, also VRK1 has been described 




and Bartek, 2009; Lopez-Sanchez et al., 2014b; Salzano et al., 2015; Salzano et 
al., 2014; Sanz-Garcia et al., 2012).  
 Initially, evidence demonstrated that VRK1 is an early response protein, 
required for the formation of 53BP1 foci. In resting cells, the induction of DSBs 
with ionizing radiation activates VRK1, inducing the formation of p53-binding 
protein 1 (53BP1) foci in a VRK1-dependent manner. In addition, VRK1 
specifically phosphorylates 53BP1 in starvation conditions. Knock-down of VRK1 
using siRNA, results in defective 53BP1 foci formation, not only in number, but 
also in size. The use of a siRNA-mutant-resistance rescues the formation of 
53BP1 foci, being the effect of VRK1 upon the foci formation independent of ATM 
and p53. In fact, VRK1 seems to act upstream of ATM since VRK1 knockdown 
avoids the activation of ATM and other kinases such as Chk2 and DNA-
dependent protein kinase (DNA-PK) (Sanz-Garcia et al., 2012). Similar results 
were obtained using doxorubicin as damaging agent in breast cancer cell lines, 
which indicates that VRK1 is activated early independently of the type of DNA 
damage (Salzano et al., 2014). New evidence, supports the importance of VRK1 
in DNA damage early response. VRK1 exists in a basal stable complex with p53, 
before UV-induced DNA damage activates VRK1, leading to the phosphorylation 
of p53 on the Thr18 residue as well as its accumulation. The VRK1-p53 basal 
complex seems to be important as an early-warning system to respond instantly 
after DNA damage (Lopez-Sanchez et al., 2014b). Moreover, VRK1 seems to 
affect Nijmegen Breakage syndrome protein 1 (NBS1) foci formation. Knock-
down of VRK1 affects negatively the formation of NBS1 foci, being this phenotype 
rescued when using a mutant resistant to the siRNA, similarly to the results 
observed with 53BP1 foci formation. VRK1 interact and phosphorylates NBS1, 
leading to the correct formation of NBS1 foci. Moreover, VRK1 and ATM are 
necessary for NBS1 formation, avoiding the degradation of NBS1 by the ubiquitin 
proteasome pathway dependent of the ubiquitin-ligase E3 RNF8 (ring finger 





Figure 5 – Role of VRK1 on histone modifications under ionizing radiation. VRK1 
knockdown, under ionizing radiation, induces loss of histone H2A.XSer139 
phosphorylation and histones H3 and H4 acetylation.  
Lately, VRK1 was also implicated in chromatin relaxation, under ionizing 
radiation conditions and independently of ATM. The acetylation of histone H3 and 
histone H4 are critical events for the relaxation of chromatin, which is important 
for DDR. Depletion of VRK1 causes the loss of histone acetylation, not only under 
DNA damage condition, but also in basal conditions. Moreover, VRK1 interacts 
and phosphorylates the histone H2A.X on the Ser139 residue, whereas VRK1 
knockdown decreases the phosphorylation of histone H2A.X and γH2A.X foci 
formation upon ionizing radiation (Figure 5) (Salzano et al., 2015).  
3.3.7 Neurodegeneration and VRK1  
 The importance of VRK1 covers a spectrum much wider than the 
regulation of cell cycle progression and proliferation or its implication in cancer. 
Indeed, it has been shown that VRK1 also plays an important role in the 
development and maintenance of the nervous system (Renbaum et al., 2009b; 
Wee et al., 2010). So, it is expected that the deregulation of VRK1 or mutations 
on this kinase could lead to the development of neurodegenerative diseases. 
VRK1 mutation R358X, with a stop within the NLS and forming a truncated VRK1, 




















pontocerebellar hypoplasia and consequently child death. This mutation occurs 
in the VRK1-NLS domain and affects the normal nuclear localization of the kinase 
but not its activity. This syndrome only affects recessive homozygote children, 
having the heterozygosis a normal phenotype (Renbaum et al., 2009b). More 
recently, other VRK1 mutations (R89Q; R133C; V236M) were reported in 
hereditary motor and sensory neuropathies (HMSN)-related studies. VRK1 
mutations, located in the kinase domain, may affect cell cycle progression and 
induce apoptosis of neuronal cells, but the effect of such mutations in the 
neurodegeneration process is not yet fully cleared (Gonzaga-Jauregui et al., 
2013a; Najmabadi et al., 2011). Moreover, VRK1 seems to be important for the 
CBs correct assembly, more precisely to the recruitment of the scaffold protein 
coilin, essential to CBs assembly. VRK1 interacts with and phosphorylates, at 
least the Ser184 residue, on coilin regulating the formation of CBs. The VRK1-
dependent phosphorylation of coilin on Ser184 occurs in mitosis, before the 
formation of the CBs, and is important for the stability of the scaffold protein. The 
loss of coilin phosphorylation results in disintegration of CBs and degradation of 
coilin in the proteasome (Cantarero et al., 2015; Gonzaga-Jauregui et al., 2013a; 
Sanz-Garcia et al., 2011)  
3.3.8 VRK1 gene-trap hypomorphic transgenic mice 
 Hypomorphic mice expressing no more than 15% of VRK1 protein, 
comparing with wild-type mice, are viable but sterile. This sterility results from 
defects in spermatogenic cells proliferation, due to deficient mitosis and meiosis 
of the male reproductive cells. Also, VRK1 silencing does not affect other tissues, 
which may indicate a redundancy with the others members of the VRK family 
(Choi et al., 2010; Wiebe et al., 2010). Likewise, it was also reported that VRK1 
knock-out dramatically affects the gametogenesis. Mice males were initially 
fertile, but gradually become sterile due to alterations in spermatogenesis, 
whereas female mice were totally sterile due to oocyte developmental defects 
(Schober et al., 2011). Recent report in VRK1-deficient ovaries supports the 
important role of VRK1 on gametogenesis and folliculogenesis (Kim et al., 





3.3.9 The regulation of human VRK1 
 The regulation of VRK1 activity, sub-cellular localization and expression is 
important for an accurate response to extra or intracellular stimulus. VRK1 
expression is regulated by mitogens and growth factors, normally present in the 
serum, given that serum-free conditions decrease the levels of VRK1 and the re-
introduction of serum in the cellular medium restores the levels of this kinase 
(Valbuena et al., 2008b). Additionally, transcription factors, such as E2F1 and 
Myc, activate the expression of VRK1 gene promoter (Kang and Kim, 2008; 
Santos et al., 2006).  
 Recently, also the aberrant transcription factor EWS-FLI1 was described 
to activate the VRK1 promoter. EWS-FLI1 multimers recruit acetyltransferases 
(p300) and methyltransferases, which open the chromatin and create de novo 
enhancers. Consequently, this new enhancer physically interacts and activates 
the promoter of VRK1 (Figure 6). The interaction between the long distance 
enhancer, bounded to EWS-FLI1, and the VRK1 promoter was confirmed in ES 
cell lines SKNMC and A673, where the knockdown of EWS-FLI1 also induced a 
decrease in VRK1 expression (Riggi et al., 2014). 
 
Figure 6 – Regulation of VRK1 gene promoter by EWS-FLI1. The transcription factor 
binds to GGAA repeats, recruiting methyltransferases and acetyltransferases, relaxing 
the chromatin, creating de novo enhancers and activating the VRK1 gene promoter.    













However, the most well-known regulation of VRK1 subcellular localization 
and activity is related with post-translational modifications on the protein. VRK1, 
like VRK2, has high autophosphorylation activity important to maintain the 
stability of the kinase, since the inactive kinase is less stable and has reduced 
lifetime (Lopez-Borges and Lazo, 2000). Besides, the in vitro phosphorylation of 
Thr355, located in the carboxyl-terminus region of VRK1, seems to be involved 
in the regulation of this kinase, although it remains unknown how it affects the 
localization or its activity (Barcia et al., 2002). This residue was also described to 
be phosphorylated by protein kinase C δ (PKCδ), which negatively regulates 
VRK1. More precisely, in DNA damage conditions, VRK1 is phosphorylated by 
PKCδ, arresting the cell cycle and consequently inducing p53-dependent cell 
death (Park et al., 2011). Another important residue is VRK1 Thr378, which is 
suggested to be phosphorylated by ATM and ATR in response to UV light (Stokes 
et al., 2007). Moreover, it was described that VRK1 levels increase after ionizing 
radiation or UV light exposure or treatment with DNA damage-inducing drugs, 
such as doxorubicin (Sanz-Garcia et al., 2012; Valbuena et al., 2011a). In 
addition, VRK1 can also be activated through stable interactions with other 
proteins. An example is Ras-related nuclear GTPase (Ran GTPase), identified 
by proteomics, which interacts and regulates VRK1 kinase activity. When VRK1 
binds to RanGTP, the kinase is active, but when it binds to RanGDP the kinase 
is inactive. Besides VRK1, also VRK2A and VRK2B are similarly regulated by 
Ran GTPase (Sanz-Garcia et al., 2008). On the other hand, VRK1 interacts and 
it is regulated by macroH2A1.2. The interaction between VRK1 and 
macroH2A.1.2 seems to occur during interphase, avoiding the phosphorylation 
of histone H3 and BAF, without affecting the autophosphorylation activity of VRK1 
(Kim et al., 2012c). MacroH2A has three isoforms (macroH2A1.1, macroH2A1.2 
and macroH2A2) and differs from the conventional histone H2A in the C-terminus 
region, since it has a macro domain attached via a linker region. MacroH2A 
isoforms incorporate into the chromatin via their histone H2A-like region, 
changing the chromatin conformation and repressing transcription. Lately, 
macroH2A had also been associated with the transcriptional activation of 
differentiation genes in embryonic and adult stem cells, rendering them important 
in the establishment and maintenance of differentiated states (Chakravarthy et 




Finally, VRK1 can be regulated by kinase inhibitors and metals (Barcia-
Sanjurjo et al., 2013; Vazquez-Cedeira et al., 2011). The sensibility of VRK 
proteins to other kinase inhibitors is relatively low, but the fact that VRK1 and 
VRK2 show different response to different kinase inhibitors implies that the 
development of specific inhibitors for each member of the VRK family is possible 
(Vazquez-Cedeira et al., 2011). In fact, luteolin was described as a specific 
inhibitor of VRK1, inhibiting VRK1 ability to phosphorylate both BAF and histone 
H3, due to a direct interaction with the kinase domain of VRK1. Furthermore, 
luteolin regulates the progression of cell cycle by VRK1 modulation, leading to 
the suppression of cell proliferation and induction of apoptosis (Kim et al., 2014).  
3.4 The VRK2 kinase 
 VRK2 gene is located in the chromosomal region 2p16 and it produces two 
isoforms due to alternative mRNA splicing (Blanco et al., 2006). The isoform 
VRK2A contains 508 amino acids and is anchored to the membranes of 
endoplasmic reticulum, mitochondria and nuclear envelope by the carboxyl-
terminal hydrophobic transmembrane domain. VRK2B consists of 397 amino 
acids and is observed freely in the nucleoplasm and cytoplasm, since the 
transmembrane domain, characteristic of the first isoform, is absent (Blanco et 
al., 2006; Nichols and Traktman, 2004). VRK2 expression is ubiquitous in the 
tissues, having the skeletal muscle, heart, pancreas and testis higher levels of 
protein expression (Nezu et al., 1997). On the other hand, VRK2A expression is 
observed in all the studied cell lines, whereas VRK2B expression was only 
observed in a few number of cell lines (Blanco et al., 2006; Fernandez et al., 
2010). In breast cancer, it was observed that VRK2 expression correlated 
positively with estrogen and progesterone receptors and negatively with ErbB2. 
ErbB2 is overexpressed in 25%-30% breast cancer and it is a poor prognosis 
marker. Tumours positive to ErbB2 tend to lose part or completely VRK2 
expression, which can indicate that VRK2 is a marker of good prognosis for 
breast cancer (Fernandez et al., 2010).  
 Regarding the substrates of VRK2, both isoforms share several of them 
due to the high homology on the catalytic domain. VRK2 isoforms have high 
autophosphorylation capacity and phosphorylate several substrates like casein, 




2004; Sanz-Garcia et al., 2008). Moreover, it also phosphorylates VRK1 
substrates like Thr18 on p53 or Ser2, Ser3 and Thr4 on BAF. However, it is 
important to notice that these phosphorylations by VRK2A are not associated with 
in vivo studies, since the nature of the carboxyl-terminal domain responsible for 
VRK2A cytoplasmic subcellular localization and regulation prevents the access 
of this kinase to the substrates. In fact, it was observed that only VRK2B 
phosphorylates p53 in vivo, leading to the stabilization and accumulation of the 
transcriptional factor, similar to what is observed with VRK1 phosphorylation 
(Blanco et al., 2006). 
Regarding the function of human VRK2, the kinase has been described to 
participate in numerous cellular mechanisms. VRK2 modulates gene 
transcription in response to hypoxia, and cellular stress induced by interleukin 1β, 
mediated by JNK (Blanco et al., 2007; Blanco et al., 2008). Additionally, VRK2A 
in response to epidermal growth factor (EGF) acts as a negative modulator of 
ERK1/2 in the MAPK signal pathway (Fernandez et al., 2010). This function is 
dependent of VRK2A, MEK1 and KSR1 (kinase suppressor of Ras 1) direct 
interaction, and independent of VRK2A kinase activity (Fernandez et al., 2012). 
Moreover, it was observed that VRK2 isoforms phosphorylate the nuclear factor 
of activated T cells (NFAT) on the Ser32, after phorbol 12-myristate 13-acetate 
(PMA) stimulation. This phosphorylation activates NFAT and increases the 
transcription of COX-2 (cyclooxygenase-2) promoter. Besides, it was also 
observed that the COX-2 protein and mRNA levels decrease after VRK2A-siRNA 
treatment without any alteration on the expression levels of NFAT. Also, VRK2 
down-regulation reduced tumour cell invasion (Vazquez-Cedeira and Lazo, 
2012). Finally, it was reported that VRK2 interacts with the anti-apoptotic protein 
B cell lymphoma-extra-large (Bcl-xL) and regulates negatively the expression of 
Bax, modulating the intrinsic pathway for apoptosis. Down-regulation of VRK2A 
leads to increased mitochondrial Bax protein level, and consecutively increased 
the release of cytochrome C as well as caspases activation, detected by Poly- 
ADP-ribose polymerase (PARP) processing. Low levels of VRK2A increase cell 
sensitivity to apoptosis via chemotherapeutic drugs such as camptothecin 





3.5 VRK3: the inactive member of the family 
 VRK3 is a pseudo-kinase protein without kinase activity, located on 
chromosome 19q13. This protein contains 474 amino acids and it is 
predominantly nuclear due to the NLS in the amino-terminal region (Nichols and 
Traktman, 2004; Vega et al., 2003). Since VRK3 lacks kinase activity and 
conserves the catalytic domain folding it was hypothesised that the protein kinase 
might have been retained as a scaffold or a regulatory binding partner (Scheeff 
et al., 2009). In fact, VRK3 forms a complex with Von Hippel-Lindau tumour 
suppressor (VHL) and ERK1/2, stimulating the phosphatase activity of VHL and 
leading to a decrease on ERK1/2 phosphorylated levels. Here, VRK3 negatively 
regulates the EKR1/2 signalling pathway. Moreover, it seems that PMA 
stimulation activates ERK1/2, increasing the levels of VRK3, creating a negative 
feedback in which ERK1/2 positively regulates the expression of VRK3 negative 
regulator. Finally, VRK3 does not correlates with proliferation since its expression 
is equal in high- or low-proliferative tissues (Kang and Kim, 2006, 2008).    
4. The Aurora kinase family 
The human Aurora kinases are a highly conserved protein kinase family 
that contain three catalytically active kinases: the Aurora kinase A (AurKA), the 
Aurora kinase B (AurKB) and the Aurora kinase C (AurKC) (Kamaraj et al., 2013). 
Unlike the other kinase families, this family has a eukaryotic protein kinase 
domain that doesn’t fit in any major group of protein kinases. As a result, Aurora 
family branches near to the AGC group of kinases, which was named after the 
protein kinase A (PKA), G (PKG) and C (PKC) families, but was not included in 
the family (Goldberg et al., 2006; Manning et al., 2002b).  
The first member of Aurora family (AurKA) was initially described in 1995 
by Glover and colleagues in Drosophila (Glover et al., 1995). They discovered 
that mutations in AurKA resulted in irregular centrosome separation and in the 
consequent formation of ‘’monopolar spindles’’. Because of that and reminiscent 
of the North Pole, it was given the name ‘’Aurora’’ to the discovered kinase, (Fu 
et al., 2007; Glover et al., 1995). Nowadays, it is well known that Auroras have 
homologues genes in numerous species, from Saccharomyces cerevisiae that 




melanogaster and Xenopus laevis, which has two types of Aurora kinases: AurKA 
and AurKB (Brittle et al., 2007; Crosio et al., 2002; Eyers et al., 2005). Mammals, 
besides AurKA and AurKB, encode a third member, ‘’unexpectedly’’ named, 
AurKC (Bolanos-Garcia, 2005; Kollareddy et al., 2008). Moreover, phylogenetic 
trees suggest that the Auroras kinase functions, in metazoans, have diverged 
during evolution from a single urochordate ancestor. AurKA is an orthologous 
gene line in cold-blooded vertebrates and mammals, while structurally similar 
AurKB and AurKC evolved later in evolution, in mammals due to a duplication of 
a cold-blooded vertebrate ancestral Aurora B/C gene (Brown et al., 2004).   
The activity of Aurora kinases is mostly functional during mitosis, and 
therefore, these are vital mitotic kinases, essential for the regulation of cell cycle. 
In fact, several mitotic abnormalities and different types of cancer are associated 
with deregulation of Aurora kinases-dependent mechanisms such as, chromatin 
condensation, centromere function, spindle assembly, chromosome alignment, 
chromosome segregation and, cytokinesis (Bolanos-Garcia, 2005; Chu et al., 
2011; Fu et al., 2007; Kamaraj et al., 2013; Wang et al., 2010). Aurora kinases 
are overexpressed in several types of tumors, such as breast or lung cancer, 
indicating that these kinases might be important in the tumorogenesis process 
(Kollareddy et al., 2008; Takeshita et al., 2013; Zhang et al., 2015). Indeed, it is 
important to notice that the maximal expression of Aurora kinases occurs in G2/M 
phases and that high activity of these kinases due to overexpression in cultured 
cells leads to a cancer-like phenotype associated with mitotic abnormities that 
generate genomic instability (Smith et al., 2005).  
4.1 The structure of Aurora kinases 
 The Aurora family members are kinases that have an amino acid sequence 
length ranging between 309 and 403 and show a relatively small sequence 
convergence among species. For instance, AurKB shows an overall sequence 
identity of 84% between human and rodents. Auroras present a quite similar 
domain organization, having an amino-terminal domain of 39 to 129 residues in 
length, a central protein kinase domain, and a 15 to 20 residues carboxy-terminal 
domain. The catalytic kinase domain of the three members of Aurora family is 
highly conserved (around 71% between AurKA and AurKB), whereas the N-




selectivity of each Aurora kinase during protein-protein interactions (Carmena 
and Earnshaw, 2003; Kollareddy et al., 2008).  
 
Figure 7 – Aurora protein kinases structure. The percentages are relative to the level 
of homology between the several Aurora family members.  
Analysing the alignment of both AurKA and AurKB is possible to identify a 
conserved ‘’KEN’’ motif, covering from 11 to 18 residues, especially important to 
recognize Cdh1-dependent anaphase-promoting complex (APC) signals. 
Moreover, in the N-terminal region of AurKA and AurKB, lies an A-Box-activating 
motif or A-Box that confers functionality to a second motif, the Degradation box 
or D-Box that exists in the C-terminal region of kinases and is the target of Fizzy-
related proteins, in the case of AurKA. These motifs are important to regulate the 
levels of AurKA on G1 phase entrance, leading to its degradation via APC/ 
cyclosome (APC/C)-UPP dependent on hCdh1 (Castro et al., 2002). In the case 
of AurKB, the kinase is equally degraded through APC/C-UPP dependent on 
hCdh1, and it possesses the same D-Box as AurKA. However, this degradation 
occurs through a different ubiquitin ligase, undergoing degradation by binding to 
the α-subunit C8 (HC8) of the human proteasome (Bolanos-Garcia, 2005; 
Stewart and Fang, 2005). Concerning AurKC degradation, mechanisms are still 
unclear. The three human Auroras present higher homology, when compared to 
homology among the VRK family members (Figure 7). Indeed, AurKB shows a 
57% homology with AurKA and a higher score of 75% with the third member of 
the family the AurKC. AurKA shows 60% homology with AurKC (Brown et al., 




























4.2 Aurora kinases subcellular localization 
Despite the high number of similarities in terms of sequences and 
structures, Aurora kinases are completely different regarding their subcellular 
localization. Therefore, AurKA is located in the pericentriolar structures, from the 
end of S phase until the beginning of the next G1 phase. During mitosis, AurKA 
spreads to the pole, more precisely to the proximal ends of spindle microtubules. 
In anaphase, most of AurKA is located on the polar microtubules, and in a fewer 
scale at the spindle midzone. In turn, AurKB is located alongside with INCENP at 
pericentromeric regions, during the late S phase until the late G2 phase, when 
AurKB becomes more diffusely located on the chromatin (Hayashi-Takanaka et 
al., 2009). In early prophase, AurKB and the other CPC proteins are partially 
located on the chromosomal arms, moving to the inner centromeres on the 
transition from prometaphase to metaphase (Nishiyama et al., 2013; van der 
Horst and Lens, 2014). This association seems to be dynamic, since centromeric 
AurKB continuously exchanges with a cytoplasmic pool. In the beginning of 
anaphase, AurKB gradually relocates to the midzone and to the cell cortex at the 
site of cleavage furrow ingression, persisting in this zone until the end of 
cytokinesis. The association with the central spindle microtubules during 
anaphase reduces considerably the mobility of AurKB. In cytokinesis, both AurKA 
and AurKB are concentrated in the midbody (Figure 8) (Carmena and Earnshaw, 
2003; Carmena et al., 2014; Fu et al., 2007; Gohard et al., 2014; Vader and Lens, 





Figure 8 – Subcellular localization of AurKA and AurKB during cell cycle (Adapted 
from (Carmena and Earnshaw, 2003)). 
The changes on AurKB localization occur alongside with at least three 
other proteins: INCENP, Survivin and Borealin. All four proteins are named 
‘’chromosomal passengers’’, as they move precisely from different locations at 
























(CPC) during mitosis (Figure 9) (Fu et al., 2007). In terms of localization, AurKC 
behaves similarly to AurKB. 
 
Figure 9 – Microscopy analysis of AurKB subcellular localization during cell cycle 
in HeLa cells. AurKB (green staining) and DNA (blue staining) (unpublished results).  
4.3 The human AurKB  
 AurKB was first identified in 1998 by polymerase chain reaction (PCR) in 
a search for kinases overexpressed in colorectal tumours (Bischoff et al., 1998). 
AurKB is part of the CPC and is involved in the regulation of many mitotic 
processes. Therefore, AurKB expression peaks at the G2-M transition and its 
kinase activity is higher during mitosis. Chronologically, AurKB activity is 
important for chromosome condensation, sister chromatid cohesion, mitotic 
spindle assembly, correct chromosome bi-orientation, SAC, chromosome 
segregation and cytokinesis (Carmena and Earnshaw, 2003). 
4.3.1 The role of AurKB on chromatin condensation 
 The condensation of chromosomes compacts the chromatin in order to 
avoid errors during sister chromatid segregation and is driven by the activity of 
the Condensin I and II complexes (Vagnarelli, 2012). In turn, AurKB plays an 
important role in this process by promoting the chromosomal association of the 
Condensin I complex during prometaphase and, maintaining this association in 
the late phases of mitosis. Furthermore, this regulation is probably due to direct 
phosphorylation of the three non-SMC (structural maintenance of chromosomes) 
subunits and, is specific of the Condensin I complex, since AurKB does not 
regulates the association of the Condensin II complex (Lipp et al., 2007).  
Another important mechanism for chromosome condensation is the 
phosphorylation of the Ser10 residue, in the amino-terminal region of histone H3 
AurKB
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by AurKB, at early G2 phase (Crosio et al., 2002). In Tetrahymena it has been 
shown that the mutation of this residue on histone H3, results in abnormal 
chromosome segregation and extensive chromosome loss during mitosis (Vader 
and Lens, 2008; Wei et al., 1998). Nevertheless, the similar mutation in budding 
yeast Saccharomyces cerevisiae didn’t originate the same mitotic defects, 
perhaps due to differences in the chromosomal structure between the two 
species (Hsu et al., 2000; Vader and Lens, 2008).  
 
Figure 10 – Histone cross-talk between the phosphorylation of H3S10 and the 
methylation of H3Lys9. The phosphorylation of Histone H3 by AurKB, affects negatively 
the binding of the HP-1 to the chromatin.  
In human cells, phosphorylation of H3S10, by AurKB, causes the 
displacement of the Heterochromatin Protein 1 (HP-1) family of proteins from the 
heterochromatin during mitosis. HP-1 recognizes and binds to the H3Lys9 when 
this residue is tri-methylated and it seems that the phosphorylation of the H3S10 
is sufficient to eject the HP-1 from the chromatin, even when tri-methylation levels 
of H3Lys9 remain unaffected. In the same way, the inhibition or depletion of 
AurKB causes the retention of HP1 on mitotic chromosomes, suggesting that 
histone H3Ser10 phosphorylation is necessary for the dissociation of HP1 from 
chromatin in mitosis (Fischle et al., 2005; Hirota et al., 2005). However, it is 















chromosome condensation at the beginning of mitosis. These results suggest a 
possible histone modification cross-talk, in which the mitotic phosphorylation of 
H3Ser10, by AurKB, negatively affects the recognition of tri-methylation of the 
H3Lys9 by specific readers, as HP-1 (Figure 10) (Baek, 2011; Bannister and 
Kouzarides, 2011; Hirota et al., 2005; Kouzarides, 2007).  
4.3.2 The role of AurKB on the cohesion of the sister chromatids 
 Chromosome cohesion depends on a ring-like Cohesin complex closely 
related with the Condensin complexes. The Cohesin proteins are responsible for 
maintaining the two sister chromatids trapped inside the ring structure until the 
metaphase to anaphase transition. So, at the metaphase-anaphase transition 
Cohesin removal is important for the correct progression of the cell cycle. Cohesin 
is removed through two different pathways, being the first one the ‘’prophase 
pathway’’ that depends on the activity of the mitotic kinases polo-like kinase 1 
(Plk-1) and AurKB. Regarding the role of AurKB in this pathway, this kinase is an 
important player in the regulation of the Shugoshin-1 (Sgo-1) localization on the 
centromeres in mitosis. Thereby, Sgo-1 protects the centromeric Cohesin 
recruiting the PP2A (protein phosphatase 2A) complex to the centromeres. 
Downregulation of AurKB affects the centromeric localization of Sgo-1, leading to 
a more diffused localization along the chromosome arms. This alteration on Sgo-
1 localization blocks the removal of the Cohesin-complexes placed on the 
chromosome. Cohesin of sister chromatids is removed in a separase-dependent 
manner, but no role has yet been assigned to AurKB in this mechanism (Dai et 
al., 2006; Gimenez-Abian et al., 2004; Watanabe, 2010). 
4.3.3 The role of AurKB on the mitotic spindle assembly and chromosomal 
bi-orientation 
 The mitotic spindle assembly relies also on the activity of AurKB, has the 
inhibition or depletion of AurKB in Xenopus extracts disturbs the mitotic spindle 
formation (Kelly et al., 2007). Moreover, it seems that AurKB operates in parallel 
to the Ran-dependent pathway, phosphorylating two different substrates, 
important in the mitotic spindle assembly: i) the mitotic centromere-associated 
kinesin (MCAK) that is phosphorylated in several residues by AurKB and ii) the 




phosphorylation neighbouring the chromosomes (Kelly et al., 2007; Zhang et al., 
2007). Concerning MCAK, the interplay between multiple phosphorylation sites 
of this protein, is critical for the temporal and spatial control of MCAK function. In 
fact, AurKB seems to phosphorylate MCAK in three different residues (Thr95, 
Ser110, Ser196), which creates a two-site phosphoregulatory mechanisms 
targeting MCAK to chromosome arms or to centromeres. MCAK binding to the 
chromatin precedes the centromeric location of the protein, and creates a pool of 
MCAK ready to load onto the centromeres. Phosphorylation of Thr95 associates 
MCAK with the chromosome arms, whereas the phosphorylation of Ser196 
promotes de disassociation of the chromosome arms. The phosphorylation of 
Ser196 inhibits also the microtubule depolymerizing activity of MCAK. In turn, 
MCAK centromere targeting is accomplished by a balance between 
phosphorylation at Ser110 and dephosphorylation at Thr95. Centromeric MCAK 
is important for mal-attachment corrections of kinetochores to microtubules, 
critical for proper chromosome alignment and segregation. Because of that, 
centromeric MCAK at mal-attached kinetochores is hyper-phosphorylated on 
Ser110, but hypo-phosphorylated on Ser196 (Andrews et al., 2004; Zhang et al., 
2007). 
The kinetochores are structures assembled on the centromere, where the 
spindle apparatus attaches to a chromatid, during cell division (Vader and Lens, 
2008). These structures are fundamental in order for the paired of chromatids to 
achieve bi-orientation on the mitotic spindle, since they participate on the 
microtubule capture, chromosome movement and checkpoint signalling. Bi-
orientation is important for chromosomal segregation, where each of the two 
sister chromatids is attached to a different pole of the bipolar spindle. The tension 
caused by the pulling forces generated by the mitotic spindle on the two sister 
chromatids are counterbalanced by cohesion forces. When each kinetochore is 
attached to an opposite pole of the bipolar spindle it is called amphitelic 
attachment. Uncorrected attachments can occur when microtubules from the 
same pole bind both kinetochores (syntelic attachment), or when kinetochores 
attach microtubules from both poles (merotelic attachment). In both cases, AurKB 
activity destabilises the formed attachment, releasing the kinetochore for a new 




chromosome bi-orientation and faithful segregation of sister chromatids 
(Kalantzaki et al., 2015; Maiato et al., 2004; Meppelink et al., 2015). 
 
Figure 11 – Mitotic spindle assembly through AurKB-dependent regulation of 
MCAK localization and function.   
In syntelic attachments, AurKB phosphorylates and regulates MCAK and 
two other important kinetochore microtubule-capture factors: Ncd80/Hec1 and 
Dam1 complex (Figure 11). AurKB-dependent phosphorylation of NCD80/ Hec-1 
decreases the affinity of the complex to microtubules in vitro and mutations of the 
AurKB phosphorylation sites in NCD80/Hec-1 stabilise the interaction between 
microtubules and the kinetochore (DeLuca et al., 2011; Kalantzaki et al., 2015). 
Moreover, AurKB (Ipl1) phosphorylates some subunits of the Dam-1 complex in 
budding yeast, but none Dam-1 complex was found in mammals (Cheeseman et 
al., 2002). Contrariwise, AurKB corrects merotelic chromosomal attachments 
mostly through the regulation of MCAK complex during prometaphase. The 
regulation of MCAK by AurKB occurs, as previously described, at different levels 
(Figure 8) or indirectly, via inner centromere kin-I stimulator (ICIS), which 
interacts with AurKB and stimulates MCAK activity, or via Shugoshin-2 (Sgo2) 



















2003; Tanno et al., 2010). Disruption of AurKB or MCAK increases chromosomal 
misalignment and missegregation due to improper kinetochore–microtubule 
attachments (Zhang et al., 2007). 
4.3.4 The role of AurKB on the spindle assembly checkpoint 
 The SAC or mitotic checkpoint vigils the transition from metaphase to 
anaphase, preventing cell cycle progression in the presence of unattached or non 
bi-oriented chromosomes (Musacchio, 2011). As long as the amphitelic 
attachment state is not reached by all the chromosomes, SAC is active and 
avoids cell cycle progression to anaphase, through the regulation of APC/C 
activity. SAC includes core proteins such as: monopolar spindle 1 (Mps1), Mad1, 
Mad2, Mad3/ BubR1, budding uninhibited by benzimidazoles 1 (Bub1) and Bub3 
(Lens and Medema, 2003). The activation of APC/C promotes anaphase and 
consequently mitotic exit, by targeting for degradation, via the 26S proteasome, 
essential mitotic regulators like Securin and Cyclin B, among other proteins 
(Musacchio, 2011; Sudakin et al., 1995). As previously mentioned, the APC/C 
functions in combination with two different specificity factors Cdc20 or Cdh1. 
Activation of APC/CCdc20 is avoided by SAC through the formation of an inhibitory 
complex of Mad2, Mad3/ BubR1, Bub3 and Cdc20 proteins (Sudakin et al., 2001). 
All core proteins localise at kinetochores, being some of them (i.e. Mad1 and 
Mad2) completely displaced from microtubule-attached kinetochores, while 
others are retained (i.e. BubR1) in response to the amount of tension between 
sister kinetochores. Absence of tension, like unattached kinetochores, triggers 
SAC activation and AurKB seems to be required for SAC-dependent mitotic arrest 
induced by lack of tension (Lens and Medema, 2003; Maresca and Salmon, 2010; 
Shannon et al., 2002). This activation may be induced directly through the 
complete absence of attachments, or, indirectly due to the creation of unattached 
kinetochores (Pinsky and Biggins, 2005). AurKB activity is important to 
destabilise unreliable attachments between the spindle apparatus and the 
kinetochore. So, lack of tension activates AurKB, leading to the detachment of 
kinetochore-microtubule interaction lacking tension. This process recruits 
checkpoint proteins to the kinetochores and consequently leads to the inhibition 
of APC/CCdc20 (Maresca and Salmon, 2010). Even though, the role of AurKB in 




not quite yet understood (Vader et al., 2007). In fact, only few data in Xenopus 
and Schizosaccharomyces pombe show that AurKB activity is necessary for SAC 
response to unattached kinetochores (Kallio et al., 2002; Petersen and Hagan, 
2003), but is still unclear whether there is a direct tension pathway triggering SAC 
in human cells, since tension and attachment are tightly linked (Vader and Lens, 
2008). SAC failure can lead to premature anaphase entering with unattached or 
aberrantly attached kinetochores, resulting in improper chromosomal 
segregation, loss/gain of chromosomes and increased predisposition to cancer. 
4.3.5 The role of AurKB on anaphase and cytokinesis 
  AurKB activity is necessary for the correct progression of cell cycle through 
anaphase and cytokinesis. After SAC inactivation, anaphase begins when Cyclin 
B1 and Securin are degraded by APC/CCdc20, which causes the reduction of Cdk1 
activity and the segregation of sister chromatids (Lu et al., 2014; Meadows and 
Millar, 2015). From anaphase and beyond, AurKB is restricted to the central 
spindle/ midbody or it is transported by the microtubules to the cell cortex. On the 
central spindle, AurKB promotes the rapid switch in microtubules dynamic 
(anaphase) and the well-organized disassembly of the mitotic spindle (telophase) 
(Terada, 2001; Vader et al., 2007). Regarding cytokinesis, in which the cytoplasm 
is divided between the two newly-formed cells, each one containing a single 
nucleus, AurKB activity is also required. The equatorially division of the cytoplasm 
after chromosomal segregation, depends on the formation of a cleavage furrow, 
generated by the contraction of an actinomyosin ring (Werner and Glotzer, 2008). 
GTPase RhoA is important for the contractibility of the actinomyosin ring, since 
its activation (GTP-bound), regulates various cytokinesis effectors. The activity of 
RhoA during the last phase of cell division is controlled partially by a complex 
located on the central spindle, the centralspindlin, which in turn is regulated by 
AurKB. AurKB phosphorylates the centralspindlin-associated mitotic kinesin-like 
protein 1 (Mklp-1), controlling the normal function and localization of the complex 
and consequently the end of cytokinesis. AurKB inhibition, in late anaphase, 
leads to abnormal cytokinesis without disruption of the central spindle (Guse et 
al., 2005). Moreover, AurKB phosphorylates Desmin, glial fibrillary acidic protein 




assembly ability of these proteins and thus cytokinesis (Goto et al., 2003; Kawajiri 
et al., 2003; Kondo et al., 2013).  
4.3.6 The regulation of AurKB 
 AurKB is regulated by activation, localization and degradation. Still, 
several AurKB-regulatory mechanisms are feedback loops in which AurKB plays 
an important role. Full AurKB activation and function depends on the 
autophosphorylation within the kinase activation segment, on Thr232, and 
binding to INCENP. AurKB binds to the IN-box motif within the carboxy-terminus 
region of the scaffold protein INCENP, and this interaction partially activates the 
kinase due to AurKB-activation loop changes. Yet, fully active AurKB is obtained 
only through the AurKB-dependent phosphorylation of an INCENP-transcription 
start site (TSS) motif, which possibly induces another conformational change 
within AurKB catalytic region (Sessa et al., 2005).  
  The CPC complex, besides AurKB and INCENP, includes the non-
enzymatic subunits Borealin and Survivin, These two proteins are essential for 
proper AurKB localization during mitosis and they bind to INCENP amino-terminal 
(van der Horst and Lens, 2014). Indeed, mitotic-centromeric localization and 
function of CPC, and therefore of AurKB, depends on several phosphorylation 
feedback loops that generate docking points for Survivin and Borealin (van der 
Horst and Lens, 2014). So, the predominant theory is that Survivin and Borealin 
activates AurKB and guide the kinase to its different locations to facilitate the 
AurKB-mitotic substrates phosphorylation, and thus the AurKB-dependent 
functions (Carmena et al., 2012b).  
AurKB localization and function on the inner centromere depends on the 
interaction between Survivin and Borealin with INCENP during (pro)metaphase 
(Klein et al., 2006; van der Horst and Lens, 2014; van der Waal et al., 2012; Wang 
et al., 2010). Survivin interacts with H3T3 phosphorylated, by Haspin and maybe 
by VRK1, and Borealin binds via Sgo1 and Sgo2 to H2AT120 phosphorylated, by 
Bub1 (Kang et al., 2007b; Valbuena et al., 2011b; van der Waal et al., 2012; 
Wang et al., 2010; Wang et al., 2011). Altogether, VRK1, Haspin and Bub1 
control AurKB localization and activity though direct histone phosphorylation. 
These phosphorylation mechanisms are in turn regulated by AurKB, generating 




The phosphorylation of H3T3, by Haspin and possibly by VRK1, occurs in 
early mitosis and targets AurKB to locate in inner centromeres (Figure 12) (Kang 
et al., 2007b; Valbuena et al., 2011b; Wang et al., 2010). Nonetheless, the ability 
of Haspin to phosphorylate H3T3 is regulated by AurKB due to direct 
phosphorylation on various Ser and Thr residues (Wang et al., 2011). In fact, site 
directed mutation of these residues or AurKB inhibition strongly decreases 
H3T3ph, suggesting that AurKB regulates its own centromeric accumulation 
though Haspin regulation (Wang et al., 2011).  
 
Figure 12 – Feedback loop targeting AurKB to inner centromere. The regulation loop 
involves the kinases AurKB, Haspin and potentially VRK1. 
Moreover, AurKB regulates H3T3ph through Repo-Man Ser893 
phosphorylation. PP1 (Protein Phosphatase 1) γ-Repo-Man phosphatase 
complex dephosphorylates H3T3ph and this activity is important to sustain 
H3T3ph restricted to the centromeres in (pro) metaphase (Qian et al., 2011). 
Therefore, AurKB activity regulates Repo-Man, by phosphorylation, avoiding its 
chromosomal targeting and allowing H3T3ph in the first place (Qian et al., 2011). 
To notice, that Repo-Man also interacts with PP2A, and this phosphatase 
dephosphorylates Repo-Man Ser893 phosphorylation (Qian et al., 2013). 
Instead, there is scant information about a possible feedback loop regulating 
AurKB/ CPC localization and activity involving VRK1 and AurKB. Yet, the fact that 
















centromeric accumulation of AurKB/ CPC (Figure 9) (Kang et al., 2007b; 
Valbuena et al., 2011b).  
On the other hand, Bub1 kinase phosphorylates histone H2AT120, 
through an unknown regulatory mechanism. Yet, some data point to a possible 
feedback loop between Bub1 and AurKB via ATM.  ATM phosphorylates Bub1 
and supports Bub1-dependent H2AT120 phosphorylation during mitosis. This 
phosphorylation recruits Sgo1, which interacts with Borealin and consequently 
targets AurKB/ CPC to accumulate on the centromeres. Moreover, ATM is 
phosphorylated in mitosis by AurKB on the Ser1403 residue and this 
phosphorylation is important to activate ATM. Mitotic activity of ATM is 
independent of ATM-DNA damage activity. Altogether, these results suggest a 
potential loop involving the three kinases (Bihani and Hinds, 2011; van der Waal 
et al., 2012; Yang et al., 2011). Additionally, kinetochore localization of Bub1 is 
also essential for the H2AT120ph and relies on Mps1 activity not only in yeast but 
also in human cells. Mps1 is regulated by AurKB direct phosphorylation (van der 
Horst and Lens, 2014; Yamagishi et al., 2010). Thus, Mps1 is phosphorylated by 
AurKB and phosphorylates the kinetochore-null protein 1 (Knl1), enhancing the 
binding between Bub1 and Knl1. Then, Bub1 on the kinetochores phosphorylates 
H2AT120 and leads to CPC accumulation on the inner centromeres via Sgo1-
Borealin interaction (van der Waal et al., 2012). Besides, also Plk1 seems to 
regulate AurKB localization and activity. Plk1 phosphorylates the Ser20 in 
Survivin and this phosphorylation seems to be relevant for proper activation of 
AurKB. Plk1 inhibition prevents AurKB activation and correct kinetochore-
microtubule attachment (Chu et al., 2011). Instead, AurKB phosphorylates the 
Thr210 in Plk1 at centromere in early mitosis, activating the late kinase, and 
generating another feedback loop that enhances inner centromere localization 
and activity of CPC (Carmena et al., 2014; Carmena et al., 2012a).  
5. Pluripotency reprogramming factors 
 The study of embryonic stem cells (ESCs) led to the discovery of induced 
pluripotent stem cells (iPSCs). ESCs can grow indefinitely, maintaining 
pluripotency, high proliferation potential, and the capability to differentiate in all 




treat numerous disorders such as Alzheimer’s and Parkinson’s diseases or 
diabetes (Isobe et al., 2015). However, mostly due to ethical complications 
regarding the use of human embryos, the induction of pluripotent cells directly 
form the patient cells, became necessary.  
Somatic cells can be reprogrammed, not only transferring their nuclear 
content into oocytes, but also by fusion with ESCs (Kim et al., 2009; Takahashi 
and Yamanaka, 2006). This indicates that both unfertilized eggs and ESCs hold 
factors that can convert a somatic cell into a pluripotent cell. Based on this fact, 
Takahashi and Yamanaka discovered that the introduction of four defined 
transcriptional factors, critical in the maintenance of ESC identity, could 
reprogram somatic cells into iPSCs. These factors are known as OSKM and 
include: Oct4 (octamer-binding transcription factor 4), Sox2, Klf4 (Kruppel-like 
factor 4) and c-Myc (Takahashi and Yamanaka, 2006). Previous evidence 
showed that other set of transcriptional factors (Sox2, Oct4, Nanog and Lin28) 
convert somatic cells into iPSCs (Yu et al., 2007) and nowadays it is known that 
the OSKM factors can be replaced by others functionally divergent factors and 
delivered by different systems (Kim et al., 2009; Soufi, 2014). OSKM factors are 
expressed in the early phases of development and are especially intriguing since 
Oct4, Sox2 and Klf4 can bind to DNA, engaging silent chromatin at distal 
enhancers and triggering gene activation, early in reprogramming (Gao et al., 
2013). c-Myc, however, is not able to access closed chromatin (Zaret and Carroll, 
2011). Reprogramming is accompanied by dynamic epigenetic modifications, 
essential for chromatin remodelling. This capacity of reprogramming factors is 
quite important, allowing the cell to adapt different chromatin states in alternative 
cell types. Likewise, it is also important to notice that OSKM factor can also 
interact between them. An example is the Oct4-Sox2 interaction, which seems 
important in terms of self-renewal, pluripotency and somatic cell reprogramming 
in mouse ESCs (Ding et al., 2012; van den Berg et al., 2010).  
Nonetheless, reprogramming factors, such as c-Myc, Klf4, Nanog, Oct4 
and Sox2 have also been associated with cancer development, mostly when 
these are overexpressed. These factors are vital players on transformation, 
tumorigenesis, tumour metastasis and tumour proliferation, but the precise 
underlying mechanisms are yet poorly understood. Moreover, reprogramming 




sustain tumour growth and resistance to conventional cancer therapy while 
exhibiting the ability to self-renew as well as give rise to differentiated tissue cells. 
CSCs may be related to the origin of cancer (Amini et al., 2014; Huang et al., 
2014; Iv Santaliz-Ruiz et al., 2014; Li et al., 2012a; Liu et al., 2013a; Tan et al., 
2006; Wang et al., 2014a; Yu et al., 2015).  
5.1 The transcriptional factor Sox2 
The SOX2 gene was first discovered and characterized in humans in 1994. 
Sox2 belongs to the Sox (Sry-related HMG box) family of transcriptional factors, 
which are important in embryonic development and stem cell biology. Sry gene 
is located in the sex-determining region on the chromosome Y and is the 
mammalian testis-determining factor. This gene contains a peculiar high-mobility 
group (HMG) domain, essential for DNA recognition and binding. All the proteins 
containing a HMG domain with an amino acid motif 50% similar to the HMG 
domain of Sry are included in the Sox family (Gubbay et al., 1990; Sarkar and 
Hochedlinger, 2013; Sinclair et al., 1990). The Sox2 HMG domain recognizes 
DNA through the consensus sequence A/TA/TCAAAG (Bowles et al., 2000; 
Chambers and Tomlinson, 2009). Nonetheless, even if it is known that Sox2 
binds to and activates numerous promoters like CCND1 or Baculoviral IAP 
Repeat Containing 5 (BIRC5) (Lin et al., 2012; Wu et al., 2012), it seems to be a 
relatively weak/ moderate activator of cellular transcription by itself. Accordingly, 
Sox2 associates with several others transcriptional factors in the activation of 
specific targets, like in the transcriptional activation of NANOG gene, in human 
ESCs, alongside with Oct4 (Kuroda et al., 2005). In cellular differentiation, Sox2 
marks the immature cells of the early neuroepithelium and although the 
transcriptional factor is lost as cells differentiate, it is retained in adult neural stem 
cells (Fauquier et al., 2008). Similar observations were obtained in mouse cortex 
(Hagey and Muhr, 2014). 
The SOX2 gene is located on the chromosome 3q26.3-q27 and encodes 
a 317 amino acids protein belonging to the SoxB1 group of proteins. Sox2 
proteins contain three main domains. The N-terminal (residues 1-40), containing 
a poly-glycine domain and the HMG domain (resides 41-109), which is fairly 
conserved between species and serves as potential binding site for protein 




fact elucidates an important mechanism for Sox2 regulation. Moreover, Sox2 
contains a transactivation domain (residues 110-317) that binds to promoters, 
activating or repressing target genes (Figure 13) (Collignon et al., 1996; Fang et 
al., 2011a).  
 
Figure 13 – The structure of Sox2 protein. The HMG domain is quite conserved 
between Homo sapiens, Mus musculus and Danio reri.  
Besides its role in stem cell maintenance and cellular reprogramming, 
Sox2 has been also associated with anophthalmia-esophageal genital (AEG) 
syndrome that occurs in the presence of heterozygous mutations of SOX2. These 
mutations lead to abnormal development of ectodermal and endodermal tissues 
(Williamson et al., 2006). Additionally, Sox2 has been also shown to be strongly 
associated with numerous cancer types, acting in some cases as an oncogene, 
controlling the oncogenic signalling and promoting and maintaining CSCs (Liu et 
al., 2013c; Sarkar and Hochedlinger, 2013). CSCs overexpressing stem cell 
markers such as Sox2 are a critical attribute of tumours, providing resistance to 
therapy (Piva et al., 2014; Rothenberg et al., 2015). 
5.2 Sox2 amplification in cancer 
  A particular feature observed in several cancer types, such as 
glioblastoma, lung cancer, and others is the amplification of SOX2 3q26.3 gene 
locus, which leads to an increased number of copies of the Sox2 gene (Hussenet 
et al., 2010; Weina and Utikal, 2014). Such genetic aberrations can alter the 
progression of normal cell cycle, which could culminate in tumour development. 
Indeed, comparative genomic hybridization arrays showed that Sox2 was 
amplified in lung squamous cell carcinomas (LSCCs) and regulated genes 
involved in tumour formation, proliferation, cell migration, and cell growth 
(Hussenet et al., 2010). In addition, several others genes have been described to 








3q26, of the oncogene PRKC1 (protein kinase C iota type) alongside with SOX2 
that determine the stem cell phenotype observed in lung squamous cell 
carcinoma (Justilien et al., 2014). In some cases, Sox2 amplification could be due 
to aberrant Sox2 transcription (Sox2 regulation at transcriptional level) generated 
by chromosome instability (Liu et al., 2013c).  
Sox2 has been also reported to be overexpressed in many other cancer 
types like breast and colorectal cancer or even in ES or osteosarcoma. However, 
in these cases the overexpression of Sox2 is not related with gene amplification, 
indicating that the aberrant Sox2 expression is due to unidentified mechanisms 
(Basu-Roy et al., 2012; Leis et al., 2012; Lengerke et al., 2011; Lundberg et al., 
2014; Riggi et al., 2010). The overexpression of Sox2 in various cancer types 
may indicate that reactivation of this transcriptional factor is an early step in 
tumour initiation since normal differentiated tissue present residual levels of Sox2. 
5.3 Regulation of Sox2 
The regulation of Sox2 could occur not only transcriptionally, but also due 
to translational and post-translational modifications. At the transcriptional level, 
even if Sox2 is overexpressed, mostly due to gene amplification, only one 
transcript occurs after Sox2 expression. In turn, in somatic cells, macroH2A 
regulates the expression of Sox2. MacroH2A isoforms are structural components 
of the repressed chromatin of pluripotency genes, such as Sox2, acting as an 
epigenetic barrier to pluripotency induction. Indeed, chromatin 
immunoprecipitation (ChIP) studies revealed that the macroH2A.1 isoform was 
greatly enriched in the chromatin of SOX2 regulatory regions in mouse embryonic 
fibroblasts but not in adult neural stem cells, where this gene is highly expressed. 
The removal of macroH2A.1, macroH2A.2 or both increased the efficiency of 
pluripotency induction up to 25-fold, with reactivation of pluripotent genes 
(Pasque et al., 2012). Likewise, loss of macroH2A1 in ESCs resulted in the 
incomplete inactivation of pluripotent genes encoding key regulatory transcription 
factors such as Sox2, alongside with reduced or delayed activation of 
differentiation genes (Creppe et al., 2012a). Besides, the incorporation of 
macroH2A isoforms in the chromatin directly regulates the transcriptional activity 




Besides, Sox2 expression can be regulated by different signalling 
pathways, as occur in osteoblasts, where the expression of Sox2 is induced by 
fibroblast growth factor (FGF), inhibiting the Wnt signalling (Mansukhani et al., 
2005). Also, the EWS-FLI1 protein, associated with the majority of ES cases and 
believed to be the initiation factor, induces the expression of stem cell markers, 
including Sox2, in mesenchymal stem cells (MSCs). As for VRK1, EWS-FLI1 
opens the chromatin and creates de novo enhancers, which physically interact 
and activate the promoter of Sox2. Besides the direct effect on Sox2 promoter 
activation, EWS-FlI1 represses the promoter of miRNA-145, which is a repressor 
of Sox2, further enhancing the levels of the transcription factor (Riggi et al., 2014; 
Riggi et al., 2010; Xu et al., 2009).  
Sox2 can also be inhibited by microRNAs, such as microRNA-126 (miR-
126) and again by miRNA-145 at translational level (Riggi et al., 2010; Xu et al., 
2009; Zhao et al., 2015). This last miRNA presents low levels in self-renewing 
human ESCs, and increases considerably during differentiation. Besides, 
pluripotency factors OCT4, SOX2, and KLF4 are direct targets of miR-145, which 
represses the 3' untranslated regions of OCT4, SOX2, and KLF4. Thus, this 
suggests that this specific miRNA can inhibit the self-renewal process of human 
ESCs, and direct repress pluripotency genes such as SOX2 and OCT4 and, 
therefore promote lineage-restricted differentiation (Xu et al., 2009). Moreover, 
Sox2 is also regulated by post-translational modifications, for instance 
phosphorylation, methylation, SUMOylation, acetylation and ubiquitination. In 
summary, these post-translational modifications interfere with Sox2 stability and 
localization and consequently enhance or block it transcriptional activity (Jeong 
et al., 2010; Mao et al., 2015; Ouyang et al., 2015). 
5.4 The contribution of Sox2 to cancer 
 Sox2 has been implicated, through numerous cellular pathways, in several 
hallmarks of cancer such as in cell proliferation and self-renewal of CSCs (Basu-
Roy et al., 2012; Chen et al., 2008a; Chou et al., 2013; Fang et al., 2014; Fang 
et al., 2011b; Hutz et al., 2014; Lin et al., 2012), cell invasion, migration and 
metastasis (Fang et al., 2014; Han et al., 2012; Li et al., 2013; Singh et al., 2012; 
Xiang et al., 2011; Yang et al., 2014), or even cell survival and chemoresistance 




Lin et al., 2012; Rothenberg et al., 2015). Some of the mechanisms underlying 
the role of Sox2 in such events will be explained in the following paragraphs. 
 
Figure 14 – Implication of Sox2 in cancer. Sox2 overexpression regulates many 
processes of cancerous cells (adapted from (Liu et al., 2013c)).  
 Cellular proliferation is strongly regulated by Sox2 in many cancer types 
and numerous publications ascertain the role of Sox2 in this process. For 
example, in pancreatic and gastric cancer, Sox2 knockdown caused cell growth 
inhibition, inducing cell cycle arrest, due to the transcriptional activation of p21 
and p27, whereas Sox2 overexpression induced S-phase entry and cell 
proliferation through CCND3 gene transcriptional activation (Herreros-Villanueva 
et al., 2013; Hutz et al., 2014). In fact, negative regulators of CDKs, such as the 
Kip/ Cip proteins that inhibit most cyclin-CDK complexes, seem to have a tight 
relationship with Sox2 and Sox2-dependent regulatory mechanisms. For 
instance, p27 levels seem to be relevant for SOX2 gene repression in mice 
models. Cells and tissues from p27 null mice, showed elevated levels of Sox2 
and failed to repress Sox2 under differentiation stimuli. The negative regulator 
p27 binds, along with a complex of p130-E2F4-SIN3A, to the SRR2 enhancer of 
the SOX2 gene under differentiation and represses gene transcription (Li et al., 
2012b). Similarly, treatment of the embryonal carcinoma cell line NTERA-2/ clone 
D1 (NT2/D1) with all-trans retinoic acid (RA) induces cell growth arrest and neural 














degradation by the ubiquitin/ proteasome-dependent pathway, resulting in 
increased association of this protein with cyclin E/ Cdk2 complexes and 
suppression of their activity (Baldassarre et al., 2000). NT2-RA-dependent 
increase in p27 expression occurs inversely to Sox2, Oct4, Nanog, cyclin D1, 
Vimentin and Nestin downregulation and in parallel with upregulated levels of 
Pax6, Tau, βIII-Tubulin and Synapsin (Figure 15) (Kakhki et al., 2013; Megiorni 
et al., 2005; Pleasure and Lee, 1993; Podrygajlo et al., 2009; Spinella et al., 
1999). Besides, it was also reported that NT2-RA-treatment activates p53, 
independently of the protein levels, contributing to NT2 RA-mediated G1 arrest 
(Curtin et al., 2001).  
 
Figure 15 – NT2 cell line downregulated and upregulated proteins, upon retinoic 
acid (RA) differentiation. RA enhances cell cycle arrest and expression of protein 
associated with cell differentiation, over proliferation-related proteins. 
 Moreover, in LSCC, Sox2 downregulation induced the expression of the 
downstream target bone morphogenetic protein 4 (BMP4), causing cell 
proliferation inhibition. BMP4 is repressed by Sox2, as proved by ChIP analysis 
and luciferase assay, and reactivation of BMP4 signaling, upon Sox2 silencing, 
could partially induce cell cycle arrest as observed in cell-based experiments 
(Fang et al., 2014). Knockdown of Sox2 had been reported to reduce cell 
proliferation in many other cancer types such as glioblastoma (Fang et al., 2011b) 
and breast cancer (Stolzenburg et al., 2012). 
Furthermore, Sox2 also contributes to maintain a less cellular 
differentiated state and the stemness characteristics of CSCs. For instance, Sox2 
is required to maintain self-renewal proprieties of CSCs in osteosarcoma and 
antagonizes the pro-differentiation Wnt pathway. Sox2 depletion results in 
increased expression of cell cycle inhibitor p16 and p27 and in the activation of 



















lineage commitment and maturation. Consistently, Sox2 depleted cells fail to form 
osteo-spheres and tumors in murine xenografts (Basu-Roy et al., 2012). 
Recently, it was reported that Sox2 antagonizes also the Hippo pathway to 
maintain CSCs in osteosarcoma (Basu-Roy et al., 2015). These results indicate 
that Sox2 play a critical role in maintain a self-renewing state in tumors of 
mesenchymal origin, just as observed in ES (Riggi et al., 2010). Besides 
osteosarcoma and Ewing sarcoma, the antagonizing effect of the Wnt pathway 
on Sox2 levels and in CSCs self-renewal was also described in nasopharyngeal 
carcinoma (Chan et al., 2015).  
Contrariwise, it was reported that Sox2 can activate and act synergistically 
with the Wnt signalling-related protein β-catenin, promoting cell proliferation. In 
breast cancer, both proteins act together in the transcriptional activation of 
CCND1 gene, facilitating G1/ S-phase transition and cell proliferation (Chen et 
al., 2008a). This same observation was reported in detail in colorectal cancer. 
Sox2 could reduce the expression of E-cadherin at plasma membranes, and 
therefore decrease the binding of β-catenin with of the adhesion complexes. 
Consequently, β-catenin is recruited to the nucleus by Wnt signalling components 
and activates downstream targets of the Wnt pathway such as c-Myc and cyclin 
D1. The activation of the Wnt pathway by Sox2 facilitated the epithelial-
mesenchymal transition (EMT) process (Han et al., 2012).  
Curiously, in colorectal cancer some reports showed that Sox2 is 
implicated in cell proliferation, while others reject the involvement of Sox2 in the 
proliferative process. While Sox2 knockdown, in SW620 colorectal cancer cell 
line, decreased their growth rates in vitro, and in vivo xenograft models, the 
overexpression of Sox2 significantly inhibited the proliferation of colorectal 
adenocarcinoma cells HT-29, SW480 and LoVo (Fang et al., 2010; Liu et al., 
2013b). These contradictory results may be due to the fact that were used distinct 
colorectal cancer cell lines or due to different experimental conditions.  
 On the other hand, Sox2 was also implicated as a new regulator of cell 
invasion, migration and metastasis. In colorectal cancer, Sox2 mediates invasion 
and migration, in vitro, through matrix metalloproteinase-2 (MMP-2) activity (Han 
et al., 2012). Similarly, in melanoma, the downregulation of Sox2 resulted in 
decreased invasion in vitro, but in this case via metalloprotenase-3 (MMP-3) 




also confirmed in glioma, where Sox2 downregulation decrease migration and 
the overexpression of the transcriptional factor increases the number of migratory 
and invasive cells (Girouard et al., 2012), in laryngeal cancer, where Sox2 
promotes invasion via PIK3/ Akt/ mTOR and MMP-2 activation (Yang et al., 
2014), in ovarian cancer, through Src kinase activity (Wang et al., 2014b)  and, 
in breast and prostate cancer, where it promotes metastasis through CTNNB1 
promoter activation and consequently by triggering EMT via Wnt/ β-catenin 
pathway (Li et al., 2013).  
 Sox2 is also an important player in cell survival pathways. For instance, in 
prostate cancer, Sox2 overexpression increases apoptotic resistance, in in vitro 
and in vivo experiments, due to the repression of ORAI1 (Jia et al., 2011). 
Moreover, in non-small cell lung carcinoma (NSCLC), Sox2 is also implicated in 
cell surviving, since its knockdown induces apoptosis via mitogen-activated 
protein kinase kinase kinase kinase 4 (MAP4K4) activation with increased 
expression of tumor necrosis factor-α (TNF-α) and p53, and loss of Survivin. 
Upon activation, MAPK4K translocates from the cytoplasm to the nucleus and 
activates some transcriptional factors such as, c-Myc, c-Jun and c-Fos to regulate 
the expression of key apoptosis-related proteins, such as TNF-α, p53 and 
Survivin (Chen et al., 2014). Inquiringly, Sox2 was also implicated in the activation 
of Survivin and the mitochondria-dependent apoptotic pathway inhibition in neural 
stem cells. This could indicate the existence of conserved regulatory mechanisms 
between cancer and neurological diseases (Feng et al., 2013)  In addition, Sox2 
downregulation has been reported to induce apoptosis in several other cancer 











































































In this work we hypothesize that VRK1 participates in the regulation of cell 
proliferation, via two new and independent mechanisms. One by actively 
regulating AurKB and the other by regulating the balance between cell 
proliferation and cell differentiation.  
 
Aims 
Therefore this work was sub-divided into two main aims:  
1) To characterize the role of the human kinase VRK1 in the control of the AurKB 
mitotic localization and activity; 
2) To analyze the implication of the reprogramming transcriptional factor Sox2 in 









































































1. Cell Lines  
The cell lines used in this work and the respective culture medium used 
for the correct growth are represented in the Table II. Briefly, human embryonic 
kidney HEK293T, human cervix adenocarcinoma HeLa, human breast 
adenocarcinoma MCF7 and MDA-MB-231, human bone osteosarcoma U2OS 
and, human pluripotent embryonal carcinoma NT2/D1 (shortly abbreviated to 
NT2) cell lines were cultured in Dulbecco’s modified Eagle’s-low glucose (DMEM) 
medium (Sigma-Aldrich; St-Louis, MO, USA), with 10% fetal bovine serum (FBS) 
(Gibco® - Life Technologies-Invitrogen; Paisley, UK), 2mM L-glutamine, both the 
antibiotics penicillin (50units/mL) and streptomycin (50μg/mL) (Gibco®) and 
ciprofloxacin Kabi (10μg/mL) (Fresenius SE; Hesse, Germany). Human lung 
carcinoma A549 and human non-small cell lung carcinoma H1299 cell lines were 
cultured in Roswell Park Memorial Institute (RPMI) medium (Gibco®) 
supplemented with 10% FBS (Gibco®), 2mM L-glutamine (Gibco®), both the 
antibiotics penicillin (50units/mL) and streptomycin (50μg/mL) (Gibco®) and 
ciprofloxacin Kabi (10μg/mL) (Fresenius SE; Hesse, Germany). All the cell lines 
were cultured in culture treated flasks (BD FalconTM - BD Biosciences; San Jose, 
CA, USA) in an incubator at 37ºC, 5% CO2 and 98% of relative humidity.  
The process of collecting the cells from the culture flasks was performed 
with trypsin-ethylenediaminetetraacetic acid (EDTA) (Gibco®), or with TrypLETM 
express stable trypsin replacement reagent (Gibco®). This reagent is free of 
animal/ human derived components allowing a fast and effective cell harvesting 
without harm the cells or affecting intracellular pathways. Normally, the cell lines, 
after being harvested, were plated, accordingly with the experiment, in 10mm, 
15mm or 20mm Style cell culture dishes. All the cell culture dishes were 
purchased from BD FalconTM - BD Biosciences. 
All the different cell lines were examined in an inverted microscope Zeiss 
Axiovert 25 (Carl Zeiss AG; Jena, Germany).  




Table II – Cell lines 
Cell Lines 
Cell Line   Organism      Tissue       Characteristics Medium 
A549 Human Lung carcinoma  RPMI   
10% FBS 
H1299 Human Non-small cell lung 
carcinoma 
p53-deficient RPMI   
10% FBS 
HEK-293T Human Embryonic kidney Express SV40 
large antigen 
DMEM   
10% FBS 
HeLa Human Cervix carcinoma HPV-18 
transformed 
DMEM   
10% FBS 
MCF7 Human Breast carcinoma Luminal-type cell 
line 
DMEM   
10% FBS 
MDA-MB-231 Human Breast carcinoma Basal-type cell 
line 
DMEM   
10% FBS 
NTera-2 cd.D1 Human Pluripotent 
embryonal carcinoma 
 DMEM   
10% FBS 
U2OS Human Bone osteosarcoma  DMEM   
10% FBS 
All the cell lines were cultured in the respective culture medium in normal conditions at 37ºC, 5% 
CO2 and 98% relative humidity.    
2. DNA-related assays 
2.1 Extraction and purification of DNA plasmid from Escherichia coli 
The alkaline lysis technique described in 1979, by Birnboim and Doly 
(Birnboim and Doly, 1979), was used to obtain deoxyribonucleic acid (DNA) 
plasmid from Escherichia coli (E. coli). In this method, the plasmids are attained 
after the E. coli lysis, together with the chromosomal DNA and protein 
denaturation. A process that depends on the alkalization of the bacteria with 
NaOH (sodium hydroxide) in the presence of the anionic detergent SDS (sodium 
dodecyl sulfate).  
The extraction of high-purity DNA plasmid was performed using with the 
classic method of phenol-chloroform extraction, in which the proteins were 




eliminated by a series of washings with phenol-chloroform and the DNA plasmid 
was precipitated with ethanol. Normally, the extraction of small-scale DNA 
plasmid (mini-prep) was performed using the commercial kit NucleoSpin® plasmid 
(MACHEREY-NAGEL; Dueren, Germany) following the company protocol. 
Briefly, saturated E. coli were pelleted in a microcentrifuge (Eppendorf; Hamburg, 
Germany) at 11000xg during 30s, discarding the supernatant. Next, the cells 
were lysed at room temperature (RT) and the cell lysate clarified by centrifugation 
at 11000xg during 5min. Next, the supernatant was decanted on a column with a 
silica membrane to bind the DNA (1min at 11000xg), washed twice (2min at 
11000xg) and eluted in Tris-EDTA (TE) buffer solution (1min at 11000xg). On the 
other hand, the extraction of large-scale DNA plasmid (maxi-prep) was performed 
using the commercial kit JETStar Plasmid Purification System (Genomed; Löhne, 
Germany), adapted from the manufacturer’s protocol. Initially, the E. coli were 
pelleted in an AvantiTM J-25 centrifuge (Beckman Coulter, Inc.; Pasadena, CA, 
USA), at 2500xg during 8min. Next, the cells were lysed at RT, neutralized and 
centrifuged at 12000xg for 10min. After loading the supernatant in a column, the 
column was washed once, and the DNA plasmid eluted. Then, the plasmid was 
precipitated with isopropanol (12000xg for 30min) and washed with ethanol 70% 
(12000xg for 15min). After that, the pellet was air dried around 10min and eluted 
in TE buffer solution.  
2.2 Quantification of DNA plasmid  
 The final concentration of extracted and purified DNA plasmid was 
quantified by measuring the absorbance of each sample at 260nm, in one Hitachi 
U-2001 spectrophotometer (Hitachi High-Tech; Tokyo, Japan). In order to 
calculate the purity of DNA both the A260/280 and A260/230 absorbance ratios were 
taken into account. These two ratios should rank between 1.8 and 2.0, and if not, 
lower A260/280 ratio indicates probably contamination by chemical compounds 
such as phenol, which is commonly used to purify the DNA or in a low-scale by 
proteins. In turn, lower A260/230 ratio indicates probably contamination by 
phenolate ion, thiocyanates and other organic compounds found in some of the 
solutions used to extract and purify the DNA. Ratios below 1.7 were not accepted 
and the extraction and purification protocols were repeated. Later, the DNA 
concentration was confirmed by electrophoresis in 1% agarose gel.   
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2.3 Agarose gel electrophoresis 
 The DNA fragments were separated by electrophoresis, accordingly with 
their size and charge (due to the phosphate groups present in the DNA), in an 
agarose gel/ 1% TAE buffer (40mM Tris-acetate, pH 8.0 and 1mM EDTA). This 
buffer maintains the pH close to 8.0 during the electrophoresis, which is important 
since the DNA migration on the agarose gel depends on the DNA phosphate-
negative charge and on the charged-ions present in the medium. Since DNA is 
negative-charged it migrates to the positive pole when submitted to an electrical 
field.  
The visualization of the DNA fragments, in the agarose gel, was attained 
using ethidium bromide (0.5μg/ml), diluted in the electrophoresis buffer. Ethidium 
bromide is an agent that intercalates into the nitrogenous bases of the DNA and 
emits fluorescence when exposed to UV light. Then, the fluorescence emitted by 
the DNA fragments can be visualized and captured through a digital camera 
attached to the Gel Doc TM analyzer (Bio-Rad; Hercules, CA, USA). The results 
were impressed in thermal paper. Furthermore, it was used a molecular-weight 
size marker, the DNA ladder 1Kb (Promega; Madison, WI, USA), which facilitates 
the determination of the size of the different fragments captured with the analyzer 
from Bio-Rad.  
2.4 Recombinant DNA and cloning 
 Recombinant DNA was obtained through the insertion of a specific coding 
DNA sequence (CDS) into a cloning vector. Usually, these CDSs were attained 
by PCR followed by the digestion of DNA fragments with restriction endonuclease 
enzyme(s) (Fermentas – Thermo Scientific; Ontario, Canada) or by digesting 
directly the CDS from another cloning vector. Meanwhile, the cloning vector was 
also digested with the same restriction endonuclease enzyme(s) used on the 
CDS digestion and dephosphorylated with the Calf intestinal (CIP) alkaline 
phosphatase (New England Biolabs, Inc.; Ipswich, MA, USA), to avoid re-ligation 
of the vector. All the restriction digestions were performed accordingly with the 
web tool DoubleDigest (Thermo Scientific; Waltham, MA, USA) and the primers 
used on the cloning process are represented on Table II. Thereafter, the digested 
CDS and the digested and dephosphorylated vector were ligated with the enzyme 




T4 DNA-ligase (Promega), overnight (ON) at 14ºC on a thermocycler (Bio-Rad). 
Next, the constructions were transformed in competent E. coli bacteria (DH5α or 
BL21DE3), plated on LB (Lysogeny Broth) medium with ampicillin (10μg/mL) or 
kanamycin (25μg/mL), in conformity with the cloning vector resistance, and 
incubated ON at 37ºC. Since the vector had a specific resistance against one 
antibiotic, only the E. coli incorporating the cloning vector grew on the LB petri 
dish. Afterward, the DNA was extracted and purified by mini-prep, and the vector-
CDS constructions analyzed by enzymatic digestion and DNA sequencing. The 
alignment of the DNA sequencings was performed with both Chromas 
(Technelysium Pty, Lda; South Brisbane, Australia) and DS-Gene (Accelrys, Inc.; 
San Diego, CA, USA) software.   
2.5 Escherichia coli transformation 
 The recombinant DNA, as described in the chapter 2.4, was transformed 
in competent E. coli bacteria, such as DH5α or BL21DE3. The first strain (DH5α) 
is usually used to express DNA plasmid, and the second one (BL21DE3) used to 
express recombinant proteins. The transformation was performed through the 
heat shock method.  
Briefly, a small amount of DNA (50-100ng) was added to the thawed 
bacteria strain, mixing homogenously and left incubating on ice around 30min. 
Subsequently, the heat shock transformation was done at 42ºC during 1min in a 
bath, moving quickly the cell/ DNA mixture to ice again (2min incubation). Next, 
1mL of LB medium was added and the final cell/ DNA/ LB mixture grew at 37ºC 
on a shaking incubator between 45min to 60min. Later, the bacteria were plated 
in LB Petri dish with the specific antibiotic (ampicillin (10μg/mL) or kanamycin 
(25μg/mL)), in order to grow the bacteria expressing the resistance gene present 
in the cloning vector. The bacteria were incubated ON at 37ºC. Next day, the 
isolated colonies were picked to further analysis by enzymatic digestion and/or 
DNA sequencing. The positive colonies, expressing the recombinant DNA, were 
cryopreserved with sterile glycerol at 30% (v/v) (at -80ºC). 
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2.6 Site-directed mutagenesis 
 Site-directed mutagenesis was executed following the protocol from the 
commercial system ‘’QuickChange Site-Directed Mutagenesis’’ (Stratagene; La 
Jolla, CA, USA).  
Briefly, the PCR reaction was prepared using 20ng of DNA template, 
125ng of each primer with the mutagenesis site included (Table III), 0.2mM 
dNTPs (Hoffman- La Roche; Basel, Switzerland), buffer 1x (100mM KCl, 100mM 
(NH4)2SO4, 200mM Tris-HCl pH8.8, 20mM MgSO4, 1% Triton X-100, BSA 
1mg/mL) and 1 unit of Pfu turbo DNA polymerase (Stratagene) into a final volume 
of 50μl. Before adding the polymerase, the PCR reaction was incubated at 95ºC 
during 10min to denature the DNA strands. Subsequently to the addiction of the 
Pfu turbo DNA polymerase, the PCR was carried out during 16 cycles of: 
 0.5min at 95ºC (Denaturation) 
 1min at 55ºC (Annealing) 
 22min at 68ºC (Elongation).  
Table III – List of primers 
Primers 


























Amplify GAPDH for RT-
PCR 
GAPDH3’ ACCTAACTACATGGTTTACATGTT 
Amplify GAPDH for RT-
PCR 





Amplify macroH2A2 for RT-
PCR 
macroH2A2-R CGTTTCCGACTTGCCTTTGGTC 
Amplify macroH2A2 for RT-
PCR 
OCT4-F AAGCGATCAAGCAGCGACTAT Amplify OCT4 for RT-PCR 
OCT4-R GGAAAGGGACCGAGGAGTACA Amplify OCT4 for RT-PCR 
Pex2hVRK1F CCAACGAGCTGCAAAACC Amplify VRK1 for RT-PCR 
Pex2hVRK1R TGTCATGTAGACCAGACCCCC Amplify VRK1 for RT-PCR 
SOX2-F ACCTCTTCCTCCCACTCC Amplify SOX2 for RT-PCR 




Mutagenesis of Aurora B on 




Mutagenesis of Aurora B on 




Mutagenesis of VRK1 on 




Mutagenesis of VRK1 on 
Threonine 51 to Isoleucine 
*Used in phenotypic rescue 
 Subsequently to PCR, the DNA template was eliminated by the enzyme 
DpnI (Fermentas – Thermo Scientific), which cuts the methylated and 
hemimethylated DNA, but not the mutated copies, allowing the selection of the 
latter ones. As usual, the PCR product was transformed in E. coli DH5α, selecting 
the positive colonies through the specific antibiotic resistance, and the DNA 
extracted and purified with the kit NucleoSpin® plasmid (MACHEREY-NAGEL) as 
described in the chapter 2.1. To confirm the correct substitution of the nucleotide, 
the DNA was sequentiated and the results analyzed with Chromas (Technelysium 
Pty, Lda) and DS-Gene (Accelrys, Inc.) software. 
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2.7 Cell cycle analysis 
The propidium iodide (PI) staining was used for cell cycle analysis. PI 
molecule has the ability to intercalate the double helix of the DNA emitting self-
fluorescence that can be detected by fluorescence-activated cell sorting (FACS). 
These allows the rate-analysis of cell cycle stages (G0/G1; S-phase; G2/M). 
Initially, cells were seeded in 10mm Style cell culture dishes and incubated 
with the appropriated treatment. Then, cells were fixed in 70% ethanol (Sigma-
Aldrich) in 1x phosphate buffered saline (PBS) for 30min. After the removal of the 
fixation agent, through centrifugation, the cells were stained with a solution of 
0.5% PI (1mg/mL) (Sigma-Aldrich) and 0.5% RNAase (Sigma-Aldrich) in 1x PBS, 
in the absence of light for 1h. Finally, the cells were acquired (20000 events) in a 
FACSort Cytometer (Becton Dickinson; Franklin Lakes, NJ, USA) and the 
analysis of the results was performed using both Paint-a-Gate (Becton Dickinson; 
Franklin Lakes, NJ, USA) and ModFit softwares (Verity Software House; 
Topsham, ME, USA).    
3. RNA-related assays 
3.1 RNA extraction 
 The cells were seeded in 10mm Style cell culture dishes and 24h later they 
were submitted to the respective treatment or transfection. Then, the cells were 
scraped and the pellet was recovered to a 2ml eppendorf and centrifuged. The 
medium was carefully removed and the cell pellet was resuspended in 1ml of 
TRIzol® (InvitrogenTM – Life Technologies; Carlsbad, CA, USA), for 5min 
incubation. Next, the mixture was careful homogenized with chloroform (Merck; 
Whitehouse Station, NJ, United States of America) and after 2min of incubation 
at RT, the tubes were centrifuged at 4ºC at 13500xg during 15min. At this point 
three phases were distinguishable according to the particles that constitute it:  
 Upper aqueous phase of ribonucleic acid (RNA) 
 Middle white phase of DNA 
 Lower red phase of proteins. 
The upper-RNA phase was transferred to a new eppendorf and 2-propanol 
(Merck) was added to the mixture. Afterwards, the tubes were incubated for 




10min on ice and centrifuged at 4ºC, at 13500xg, during 10min. Finally, the 
supernatant was eliminated, 75% ethanol (Sigma-Aldrich) was added and after a 
5min centrifugation at 4ºC at 13500xg, the pellet was resuspended in RNase-free 
water (Qiagen; Venlo, Netherlands). 
3.2 RNA purification 
Purification of RNA was performed with the RNeasy® Mini Kit (Qiagen), 
following manufacturer’s instructions. Briefly, the extracted RNA was 
homogenized in lysis buffer complemented with β-mercaptoethanol (β-ME) 
(Sigma-Aldrich) and 100% ethanol (Sigma-Aldrich). Then, the complete volume 
was transferred to a RNA-purification column and centrifuged at 9350xg for 15s 
at RT. Next, the RNA was washed with distinct washing membrane-bound RNA 
buffers (9350xg for 15s at RT), through the RNA-purification column and finally, 
the RNA was eluted in RNase-free water (Qiagen).  
3.3 Evaluation of RNA quality 
 The RNA was quantified with the spectrophotometer NANOdrop 
(NanoDrop Technologies; Wilmington, DE, USA) and the 260nM/280nM and 
260/230nM ratios were analyzed in order to evaluate the quality of the RNA. 
Ideally, both ratios (A2660/A2880 and 260/230) should be near to 2.0. In those 
cases where ratio was lower than 1.7, the RNA was re-purified since it indicates 
that the sample may be contaminated with proteins and/ or organics compounds. 
3.4 Quantitative RT-PCR 
Quantitative reverse transcriptase-PCR (qRT-PCR) is a reliable and 
effective technique that allows the amplification and quantification of a particular 
RNA molecule. This system uses the activity of reverse transcriptase enzyme to 
transform RNA in DNA, which is amplified by PCR. The number of copies of the 
target oligonucleotide can be precisely quantified, at the beginning of the reaction, 
through the cycle threshold (Ct), that it is defined as the number of cycles required 
for the fluorescent signal to pass the threshold (i.e. exceeds the background 
level). Ct levels are inversely proportional to the amount of nucleic acid in the 
samples. Moreover, for qRT-PCR is necessary to have specific primers to amplify 
the precise fragment that we want to analyze the expression. The primers were 
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designed according to the sequences obtained in the PubMed database for each 
gene and taking into account that the amplicon should be around 90 to 110bps 
and the melting temperature (TM) must be of 60-61ºC. 
The qRT-PCR was prepared using 100ng of the purified RNA (diluted at 
50μg/μL), the primers designed for each target gene (Table II) and the 
commercial kit iScriptTM One-Step RT-PCR Kit With SYBR® Green (Bio-Rad) in 
a total volume of 25μL. The reaction was performed in one thermocycler iCycler 
(Bio-Rad) and the data analyzed using the BioRad iQ5 software (Bio-Rad), 
exporting the CT values, the mean CT values and the standard deviations to an 
excel file. The melting curve was examined to determine if only one clean peak 
per primer was observed.  
In each experiment, the RNA levels of each target gene were normalized 
to the RNA levels of the housekeeping gene glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), which was determined for each sample. The 
normalization of the values is essential to avoid high variability of results. 
4. Protein-related assays 
4.1 Purification of glutathione S-transferase fusion proteins 
 The expression and purification of glutathione S-Transferase (GST)-
tagged proteins, is a technique extremely useful to produce large amounts of 
protein, to use in a wide range of studies, including antigen and vaccine 
production, molecular immunology and structural, biochemical and cell biology 
studies. The expression and purification was obtained from E. coli Bl21DE3 
strain, which was previously transformed with a pGEX-4T-GST plasmid 
containing the protein to express. This plasmid has an inducible lac promoter that 
can be chemically activated by lactose or any lactose-analogue, such the 
isopropyl β-D-1-thiogalactopyranoside (IPTG). 
 Briefly, the bacteria expressing the GST-tagged proteins of interest were 
pre-incubated ON, at 37ºC, in LB medium with ampicillin (50μg/mL). Then, the 
pre-inoculum was diluted in fresh LB with ampicillin (1:10 dilution) and this dilution 
incubated at 37ºC under agitation, until achieve an optical density between 0.6-
0.8 (600nm). At this point the bacteria are in exponential growth and, it possible 
to induce the expression of the protein. The expression of the protein was 




accomplished with 0.2mM IPTG (Roche Applied Science), under agitation, at 
37ºC for 2 to 4h. Next, the bacteria culture was centrifuged at 4000xg, during 
10min, and the pellet resuspended in lysis buffer (1% triton x-100, 0.2μg/mL 
lyzosyme, 1mM phenylmethylsulfonyl fluoride (PMSF), 5mM dithiothreitol (DTT), 
10μg/mL aprotinin and 10μg/mL leupeptin in 1x PBS). The suspension was 
submitted to sonication using the sonicator Misonic XL2010 (Misonix Inc.; 
Farmingdale, NY, USA), performing 3 to 5 short ‘’10s’’ bursts, alternated with 
‘’10s’’ on ice. Subsequently, the suspension was incubated at 4ºC, for 30min and 
centrifuged, at 10000xg, for 30min.  
 At this point, all the soluble proteins and GST-tagged protein are in the 
supernatant. However, to confirm that in fact the protein of interest is present in 
the soluble fraction, it was collected an aliquot from the pellet and another from 
the supernatant, which were analyzed in one gel. Afterward, the soluble fraction 
was incubated ON, at low agitation, with the resin Glutathione Sepharose 4B 
beads (GE Healthcare; Buckinghamshire, UK), which has a high-affinity to the 
GST-tagged proteins. When the time of incubation was over, the resin was 
washed several times with 1x PBS with proteases inhibitors, at 400xg, during 
3min (4ºC), and the GST-tagged protein eluted from the resin with a solution of 
10mM glutathione reduced in 50mM Tris-HCl (pH 8.0), at 4ºC, during 4h to 12h 
in rotation. The eluted protein was separated from the resin by centrifugation, at 
400xg for 3min. In the end, the purification of GST-tagged protein was confirmed 
by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
followed by Coomassie blue staining or Western blot (WB). The protein levels 
were quantified by colorimetry, through the Bio-Rad protein assay (Bio-Rad), 
using bovine serum albumin (BSA) in order to build the standard curve.  
4.2 Protein extraction 
 The cells were scraped in cold 1x PBS and transferred to an eppendorf. 
After centrifugation, the PBS was removed, the pellet resuspended in lysis buffer, 
and the cell lysate incubated on ice, during 20min. Finally, the tubes were 
centrifuged for 20min at 16100xg (4ºC) and the pellet was removed.  
The protein extracts were obtained using two different lysis buffers: the 
Suave and the RIPA buffers. The lysis buffer Suave was prepared using 50mM 
Tris-HCl (pH 8.0), 1mM EDTA, 150mM NaCl and 1% triton X-100 in milliQ H2O 
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and the lysis buffer RIPA was prepared using 150mM NaCl (sodium chloride), 
1.5mM MgCl2 (magnesium chloride), 10mM NaF (sodium fluoride), 4mM EDTA, 
50mM Hepes, 1% triton X-100, 0.1% SDS and 10% glycerol in milliQ H2O. At the 
time of the lysis, the buffers were complemented with phosphatases inhibitors 
(1mM NaF and 1mM NaOv (sodium orthovanadate)) and proteases inhibitors 
(1mM PMSF, 10μg/mL aprotinin and 10μg/mL leupeptin). The cell lysates were 
always kept on ice.  
4.3 Acid extraction of histones 
 Histones were acid extracted, according to Shechter and colleagues 
protocol (Shechter et al., 2007). Briefly, culture cells (3 x 106 cells/ ml) were 
collected, pelleted and once washed with 1x PBS. Next, the cells were 
centrifuged (10min, 300xg) and the pellet lysed in a hypotonic lysis buffer (10mM 
Tris-HCl pH 8.0; 1mM KCl (potassium chloride); 1.5mM MgCl2; 1mM DTT, 
supplemented with proteases and phosphatases inhibitors) for 30min, at 4ºC, on 
rotation. Them, the intact nuclei were recovered by centrifugation, at 4ºC, (10min, 
10000xg), and after discard the supernatant with a pipette, they were re-
suspended very well in 0.4N H2SO4 (sulfuric acid) (Merck). If required, the 
samples were submitted to vortex until all the clumps were dissolved, and only at 
this time they were incubated ON with rotation, at 4ºC. Next day, the samples 
were centrifuged (10min, 16000xg), at 4ºC, to remove nuclear debris, and the 
supernatant, containing the histone fraction, was transferred to a new eppendorf.  
Subsequently, the histones were precipitated with trichloroacetic acid 
(TCA) (Merck), adding the acid drop by drop and mixing the solution gently by 
inversion, until a 33% final TCA concentration in solution. At this point, the 
solution seemed lightly milky and it was incubated on ice around 90min. Later, 
the histones were recovered by centrifugation, at 4ºC (10min, 16000xg), and the 
pellet-containing histones was carefully washed with ice-cold acetone (Merck), at 
4ºC (5min, 16000xg). Next, the supernatant was discarded with a pipette and the 
histone pellet air-dried, during 20 to 30min at RT. Finally, the histones were very 
well resuspended in milliQ H2O, quantified by Bradford protein assay and 5μg to 
7.5μg protein was boiled 5min at 100ºC, in sample buffer. The histones 
posttranslational modifications were analyzed by electrophoresis in 12.5% SDS-
PAGE for WB. 




4.4 High-salt extraction of histones 
 The high-salt extraction was performed following the protocol from 
Shechter and colleagues (Shechter et al., 2007). Initially, the culture cells were 
collected, pelleted and once washed with 1x PBS. Then, the cells were 
centrifuged (5 min, 6500xg), and lysed in an extraction buffer (10mM HEPES (pH 
7.9), 10mM KCl, 1.5mM MgCl2, 0.34M sucrose, 10% glycerol, 0.2% NP40, 1mM 
NaF and 1mM NaOv, 1mM PMSF, 10μg/mL aprotinin and 10μg/mL leupeptin in 
milliQ H2O), during 10min on ice. Then, the cell lysate was centrifuged, at 4ºC, 
during 5min (6500xg) and the pellet (nuclei) washed with extraction buffer 
(without NP40) and centrifuged, at 4ºC, for 5min (6500xg). Afterward, the nuclei 
were lysed with a no-salt buffer (3mM EDTA, 0.2mM ethylene glycol tetraacetic 
acid (EGTA), 1mM NaF and 1mM NaOv, 1mM PMSF, 10μg/mL aprotinin and 
10μg/mL leupeptin in milliQ H2O), during 30min at 4ºC with rotation. 
Subsequently, the chromatin was pelleted by micro-centrifugation, at 4ºC, for 
5min (6500xg) and lysed in a high-salt solubilization buffer (10mM Tris-HCl (pH 
8.0), 2.5M NaCl and 0.05% NP40 in milliQ H2O) for 30min with rotation, at 4ºC. 
Successively, the solution was centrifuged, at 4ºC, for 10min (16000xg) and the 
supernatant, containing the histones, was submitted to dialysis using a 16mm 
dialysis tubing (Serva; Heidelberg, Germany) during 2h and changing the dialysis 
medium (10mM Tris-HCl (pH 8.0) in 2L milliQ H2O) once. Finally, the histones 
extracts were quantified, by Bradford protein assay, and boiled 5min, at 100ºC, 
in sample buffer.  
4.5 Chromatin isolation by cell fractionation 
 The isolation of chromatin was executed following the method described 
by Wysocka and colleagues in 2001 (Wysocka et al., 2001) and using the 
commercial kit NE-PER nuclear and cytoplasmic extraction reagents (Thermo 
Scientific). The protocol was the following: the cells were harvested with 1xPBS, 
lysed with the cytoplasmic extraction buffer, provided by the kit, during 10min on 
ice, and the cytoplasm was separated from the nuclei by centrifugation (10min; 
16000xg). Next, the nuclei were lysed, during 40min on ice, with the nuclear 
extraction buffer, provided with the kit, and the nucleoplasm separated from the 
chromatin by centrifugation (10min; 16000xg). Then, the chromatin was 
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resuspended in chromatin buffer (10mM HEPES (pH 7.9), 10mM KCl, 1mM 
MgCl2, 10% glycerol, 1mM CaCl2 (calcium chloride), 1mM EDTA, 1mM NaF and 
1mM NaOv, 1mM PMSF, 10μg/mL aprotinin and 10μg/mL leupeptin in milliQ 
H2O), complemented with 5units of Micrococcal nuclease (Sigma-Aldrich), and 
the mix incubated, at 37ºC, for 45min. The Micrococcal nuclease reaction was 
stopped with 10mM EGTA and the cytoplasm, nucleoplasm and chromatin 
fractions handled for SDS-PAGE and WB.    
4.6 Protein quantification 
The protein extracts were quantified using the Bradford method. The 
Bradford method for protein quantification is a colorimetric assay able to 
determine the amount of protein in each sample, by measuring the absorbance 
from the established Bradford reagent-protein complexes. The Bradford reagent 
(use the dye G-250 Coomassie blue) alone is red and turns to blue, when specific 
and relatively stable complexes are established with proteins. This changes the 
maximum absorbance from 465nm to 595nm. Higher protein concentrations lead 
to stronger shades of blue. The extracts were quantified with the reagent Bio-Rad 
protein assay (Bio-Rad), using BSA to build the standard curve. Usually, six 
standards were prepared, diluting the BSA in milliQ H2O, and the samples were 
prepared by adding 2 and 3 µl of the protein extract to the appropriate amount of 
milliQ H2O and Bradford reagent, up to a total volume of 1ml. After 
homogenization, absorbance was read in a spectrophotometer (Bio-Rad), at 
595nm, and the protein concentration determined according to the Beer-Lambert 
Law. 
4.7 SDS-PAGE electrophoresis 
 The separation of proteins was performed, accordingly with their size, in 
denaturating conditions, through SDS-PAGE vertical electrophoresis. SDS is an 
anionic detergent with the ability to linearize and to bond to proteins, giving them 
a uniform negative charge, due to the sulfate groups present in the molecule, 
which masks the protein charge. Thus, the proteins have a ratio charge/ mass 
uniform that allows their separation by size.  
For immunoblotting, three different resolving gels were used according to 
the size of the target protein(s). To small proteins (<30kDa) were used 12.5% 




acrylamide gels, to proteins between 30-100kDa, 10% acrylamide gels and to 
larger proteins (>100kDa), 7.5% acrylamide gels. The resolving gels were 
prepared with 7.5%-12.5% acrylamide, 0.13%-0.4% bis-acrylamide, in 0.375M 
Tris-HCl (pH 8.8) and 3.5mM SDS. On the other hand, the stacking gel was 
prepared with 4.8% acrylamide, 0.128% bis-acrylamide in 0.125M Tris-HCl (pH 
6.8) and 3.5mM SDS on top of the resolving gel. To solidify both the resolving 
and the stacking gels, it was added the catalysts agent ammonium persulfate 
(APS) and tetramethylethylenediamine (TEMED). Before being loaded on the 
acrylamide gel, the samples were re-suspended in sample buffer (62.5mM Tris-
HCl (pH6.8), 10% glycerol, 2.3% SDS, 0.1% bromophenol blue, and 5% β-ME) 
and boiled at 100ºC, during 5min. The electrophoresis was performed in 
denaturating conditions in the appropriated buffer (25mM Tris-HCl, 200mM 
glycine and 1.7mM SDS) and using the protein ladder Precision plus ProteinTM 
Standards Dual Color (Bio-Rad).  
4.8 Staining protein gels with Coomassie blue 
 The visualization of proteins in polyacrylamide gels was achieved by 
Coomassie Blue staining. Coomassie Blue was prepared with 0.5% Coomassie 
brilliant blue R250 (Merck), 50% methanol (Sigma-Aldrich) and 10% acetic acid, 
glacial (Merck). This solution was added directly on the polyacrylamide gels (5min 
incubation on agitation), and it was washed out with a washing solution of 50% 
methanol (Sigma-Aldrich) and 10% acetic acid, glacial (Merck). When the protein 
bands where visible the gels were transferred to Whatman 3M paper and dried 
during 2h, at 80ºC, in a gel dryer (Bio-Rad).   
4.9 Transference and Western Blot 
Following SDS-PAGE electrophoresis, the proteins were transferred to 
PVDF Immobilon-P or Immobilon-FL membranes (Millipore), following the 
protocol described by Towbin (Towbin et al., 1979). Firstly, the membranes were 
activated for 2min in methanol (Sigma-Aldrich) and equilibrated 2min in milliQ 
H2O. Then, the transference (90min; 90V; 4ºC) was performed with a 
transference buffer (25mM Tris HCl, 19.2mM glycine and 10%-20% methanol in 
milliQ H2O), which varies on methanol concentration due to the size of the 
proteins that we want to analyze. Smaller proteins used higher methanol 
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concentrations and larger proteins used lower methanol concentrations. If 
necessary, PVDF membranes were incubated for 5-10 minutes with red Ponceau 
(chapter 4.8) to determine whether the transference was perfectly achieved. Next, 
the membranes were washed several times in TBS-T (25mM Tris-HCl (pH 8.0), 
50mM NaCl, 2.5mM KCl and 0.1% Tween-20 (Sigma-Aldrich) in milliQ H2O) and 
the membranes blocked in 5% non-fat dried milk or BSA, in TBS-T (1h at RT).  
Afterward, the membranes were incubated with the specific primary 
antibody, following the datasheet instructions (Table IV). Normally the primary 
antibodies were prepared in 1%BSA-TBS-T or in TBS-T and the incubations 
times were 1h to 2h, at RT, or ON, at 4ºC. Subsequently, the membrane was 
washed (3x, 10min washes with TBS-T) and incubated with the secondary 
antibody. Both the secondary antibodies Goat Anti-Mouse IgG, DyLightTM 680 
(red colored) and Goat Anti-Rabbit IgG, DyLightTM 800 (green colored) (Thermo 
Scientific) were incubated at 1:10000 dilutions in TBS-T, during 1h (in the dark). 
Successively, the membranes were washed with TBS-T (3x, 10min washes) and 
scanned in the LI-COR Odyssey Infrared Imaging System (LI-COR Biosciences; 
Lincoln, NE, USA) that detects the fluorescence associated with the secondary 
antibody.  
Sporadically, the secondary antibody used was conjugated with 
peroxidase (ECL Anti-Mouse IgG, Horseradish peroxidase-Linked Species-
Specific Whole Antibody (Amersham Biosciences; Amersham, UK) or Anti-Rabbit 
IgG (Whole Molecule) Peroxidase Conjugate (Sigma-Aldrich)). In these cases, 
after a 1h incubation with the secondary antibody (1:10000), the luminescence 
was detected with the ECL Western Blotting Detection Reagent (5min incubation) 
(Amersham Biosciences) through X-ray film (Fujifilm; Tokyo, Japan). 
Table IV. List of antibodies 
Antibodies 
Antibody Type Dilution 
(WB/IF) 
MW(kDa) Origin 
Acetyl-Histone 4 Rabbit polyclonal 1:1000 14 Millipore 






Rabbit polyclonal 1:1000 14 Cell Signaling 
Acetyl-Histone H3 
(Lys14) 
Rabbit polyclonal 1:1000 17 Millipore 
Acetyl-Histone H3 
(Lys9) 
Rabbit polyclonal 1:1000 17 Millipore 
AU5-Tag Mouse monoclonal 1:1000  Covance 
AU5-Tag Rabbit polyclonal 1:1000  Covance 
AurKB Rabbit monoclonal 1:1000/ 1:100 39 Abcam 
AurKB Rabbit polyclonal 1:100 39 Santa Cruz 
CREB Mouse monoclonal 1:1000 43 Cell Signaling 
Cyclin A Rabbit polyclonal 1:1000 54 Santa Cruz 
Cyclin B1 Rabbit Polyclonal 1:2000 55 Santa Cruz 
Cyclin D1 (M20) Rabbit polyclonal 1:1000 37 Santa Cruz 
E-cadherin Mouse monoclonal 1:1000 135 BD 
Flag-Tag Rabbit polyclonal 1:1000  Sigma-Aldrich 
Flag-Tag (M2) Mouse monoclonal 1:1000  Sigma-Aldrich 
Flag-Tag (M5) Mouse monoclonal 1:1000  Sigma-Aldrich 
GFP-Tag Mouse monoclonal 1:1000  Santa Cruz 
GST-Tag (B-14) Mouse monoclonal 1:1000  Santa Cruz 
H2A.X Rabbit polyclonal 1:1000 15 Cell Signaling 
HA-Tag Rabbit polyclonal 1:1000  Sigma-Aldrich 
HA-Tag (F-7) Mouse monoclonal 1:1000  Santa Cruz 
Histone H3 Rabbit polyclonal 1:5000 17 Cell Signaling 
Lamin A/C (H110) Rabbit polyclonal 1:500 50-41 Santa Cruz 
Lamin B (M-20) Goat polyclonal 1:500 66 Santa Cruz 
Myc-Tag Mouse monoclonal 1:1000  Millipore 
Myc-Tag Rabbit polyclonal 1:1000  Millipore 
N-cadherin Rabbit polyclonal 1:200 130 Santa Cruz 
Nanog (D73G4) XPTM Rabbit monoclonal 1:1000 40 Cell Signaling 
Oct4  Rabbit monoclonal  1:1000 45 Cell Signaling 
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p27 Mouse monoclonal 1:1000 27 BD 
p53 (DO-1) Mouse monoclonal 1:1000 53 Santa Cruz 
p53 (Pab 1801) Mouse monoclonal 1:1000 53 Santa Cruz 
p53 (phospho 18) Rabbit polyclonal 1:1000 53 Abcam 
PAX6 Rabbit polyclonal 1:1000 46 Abcam 
PCNA Mouse monoclonal 1:1000 36 Santa Cruz 
Phospho-CREB 
(Ser133) 
Rabbit polyclonal 1:1000 43 Cell Signaling 
Phospho-Histone 
H2A.X (Ser139) 
Rabbit polyclonal 1:1000 15 Cell Signaling 
Phospho-Histone H3 
(Ser10) 
Rabbit polyclonal 1:500/ 1:100 17 Millipore 
Phospho-Histone H3 
(Thr3) 
Rabbit polyclonal 1:5000/ 1:100 17 Millipore 
Phospho-Rb 
(Ser807/811) 
Rabbit polyclonal 1:1000 110 Cell Signaling 
Rb (C-15) Rabbit polyclonal 1:1000 110 Santa Cruz 
Sox2 (D6D9) XPTM Rabbit monoclonal 1:1000/ 1:100 40 Cell Signaling 
Sox2 (E-4) Mouse monoclonal 1:500 40 Santa Cruz 
Sox2 (Y-17) Goat polyclonal 1:500 40 Santa Cruz 
Trimethyl Histone H3 
(Lys 4) 
Rabbit polyclonal 1:1000 17 Cell Signaling 
Trimethyl-Histone H3 
(Lys 9) 
Rabbit polyclonal 1:500 17 Millipore 
Trimethyl-Histone H3 
(Lys 9) 6F12-H4 
Mouse monoclonal 1:1000 17 Millipore 
V5-Tag (SV5-Pk1) Mouse monoclonal 1:1000  Abcam 
V5-Tag (G-14) Rabbit polyclonal 1:1000  Santa Cruz 
Vimentin Mouse monoclonal 1:1000 54 Abcam 
Vimentin Rabbit polyclonal 1:1000 54 Cell Signaling 
VRK1 (1B5) Mouse monoclonal 1:1000/ 1:200 45 
Own 
Production 
VRK1 (1F6) Mouse monoclonal 1:1000/ 1:200 45 
Own 
Production 




VRK1 (N-Term) Rabbit polyclonal 1:1000/ 1:200 45 Sigma-Aldrich 
VRK1 (VC) Rabbit polyclonal 1:1000 45 
Own 
Production 
VRK1 (VE) Rabbit polyclonal 1:1000 45 
Own 
Production 
α-Tubulin Rabbit polyclonal 1:500 50 Santa Cruz 
α-Tubulin Mouse monoclonal 1:500 50 Santa Cruz 
β-actin Mouse monoclonal 1:5000 42 Sigma-Aldrich 
βIII-Tubulin Rabbit polyclonal 1:1000 55 Biolegend 
The antibodies were used for WB following the manufacturer’s instructions.  
4.10 Ponceau S staining 
 In particular experiments, the PVDF membranes were submitted to 
Ponceau S staining, in order to verify whether the transference was correctly 
performed. In these cases, the membranes were incubated around 5min with a 
solution of 0.2% Ponceau S (3-Hydroxy-4-[2-sulfo-4-(4-sulfophenylazo)-
phenylazo]-2, 7-naphthalenedisulfonic acid), 3% 5-sulfosalicylic acid, 3% 
trifluoroacetic acid and 1% acetic acid. Following the incubation, the membranes 
were washed until the bands were visualized.  
5. Transfection assays  
5.1 Transfection with JetPEITM 
 The overexpression of proteins was mediated by cell transfection with 
DNA plasmids (Table V). Initially, the cells were platted in Style cell culture 
dishes, 24h before to transfection, in order to obtain a 50% to 70% of confluence 
at the time of the transfection. Then, the transfections were performed with 
JetPEITM (Polyplus Transfection SA; New York, NY, USA), following the 
manufacturer’s instructions. This polymer based reagent (polypropylenimine 
(PPI)) compacts the DNA inside positive charged particles that adhere to the 
negative charged proteoglycan proteins in the cell surface, allowing their 
entrance in the cell by endocytosis. Usually, the DNA was re-suspended in 
150mM NaCl and the JetPEITM (also re-suspended in 150mM NaCl) was added 
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in a 2:1 proportion to the DNA. The quantity of DNA used was specific for each 
DNA plasmid, however the DNA final concentration, in solution, was maintained 
identical intra-experiments. Later, the mix was incubated between 20min to 30min 
and added dropwise to the cells. 
Table V. List of DNA plasmids 
DNA Plasmids 
DNA Plasmid Vector Insert Used to 
HA-VRK1 pCEFL-HA VRK1 







Eukaryotic expression; Tag on N-
terminus 
HA-VRK1 RX pCEFL-HA VRK1 (R358X) 




pCEFL-HA VRK1 (Y202A) 




pCEFL-HA VRK1 (Y204A) 




pCEFL-HA VRK1 (Y204A) 




pCEFL-HA VRK1 (Y204D) 




pCEFL-HA VRK1 (T224A) 




pCEFL-HA VRK1 (T224D) 




pCEFL-HA VRK1 (T228A) 




pCEFL-HA VRK1 (T228E) 
Eukaryotic expression; Tag on N-
terminus 
GST-VRK1 pCEFL-GST VRK1 
Eukaryotic expression; Tag on N-
terminus 
GST-VRK1 C pCEFL-GST 
VRK1 C-Terminus 
(aa 267-396) 
Eukaryotic expression; Tag on N-
terminus 
VRK1-Myc pcDNA3.1 VRK1 
Eukaryotic expression; Tag on C-
terminus 





























Murine p53 (aa 1-
85) 




pGEX4T1-GST VRK1 (Y202A) 




pGEX4T1-GST VRK1 (Y202D) 




pGEX4T1-GST VRK1 (Y204A) 




pGEX4T1-GST VRK1 (Y204D) 




pGEX4T1-GST VRK1 (T224A) 




pGEX4T1-GST VRK1 (T224D) 




pGEX4T1-GST VRK1 (T228A) 




pGEX4T1-GST VRK1 (T228E) 




pDEST3.1_nV5 Aurora A Eukaryotic expression 
pDEST3.1_nV5-
AurkB 









pGEX4T1-GST Aurora B 





Aurora B (K106R) 
(Kinase inactive) 






SOX2 Eukaryotic expression 













































Cyclin D1 promoter 
(-1745+52) 
Eukaryotic expression 
Survivin-Luc pGL2-Luc Survivin promoter Eukaryotic expression 
        
5.2 Transfection with LipofectamineTM 
 The suppression of VRK1 and Sox2 expression were attained using 
specific siRNA (Table VI), from Dharmacon RNA Technologies (Dharmacon, Inc.; 
Lafayette, CO, USA) or OriGene Technologies (Rockville, MD, USA), 
respectively. Simultaneously, it was used the ON-TARGET plus siControl 
Nontargeting siRNA (Dharmacon, Inc.), without any target on human cells, as 
negative control.  
 The genetic suppression, with siRNA, was accomplished using 
LipofectamineTM (Invitrogen) reagent, which contains lipid subunits that can 
produce liposomes in aqueous environments. The liposomes have a cationic 
nature that can form a complex with DNA (negative charged), avoiding the 
electrostatic repulsion of the cellular membrane (also negative charged). This 
allows the fusion of the complex with the cellular membrane and it penetration 
into the cell. The protocol used for siRNA-gene silencing was the following: cells 
were platted without antibiotic and when the correct confluence was achieved 
they were transfected with LipofectamineTM. This reagent was diluted in Opti-
MEM (Gibco®) and it was added to the siRNA (100nM-200nM concentration) re-




suspended in Opti-MEM for a 20min incubation. Finally the mix containing the 
siRNA and the LipofectamineTM was added dropwise to the cells. The antibiotic 
was re-introduced to the medium 24h later.    
Table VI. List of siRNA 
RNAi 
Name Sequence 5’- 3’ Used to 
























*Used to phenotypic rescue 
6. Viral transduction 
 Cell transduction uses a viral vector as a packaging device to introduce 
into the cell foreign DNA. Herein, it was used two different types of viral vectors 
to deliver the overexpressing protein or the shRNA of interest (Table VII) into the 
cell: lentiviruses and retroviruses. The main difference between these two types, 
from an experimental standpoint, is that lentiviruses are capable of transduce 
non-dividing and actively dividing cells, whereas retroviruses can only transduce 
mitotically active cells. This means that lentiviruses are more efficient transducing 
several cell types than retroviruses. Both the two viral vector systems use the 
gag, pol, and env genes for packaging. Nonetheless, the isoforms of these 
proteins used are different and lentiviral vectors may not be efficiently packaged 
by retroviral packaging systems and vice versa. Here, the lentiviral system used 
the pCMV-dRp8.91 (gag-pol genes) and the pMD26-VSV-G (env gene) packing 
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vectors and the retroviral system used the pCMVdr.9.91 (gag-pol-env genes) 
packing vector.  
The protocol used for cell transduction was the following: on the first day, 
the HEK293T were platted in order to obtain the necessary confluence at the time 
of transfection. Then, the HEK293T cells were transfected with 10μg DNA and 
the respective packing vectors, diluted in 0.25M CaCl2 and 2x HEPES-buffered 
saline solution (HeBS). Less than 20h after the transfection, the HEK293T cells 
were washed with 1x PBS and the medium of the cells was refreshed. On the 
next mourning the medium was refreshed once again and the target cells were 
platted. On the following day, the target cells were transduced adding directly the 
HEK293T cells medium over them. The medium was filtered with 0.45μm 
polysulfone filters (Pall Corporation; Ann Harbor, MI, USA) and it was 
supplemented with 4μg/mL polybrene (Sigma-Aldrich). Polybrene is a small and 
positively charged molecule that has the capacity to bind to cell surfaces and 
neutralizes it charge. This is important because it allows the viral glycoproteins to 
bind more efficiently to their receptors, because it reduces the repulsion between 
sialic acid-containing molecules leading to an increased efficiency of 
transduction. Lastly, the target cells were selected with 1μg/mL puromycin 
(Sigma-Aldrich) or in the cases in which the viral vectors weren’t puromycin-
resistant, the transduction was evaluated through the emission of fluorescence. 
Table VII. Lentiviral and retroviral vectors 
Viral Vectors 
Viral Vector Vector Insert Used to 
pLKO.1-shVRK1-H1 pLKO.1 1 shVRK1 
shRNA against 
VRK1 
pLKO.1-shVRK1-H3 pLKO.1 1 shVRK1 
shRNA against 
VRK1 
pLKO.1-shVRK1-H5 pLKO.1 1 shVRK1 
shRNA against 
VRK1 
pSUPERIOR-siVRK1-01 pSuperior 2 siVRK1 
RNA Interference 
against VRK1 
pSUPERIOR-siVRK1-03 pSuperior 2 siVRK1 
RNA Interference 
against VRK1 




pBabe-HA-VRK1 pBabe 2 VRK1 
VRK1 expression; 
Tag on N-terminus 
pQCXIP-VRK1 pQCXIP 2 VRK1 VRK1 expression 
pLVX-IRES-zsGreen-HA-VRK1 pLVX-IRES-zsGreen 1 VRK1 
VRK1 expression; 
Tag on N-terminus 
pLVX-IRES-tdTomato-HA-VRK1 pLVX-IRES-tdTomato 1 VRK1 
VRK1 expression; 
Tag on N-terminus 
pBabe-Sox2 pBabe2 Sox2 Sox2 expression 
1 Lentiviral vector; 2 retroviral vector 
7. Protein-protein interaction assays 
7.1 Immunoprecipitation 
 Immunoprecipitation (IP) was executed using between 0.5mg to 2.0mg of 
total protein extracts, in a 1mL total volume. Initially, the protein extracts were 
incubated with the equilibrated resin Gammabind plus Sepharose (GE 
Healthcare), during 1h, at 4ºC, on a rotator. This initial incubation serves to 
eliminate everything that can bind nonspecifically to the resin. Subsequently, the 
resin was eliminated by low-rotation centrifugation and the pre-cleaned extracts 
were incubated with the specific antibody, ON, with rotation, at 4ºC. Typically, the 
antibodies were used at concentrations between 1:50 to 1:500, depending on the 
datasheet instructions and as control negative it was used an unspecific antibody. 
Then, the extracts were incubated once again with equilibrated Gammabind 
Sepharose during 2h, at 4ºC, on rotation. This second incubation serves to bind 
the antibody and consequently precipitate the protein bonded to it. Next, the 
Gammabind Sepharose was washed with lysis buffer at 4ºC, resuspended on 
sample buffer and boiled at 100ªC for further analysis by SDS-PAGE and WB. 
Also important to mention is the fact that the Gammabind Sepharose was 
equilibrated through a sequence of several washes with lysis buffer at 4ºC.    
7.2 Pull-down assay 
 Pull-down assay was used to verify whether a specific protein 
(endogenous or transfected) interacted with the precipitated GST-tagged protein, 
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which was transfected in the eukaryotic cell. Briefly, the cells were transfected 
with the GST-fusion protein and they were lysed with the lysis buffer Suave, since 
a lysis buffer more aggressive could disrupt the interactions between the proteins. 
Afterward, between 0.5mg to 2.0mg of total protein extracts was incubated ON, 
at 4ºC, with the resin Glutathione Sepharose 4B beads (GE Healthcare), which 
was washed in the following day with lysis buffer at 4ºC, by low-rotation 
centrifugation. Finally, the beads were resuspended on sample buffer, boiled at 
100ºC and analyzed by SDS-PAGE and WB. Like the Gammabind Sepharose, 
the Glutathione Sepharose was equilibrated washing it with lysis buffer at 4ºC, by 
low-rotation centrifugation. In the pull-down assay, it was used as negative control 
the GST protein, by itself. 
8. Immunofluorescence and confocal microscopy 
Immunofluorescence (IF) assays were used to analyze the levels and 
subcellular localization of endogenous or exogenous proteins in culture cells.  
Briefly, the cells were cultured with or without 0.01% poly-L-lysine (Sigma-
Aldrich), which increases the cellular adhesion to the glass, in coverslips (Thermo 
Scientific) placed in 10mm Style culture dishes. Then and after 48h to 96h, 
depending on the experiment, the cells were washed with 1xPBS and fixed with 
3% paraformaldehyde (Sigma-Aldrich), during 30min, at RT. Next, the cells were 
treated with 20nM glycine during 15min to reduce the excess of aldehyde groups 
after the fixation, and permeabilized with 0.2% triton X-100 in 1xPBS, during 
30min. Successively, the cells were blocked with 1% BSA in 1xPBS with azide, 
during 1h, at RT, or ON, at 4ºC. Afterward, the cells were incubated with the 
primary antibodies diluted in 1%BSA in 1xPBS with azide. The first primary 
antibody was incubated ON, at 4ºC, and the second one (always from a different 
host in relation to the first primary antibody) was incubated between 2 to 4h, at 
RT. Subsequently, the cells were washed with 1xPBS and incubated with the 
secondary antibodies. The secondary antibodies were linked to the cyanine 
fluorophore Cy2 (CyTM2-conjugated AffiniPure Goat anti-Rabbit/ anti-Mouse 
(H+L)) or Cy3 (CyTM3-conjugated AffiniPure Goat anti-Rabbit/ anti-Mouse (H+L)) 
(Jackson ImmunoResearch; West Grove, PA, USA) and were used always at 
1:1000 dilution in 1%BSA in 1xPBS, for 1h, at RT, in the dark. Besides and from 




this point until the end, the cells were always maintained in the dark to preserve 
the fluorophore. Later, the cells were washed with 1x PBS and the nuclear DNA 
was counterstained with 4', 6-diamidino-2-phenylindole, also called DAPI (Vector 
Labs; Burlingame, CA, USA). The excess of DAPI was removed with 1xPBS and 
the coverslips were mounted in microscope slides (LineaLab; Badalona, Spain) 
using MOWIOL® 4-88 (Calbiochem; Billerica, MA, USA).  
Finally, a Leica TCS SP5 inverted fluorescence microscope (Leica 
Microsystems; Wetzlar, Germany) connected to a digital video camera Leica 
DC100 (Leica Microsystems) was used to obtain the confocal microscopy images 
and the confocal image analysis was completed using the LAS AF Lite (Leica 
Microsystems).  
9. Luciferase reporter assay 
 Reporter gene luciferase was used to study gene expression and cellular 
events coupled to gene expression. Usually, the promoter of interest was cloned 
into an expression vector with the luciferase reporter gene and then transfected 
into cells. Since the luciferase gene is downstream to the promoter, after the 
activation or repression, by a transcriptional factor complex, the expression of the 
luciferase gene respond equitably. Usually, this occurs because the 
transcriptional factor recognizes specific sequences in the transfected promoter, 
binding to them and leading to the transactivation of the luciferase reporter gene 
and to the synthesis of the protein luciferase. Afterward, the luciferase catalyzes 
the oxidation of luciferin, using ATP and Mg2+, which produces oxyluciferin that 
emitted light at 556nm. The light was quantified with a Lumat LB 9507 
luminometer (Berthold Technologies; Oak Ridge, TN, USA). 
The quantification of the luciferase reporter gene activity was performed 
with the commercial kit Dual-Luciferase reporter assay system (Promega), 
following the manufacturer’s instructions. The assay was performed always in 
triplicate and repeated at least 3 times. Student’s t-test was used to analyze data 
and the DNA plasmids used for gene reporter assay are represented in the Table 
IV.  
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10. Kinase assays 
10.1 In vitro kinase assay with radiolabeled ATP  
 The Ser-Thr kinase activity was studied through in vitro kinase assays 
using radiolabeled ATP [γ-32P]. This technique was performed using either GST-
fusion kinase proteins, expressed in E. coli, or immunoprecipitated (endogenous 
or transfected) protein kinase from cell extracts. Moreover, it was also used a 
specific buffer to casein kinases (20mM Tris-HCl (pH 7.5), 5mM MgCl2, 0.5mM 
DTT and 150mM KCl), 5μM cold ATP, 5μCi (0.1μM) [γ-32P] ATP and specific 
substrates, such as recombinant proteins (e.g. GST-p53, GST-VRK1 K179E or 
GST-Aurora B K106R) or commercial human histone H3 (Upstate® - Millipore; 
Billerica, MA, USA).  
The phosphorylation reaction was incubated during 30min, at 30ºC, with 
agitation (800rpm), in a Thermomixer Compact (Eppendorf). The phosphorylation 
conditions were the same for either recombinant protein kinase or 
immunoprecipitated kinase. Afterward, the phosphorylation reactions were 
resuspended on sample buffer, boiled at 100ºC and analyzed by SDS-PAGE and 
WB. The radioactive bands were detected exposing directly the ray-x film 
(Fujifilm) to the membranes between several minutes to several hours. The 
loading controls were stained with Ponceau S red or detected using specific 
antibodies against the protein or the tag. 
10.2 In vitro kinase assay with cold ATP 
On the other hand, if the phosphorylation site was known, the Ser-Thr 
kinase activity was also analyzed by in vitro kinase assays with cold ATP and 
phospho-specific antibodies. Like the in vitro kinase assay using radiolabeled 
ATP, it was used GST-fusion kinase proteins, expressed in E. coli, or otherwise 
immunoprecipitated (endogenous or transfected) protein kinase from cell 
extracts. The reactions were executed in the presence of the same casein kinase 
buffer, 10μM cold ATP and specific phosphorylation substrates, such as the GST-
p53 or the commercial human histone H3 (Upstate®). Also, the phosphorylation 
reaction was incubated during 30min, at 30ºC, with agitation (800rpm) in a 
Thermomixer (Eppendorf). Then, the phosphorylation reactions were 
resuspended on sample buffer, boiled at 100ºC and analyzed by SDS-PAGE and 




WB with phospho-specific antibodies. The loading controls were detected with 
antibodies against the protein or the tag. 
11. Cell cycle synchronization 
 The study of the regulatory events that occurred in the cell, dependently of 
the cell cycle, required the synchronization (or cell arrest) of the general 
unsynchronized cell population into specific cell cycle phases. In our case, this 
synchronization was obtained due serum deprivation and drug-dependent 
methods. Succinctly, cells were synchronized in G0/G1 due to serum starvation 
during 72h, in S phase by double thymidine (2mM) block and in G2/ M by double 
thymidine (2mM) block followed by nocodazole (0.33μM) arrest. Moreover, the 
cells arrested with nocodazole were released from this drug and harvested 
30min, 60min, 90min, 180min, 360min and 720min after the release, to obtain 
cell populations at different stages of the mitosis.  
Thymidine causes the cell arrest in the S phase because it blocks the DNA 
synthesis by inhibiting the synthesis of specific nucleotides (i.e. generates 
negative feedback on the production of deoxycytidine triphosphate from cytidine-
5'-phosphate). Nocodazole causes the cell arrest at G2/ M because it inhibits the 
microtubule function, which blocks the normal spindle assembly in early mitosis 
(Harper, 2005).  
12. NTERA-2 cd.D1 cell differentiation 
 The differentiation of NT2 into a neuron-like phenotype was performed 
adding 10μM RA, during 14 days, and renewing the cell medium 2 in 2 days. At 
the same time that the medium was replaced, an experimental point was 
harvested to qRT-PCR and SDS-PAGE for WB, and the morphology analyzed by 
phase-contrast microscopy. RA is a metabolite of vitamin A that mediates the 
functions of this vitamin required for epithelial differentiation and embryo 
development (Marill et al., 2003). This action occurs mainly through the retinoic 
acid receptor (RAR) and retinoid X receptor (RXR) nuclear heterodimer or by the 
covalent binding of RA to cell macromolecules. On NT2 RA direct binds to RAR, 
which bounds to DNA as a heterodimer with RXR in the retinoic acid response 
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elements (RAREs). This heterodimer affects the transcription of different sets of 
genes controlling differentiation and proliferation.  
13. Immunohistochemistry 
 Biopsies from normal human tonsil were obtained with informed consent, 
fixed in formalin and embedded in paraffin. Sections were sliced (3µm thick), 
transferred to positively (silanized) charged-surface glass slides and dried ON, at 
62ºC. Next, the sections were dewaxed and rehydrated through an increased 
series of ethanol and washed with PBS. To desmask antigens, the slides were 
treated in a PT Link of DAKO for one cycle of 20min, at 95ºC, without boiling and 
with a buffer pH8.0. Subsequently, the sections were left tempering and washed 
with PBS. Immunodetection was performed with the DAKO EnVision 
Visualization Method (DAKO), with diaminobenzidine chromogen as substrate. 
Sections were counterstained with haematoxylin. VRK1 was detected with the 
VC polyclonal antibody (1:30) and Sox2 with monoclonal antibody Sox2 (E-4) 
(1:30) (Santa Cruz). For immunofluorescence, the tissue sections, after antigen 
retrieval, were blocked with 2% nonfat dry milk and 0.1% Triton in PBS, washed 
with PBS and incubated ON with both primary antibodies (1:30 each one). 
Afterward, after wash the slides with PBS, the sections were incubated with the 
secondary antibodies α-mouse Cy3 (1:100) (Jackson ImmunoResearch) and α-
rabbit Alexa Fluor 488 (1:100) (Molecular Probes; Eugene, OR) during 2h, at RT. 
Following the staining, the slides were washed with PBS and incubated with DAPI 
for 5min. Cells were mounted with Vectashield (Vector Laboratories, Burlingame, 
CA) and analyzed with a LEICA SP5 DMI-6000B (Leica Microsystems) confocal 
microscope. 
14. Ubiquitination and protein stability assays 
 In ubiquitination assays, cells were treated with 20 µM MG-132 
proteasome inhibitor (Calbiochem). Moreover, cycloheximide (Sigma-Aldrich) 































































Part 1. Implication of VRK1 in the regulation of 
AurKB mitotic localization and activity 
1.1 VRK1 and AurKB mutual regulation 
 VRK1 is a protein kinase essential for the correct cell cycle progression 
during interphase and was also recently reported to be involved in the regulation 
of mitosis, controlling chromatin condensation, nuclear envelope assembly and 
disassembly, and Golgi fragmentation. Likewise, AurKB was described as a key 
protein kinase implicated in the control of numerous mitotic processes, such as 
centromere function, chromatin condensation, spindle assembly, chromosome 
alignment and segregation and, cytokinesis. Inquiringly, AurKB share some 
phosphorylation substrates with VRK1, of which protrude the histone H3, and the 
transcriptional factor p53 (Bolanos-Garcia, 2005; Kang et al., 2007b; Valbuena et 
al., 2008b; Vega et al., 2004a).  
 In line with all this, we tested whether VRK1 could co-operate with AurKB 
on the same regulatory processes, using a known common substrate of both 
kinases: the histone H3. Accordingly, it was performed a kinase assay with 
radiolabeled [γ-32P] ATP using as substrate the human histone H3 combined with 
recombinant proteins GST-AurKB-K106R inactive kinase and GST-VRK1, or with 
recombinant proteins GST-VRK1-K179E inactive kinase and GST-AurKB. GST-
AurKB-K106R was mutated in the ATP binding site and therefore was inactive 
and VRK1 protein with the K179E substitution, in the active kinase domain, lacks 
both autophosphorylation and kinase activity. Proteins were incubated for 30 
minutes at 30ºC. We demonstrated that VRK1-dependent phosphorylation of 
histone H3 and the autophosphorylation activity of this kinase were affected 
negatively by AurKB. Similarly, AurKB-dependent phosphorylation of histone H3 
and the autophosphorylation activity of AurKB were affected negatively by VRK1 
(Figure 16A). The quantification of histone H3 phosphorylation and 
autophosphorylation activities were performed using ImageJ and represented in 





Figure 16. VRK1 and AurKB inhibits the kinase activity of one another. A) Kinase 
assay with recombinant proteins GST-VRK1 (pGEX-GST-VRK1 and pGEX-GST-VRK1-
K179E) and GST-AurKB (pGEX-GST-AurKB and pGEX-GST-AurKB-K106R), and 
human histone H3 as phosphorylation substrate. Proteins were incubated for 30 minutes 
at 30ºC in presence of ATP and radiolabeled [γ-32P] ATP. The gels were stained with 
Coomassie Blue to analyze the controls and the incorporated radioactivity was detected. 
B) The autophosphorylation and histone H3 phosphorylation activities were quantified 
using ImageJ and represented in a graphic. (Student’s Test: *<0.05; **<0.005; 
***<0.0005).    
 Additionally, we intended to confirm the results obtained in the Figure 16, 
through a kinase assay with cold ATP and specific histone H3-phosphorylation 
antibodies. VRK1 was demonstrated to phosphorylate two residues in the histone 
H3: the Thr3 (H3T3ph) and the Ser10 (H3S10ph) sites (Kang et al., 2007b). 
Curiously, both this two phosphorylations were also described to be directly 
(H3S10ph) and indirectly (H3T3ph) affected by AurKB (Hirota et al., 2005; Wang 
et al., 2011). Since VRK1 seemed to share at least one direct phosphorylation 
residue (H3S10ph) and thereby it may be a setback in the intended experiment, 






























































and H3S10 residues. First, we performed an IP assay to analyze whether VRK1 
interacts with histone H3. VRK1 was immunoprecipitated with a mouse 
monoclonal anti-VRK1 (1F6) antibody and histone H3 was detected by 
immunoblot with a rabbit polyclonal anti-histone H3 antibody. It was shown that 
VRK1 interacts with histone H3 in unsynchronized cells (Figure 17A). 
Subsequently, it was performed a knockdown assay using siRNAs targeting 
VRK1 (siVRK1-02 and siVRK1-03), to analyze the effect of VRK1 depletion on 
the levels of H3T3ph and H3S10ph. A siRNA (siControl) lacking a specific target 
was used as control. 72 hours post-transfection, the histones were extracted 
using a high-salt extraction protocol and, H3T3ph was detected using a rabbit 
polyclonal anti-H3T3ph antibody and H3S10ph was detected using a rabbit 
monoclonal anti-H3S10ph antibody. It was demonstrated that VRK1 
downregulation induces a decline in both H3T3ph and H3S10ph (Figure 17B). 
Similar result was obtained using shRNAs targeting VRK1 (pLKO-shVRK1-01 
and pLKO-shVRK1-03). After 7 days of puromycin selection, the histones were 
extracted using an acid extraction protocol and, H3T3ph was detected using a 
rabbit polyclonal anti-H3T3ph antibody and H3S10ph was detected using a rabbit 
monoclonal anti-H3S10ph antibody. Once again, VRK1 knockdown decreases 
the levels of H3T3ph and H3S10ph (Figure 17C). However, in this later 
experiment it was observed that VRK1 downregulation led to a reduction on the 
levels of others mitotic markers such as AurKB and Rb phosphorylation. This 
observation indicates that the decline on the histone H3 phosphorylations may 
be due to the G0/ G1 cell cycle arrest, induced by the VRK1 depletion, instead of 
being a consequence of the lack of direct phosphorylation. Therefore, to verify 
which histone H3 residues were direct phosphorylation sites of VRK1, we 
performed a kinase assay using GST-VRK1 and human histone H3 as substrate. 
Besides, it was also studied the AurKB direct phosphorylation of histone H3 using 
GST-AurKB and human histone H3 as substrate. Recombinant proteins were 
incubated 30 minutes at 30ºC in the presence of the substrate. H3T3ph was 
detected using a rabbit polyclonal anti-H3T3ph antibody and H3S10ph was 
detected using a rabbit monoclonal anti-H3S10ph antibody. We observed that 
VRK1 only phosphorylated directly H3T3 and AurKB, as described in the 





Figure 17. VRK1 interacts with and phosphorylates histone H3 in the Thr3 residue. 
A) VRK1 was immunoprecipitated with a mouse monoclonal anti-VRK1 (1F6) antibody 
and histone H3 was detected by immunoblot with a rabbit polyclonal anti-histone H3 
antibody. B) The knockdown of VRK1 was performed, during 72 hours, and using specific 
VRK1-siRNAs (siVRK1-02 = siV-02; siVRK1-03 = siV-03). A siRNA lacking a specific 
target (siControl = siC) was used as control. C) VRK1 knockdown was obtained after cell 
transduction with shRNAs (pLKO-shVRK1-01 = pLKO-sh1) and pLKO-shVRK1-03 = 
pLKO-sh3) and puromycin selection. The pLKO empty vector was used as negative 
control. D) Kinase assay with GST (pGEX-GST) and recombinant proteins GST-VRK1 
(pGEX-GST-VRK1) or GST-AurKB (pGEX-GST-AurKB), and histone H3 as a substrate. 
Proteins were incubated for 30 minutes at 30ºC in presence of ATP. H3T3ph was 
detected, by immunoblot, with a rabbit polyclonal anti-H3T3ph and H3S10ph was 
detected, by WB, with a rabbit monoclonal anti-H3S10ph antibody (B, C and D). 
 As demonstrated, Thr3 residue on histone H3 is a specific phosphorylation 
site of VRK1 and histone H3-Ser10 residue is a direct phosphorylation site of 
AurKB. Since both kinases target distinct phosphorylation sites on the histone 
H3, the results obtained in the Figure 16 can be confirmed by kinase assay with 
cold ATP using human histone H3 as substrate and specific antibodies against 
its phosphorylations. Initially, we focused on the inhibitory effect of AurKB on 
VRK1 activity. So, a stable concentration GST-VRK1 was incubated alongside 
with increased concentrations of GST-AurKB or GST-AurKB-K106R and human 
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presence of ATP and H3T3ph was detected using a rabbit polyclonal anti-H3T3ph 
antibody. It was observed that AurKB affected negatively the phosphorylation of 
histone H3 by VRK1. This effect was independent of AurKB activity and was 
AurKB-dose dependent. The H3T3ph levels were quantified using ImageJ and 
represented in a graphic (Figure 18A and Figure 18B). Similarly, GST-VRK1 was 
incubated with increasing concentrations of inactive GST-AurKB-K106R and 
GST-p53 as substrate. Proteins were incubated for 30 minutes at 30ºC in the 
presence of ATP and p53T18ph was detected using a rabbit polyclonal anti-
p53T18ph antibody. It was showed that VRK1 activity, on p53T18, decreased in 










Figure 18. AurKB disturbs H3T3ph and p53T18ph by VRK1. The effect is 
independently of AurKB activity and is AurKB-dose dependent. A) Kinase assay with 
2.0µg GST-VRK1 (pGEX-GST-VRK1), alongside with increasing doses (0.0, 0.5, 1.0, 
2.5 and 5.0µg) of GST-AurKB (pGEX-GST-AurKB) and histone H3 as substrate. B) 
Kinase assay with 2.0µg GST-VRK1 (pGEX-GST-VRK1), alongside with increasing 
concentrations (0.0, 0.5, 1.0, 2.5 and 5.0µg) of inactive GST-AurKB-K106R (pGEX-GST-
AurKB-K106R) and histone H3 as substrate. C) Kinase assay with 2.0µg GST-VRK1 
(pGEX-GST-VRK1), alongside with increasing concentrations (0.0, 0.5, 1.0, 2.5 and 
5.0µg) of inactive GST-AurKB-K106R (pGEX-GST-AurKB-K106R) and GST-p53 (pGEX-
GST-p53) as substrate. Proteins were incubated for 30 minutes at 30ºC in presence of 
ATP. H3T3ph was detected using a rabbit polyclonal anti-H3T3ph antibody (A and B) 
and p53T18ph was detected using a rabbit polyclonal anti-p53T18ph antibody (C). The 
levels of H3T3ph were quantified with ImageJ and represent in a graphic (N=3).  
 Next, we focused on the inhibitory effect of VRK1 on AurKB activity. Thus, 
a fixed concentration of GST-AurKB was incubated with increased concentrations 
of GST-VRK1 or GST-VRK1-K179E, and human histone H3 as substrate. 
Proteins were incubated for 30 minutes at 30ºC in presence of ATP and H3S10ph 
- 0.5GST-AurKB K106R
GST-VRK1 (2.0µg)
































































was detected using a rabbit monoclonal anti-H3S10ph antibody. It was perceived 
that VRK1 affected negatively the phosphorylation of histone H3 by AurKB. This 
effect was independent of VRK1 activity and was VRK1-dose dependent. The 
H3S10ph levels were quantified using ImageJ and represented in a graphic 
(Figure 19). 
 
Figure 19. VRK1 disturbs H3S10ph by AurKB. The effect is independently of VRK1 
activity and is VRK1-dose dependent. A) Kinase assay with 2.0µg GST-AurKB (pGEX-
GST-AurKB), alongside with increasing doses (0.0, 0.5, 1.0, 2.5 and 5.0µg) of active 
GST-VRK1 (pGEX-GST-VRK1) and histone H3 as substrate. B) Kinase assay with 2.0µg 
GST-AurKB (pGEX-GST-AurKB), alongside with increasing doses (0.0, 0.5, 1.0, 2.5 and 
5.0µg) of inactive GST-VRK1-K179E (pGEX-GST-VRK1-K179E) and histone H3 as 
substrate. Proteins were incubated for 30 minutes at 30ºC in presence of ATP. H3S10ph 
was detected using a rabbit monoclonal anti-H3S10ph antibody. The levels of H3S10ph 
were quantified with ImageJ and represent in a graphic (N=3). 
 Then, it was evaluated whether the knockdown of VRK1 affected the ability 
of AurKB to phosphorylate the Ser10 residue on histone H3 by kinase assay with 
cold ATP and specific antibody against H3S10ph. Since the presence of VRK1 
inhibits AurKB, it was expected that the absence of VRK1 may increase the 
phosphorylation of H3S10 by AurKB. Therefore, endogenous AurKB was 
immunoprecipitated with a rabbit polyclonal anti-AurKB antibody, from HEK293T 
cells, in which VRK1 was downregulated during 72 hours with a siRNA (siVRK1-




























































rabbit polyclonal anti-HA antibody was used as control of IP. Consequently, 
immunoprecipitated AurKB was incubated with human histone H3 as substrate 
for 30 minutes at 30ºC in the presence of ATP and H3S10ph was detected using 
a rabbit monoclonal anti-H3S10ph antibody. It was not observed any change on 
the phosphorylation levels of histone H3 by AurKB, after the knockdown of VRK1, 
comparing to the control (Figure 20).  
 
Figure 20. VRK1 knockdown does not affect the phosphorylation of histone H3 on 
the Ser10 residue by AurKB. VRK1 was depleted using a specific siRNA (siVRK1-02 
= siV-02) and a siRNA lacking a specific target (siControl = siC) was used as control. 
Afterward, AurKB was immunoprecipitated with a rabbit polyclonal anti-AurKB and as 
control of IP it was used a rabbit polyclonal anti-HA antibody. Next, immunoprecipitated 
AurKB was used in a kinase assay with histone H3 as substrate. Proteins were incubated 
for 30 minutes at 30ºC in presence of ATP. H3S10ph was detected using a rabbit 
monoclonal anti-H3S10ph antibody and AurKB was detected using a rabbit monoclonal 
anti-AurKB antibody.  
1.2 VRK1 interaction with AurKB  
 Next, we decided to analyze the potential interaction between both VRK1 
and AurKB, since they are regulating, either by simply interaction or by interaction 
and direct phosphorylation, the kinase activity of one another. Thus, we studied 
the interaction between endogenous VRK1 and transfected AurKB protein in 
HEK293T cells. Likewise, we also evaluated whether transfected AurKA 
interacted with endogenous VRK1. Accordingly, the cells were transfected with 
both V5-AurKA and V5-AurKB plasmids and V5-tagged proteins were 
























detected, by immunoblot, with a mouse monoclonal anti-VRK1 (1B5) antibody. 
We observed that endogenous VRK1 interacted with transfected AurKA and 
AurKB (Figure 21). 
 
Figure 21. VRK1 endogenous protein interacts with transfected AurKA and AurKB. 
HEK293T cells were transfected with V5-AurKA (pDEST3.1_nV5-AurKA) and V5-AurKB 
(pcDNA3.1/nV5-DEST-AurKB) during 48 hours. Next, the extracts were 
immunoprecipitated with a rabbit polyclonal anti-V5 antibody. By immunoblot, VRK1 was 
detected using a mouse monoclonal anti-VRK1 (1B5) antibody and V5-tagged aurora 
kinases were detected using a mouse monoclonal anti-V5 antibody.  
 Even though VRK1 interacted also with AurKA we decided to pursuit the 
studies only with AurKB, since AurKB was described previously to phosphorylate 
or affect indirectly the same VRK1 phosphorylation residues on histone H3 (Thr3 
and Ser10), and thereby it seemed more likely to share with VRK1 some mitotic 
regulatory mechanisms (Carmena and Earnshaw, 2003).  
 Subsequently, we confirm the interaction between transfected VRK1 and 
transfected AurKB through IP and pull-down assay. Firstly, HA-VRK1 and V5-
AurKB were transfected in HeLa cell line. Then, HA-VRK1 was 
immunoprecipitated using a rabbit polyclonal anti-HA antibody. V5-AurKB was 
detected, by WB, using a mouse monoclonal anti-V5 antibody, confirming that 
both kinases interacted (Figure 22A). Moreover, GST-VRK1 active and GST-
VRK1-K179E inactive were transfected with V5-AurKB in HEK293T cells. Pull-
down experiments confirm that AurKB and VRK1 formed a stable complex and 
that this interaction was independent of VRK1 activity (Figure 22B). Similar result 


















Figure 22. VRK1 interacts with AurKB. The interaction is independent of VRK1 activity. 
A) HeLa cells were transfected with V5-AurKB (pcDNA3.1/nV5-DEST-AurKB) and HA-
VRK1 (pCEFL HA-VRK1). Cell extracts were immunoprecipitated with a rabbit polyclonal 
anti-HA antibody and AurKB was detected, by immunoblot, with a mouse monoclonal 
anti-V5 antibody. B) HEK293T cells were transfected with V5-AurKB (pcDNA3.1/nV5-
DEST-AurKB) and with GST-VRK1 (pCEFL-GST-VRK1) or GST-VRK1-K179E (pCEFL-
GST-VRK1 K179E). Cell extracts were incubated with glutathione sepharose overnight 
and AurKB was detected, by immunoblot, with a mouse monoclonal anti-V5 antibody. C) 
HEK293T cells were transfected with V5-AurKB (pcDNA3.1/nV5-DEST-AurkB) and with 
HA-VRK1 (pCEFL-HA-VRK1) or HA-VRK1 K179E (pCEFL-HA-VRK1 K179E). VRK1 
proteins were immunoprecipitated with a mouse monoclonal anti-HA antibody and 
AurKB was detected using a rabbit polyclonal anti-V5 antibody.  
 Moreover, we intended to analyze the VRK1 region with which AurKB 
interacted. Thus, HEK293T cells were transfected with V5-AurKB and with myc-
tagged VRK1 plasmids coding for different protein regions: VRK1 wild type 
(pCDNA3.1-VRK1-myc (1-396)), VRK1 large amino terminal (pCDNA3.1-VRK1-
myc-LA (1-332)), VRK1 short amino terminal (pCDNA3.1-VRK1-myc-SA (1-267)) 
and VRK1 carboxy terminal (pCEFL-GST-VRK1-C (267-396)). After V5-AurKB 
IP, VRK1 proteins were detected using antibodies anti-myc or anti-GST. We 
observed that the interaction of AurKB occurred with all the four VRK1 
constructions. This results suggests that AurKB interacts with both the amino and 
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Figure 23. VRK1 interacts trough both amino and carboxy terminal regions with 
AurKB. A) HEK293T cells were transfected, with V5-AurKB (pcDNA3.1/nV5-DEST-
AurKB) and with different VRK1 plasmids: VRK1 wild type (pCDNA3.1-VRK1-myc (1-
396)), VRK1 large amino terminal (pCDNA3.1-VRK1-myc-LA (1-332)), VRK1 short 
amino terminal (pCDNA3.1-VRK1-myc-SA (1-267)) and VRK1 carboxy terminal (pCEFL-
GST-VRK1-C (267-396)). V5-AurKB was immunoprecipitated with a rabbit polyclonal 
anti-V5 antibody and VRK1 proteins were detected, by WB, with a mouse monoclonal 
anti-myc antibody or with a mouse monoclonal anti-GST antibody. B) Schematic 
representation of VRK1 plasmids used in the immunoprecipitation assay.  
 Next, we aim to analyze the interaction between both endogenous VRK1 
and AurKB protein kinases, since the interaction was quite consistent between 
the two transfected proteins. Accordingly, HeLa cells were lysed and endogenous 
VRK1 was immunoprecipitated using a mouse monoclonal anti-VRK1 (1B5) 
antibody, which recognizes mainly the nuclear VRK1 population. Nonetheless in 
these conditions and, oppositely to what was expected, AurKB protein kinase was 


































Figure 24. Endogenous VRK1 does not interact with endogenous AurKB in 
unsynchronized cells. HeLa cells were lysed and VRK1 was immunoprecipitated with 
a mouse monoclonal anti-VRK1 (1B5) antibody. A mouse monoclonal anti-HA antibody 
was used as control of IP (IgG). AurKB was analyzed, by WB, using a rabbit monoclonal 
anti-AurKB antibody.    
 It is known that AurKB localization and levels depend on the cell cycle 
stage in which the cell are (Ruchaud et al., 2007). Thus, we confirm this 
observation, by IF, in HeLa cell line. Indeed, we observed that AurKB levels 
increase significantly from interphase to mitosis, and that the kinase localization 
change during mitosis. Initially AurKB seems to localize in the chromatin arms 
and potentially in centromeres, changing its localization during the metaphase to 













Figure 25. The levels and localization of AurKB are cell cycle-dependent. In HeLa 
cells, VRK1 was detected with a mouse monoclonal anti-VRK1 (1B5) antibody and 
AurKB was detected using a rabbit monoclonal anti-AurKB antibody. Chromatin was 
stained with DAPI.  
 Consequently and since AurKB levels and localization depends on cell 
cycle phase (Figure 25), we decided to analyze the interaction between VRK1 
and AurKB in the context of cell cycle. Therefore, we arrested U2OS cells at 
different time points of cell division: at G0-early G1, by serum starvation during 
72 hours, in S phase after double thymidine block and in early mitosis after double 
thymidine block, followed by 13 hours nocodazole treatment. Moreover and to 
obtain cells at different points of mitosis, the cells were released from nocodazole 
arrest and harvested 30, 60, 90, 180, 360 and 720 minutes post the release. The 
mechanism by which thymidine and nocodazole caused cell cycle arrest is 





described in the chapter 11 of material and methods and the alteration made in 
the cell line used, was due to the fact that osteosarcoma U2OS cell line was more 
suitable to perform cell cycle arrest experiments, compared to HeLa cell line. 
VRK1 was immunoprecipitated with a mouse monoclonal anti-VRK1 (1B5) 
antibody and AurKB was detected, by immunoblot, with a rabbit monoclonal anti-
AurKB antibody. Acid extracted histone H3 phosphorylations were detected, by 
immunoblot, with a rabbit polyclonal anti-H3T3ph antibody and a rabbit 
monoclonal anti-H3S10ph antibody. It was observed that VRK1-AurKB complex 
appeared in cells arrested with nocodazole, decreasing considerably 60 minutes 
after drug release (Figure 26A). At this point, as observed by FACS, the majority 
of the cells are in mitosis, suggesting that the interaction between VRK1 and 
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1 control sin suero.001 FL2-H 13,02 238,64 151 2,79 209,00 171,12 30,42
1 control sin suero.001 FL2-H 238,64 360,14 2760 51,07 294,00 294,69 8,08
1 control sin suero.001 FL2-H 368,81 464,27 577 10,68 425,00 420,91 6,38



























































1 control 10 suero.001 FL2-H 12,80 187,73 68 1,54 153,50 133,34 29,45
1 control 10 suero.001 FL2-H 192,00 311,47 2901 65,65 245,00 245,82 10,13
1 control 10 suero.001 FL2-H 320,00 384,00 418 9,46 351,00 350,94 5,56



























































1 timidina.001 FL2-H 34,13 234,67 80 2,25 113,50 120,33 40,87
1 timidina.001 FL2-H 238,93 384,00 1627 45,73 336,00 330,35 10,32
1 timidina.001 FL2-H 388,27 499,20 1310 36,82 436,00 437,22 7,17







































































1 timidina nocodazol.001 FL2-H 25,60 174,93 114 2,27 101,00 104,49 29,82
1 timidina nocodazol.001 FL2-H 179,20 294,40 141 2,80 244,00 239,37 12,81
1 timidina nocodazol.001 FL2-H 302,93 328,53 36 0,72 312,50 313,42 2,33































































1 30 min.001 FL2-H 25,60 217,60 116 1,85 111,50 115,73 34,97
1 30 min.001 FL2-H 226,13 409,60 70 1,11 338,50 324,33 16,27
1 30 min.001 FL2-H 426,67 452,27 19 0,30 438,00 440,35 1,81














30min release from 
Nocodazole
















































1 60 min.001 FL2-H 25,60 217,60 247 6,04 127,00 124,25 34,42
1 60 min.001 FL2-H 226,13 409,60 438 10,70 315,00 314,50 15,24
1 60 min.001 FL2-H 426,67 452,27 52 1,27 440,00 439,57 1,93














60min release from 
Nocodazole
















































1 90min.001 FL2-H 25,60 217,60 307 8,56 134,00 128,42 33,76
1 90min.001 FL2-H 226,13 409,60 1825 50,86 327,00 321,48 12,85
1 90min.001 FL2-H 426,67 452,27 66 1,84 436,00 437,58 1,65














90min release from 
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1 180 min.001 FL2-H 25,60 174,93 150 4,40 121,00 111,33 29,02
1 180 min.001 FL2-H 179,20 426,67 2980 87,47 332,00 327,66 12,76
1 180 min.001 FL2-H 435,20 460,80 55 1,61 448,00 448,27 1,68














180min release from 
Nocodazole
















































1 360 min.001 FL2-H 25,60 174,93 173 4,09 127,00 117,67 27,63
1 60 min.001 FL2-H 179,20 426,67 3910 92,54 311,00 308,18 13,81
1 360 min.001 FL2-H 435,20 460,80 40 0,95 449,50 449,14 1,60














360min release from 
Nocodazole








Figure 26. VRK1 interacts with AurKB during 
mitosis. A) U2OS cells were arrested at G0/G1 (0%) 
with serum-free medium for 72 hours, arrested in S 
phase (T) after double thymidine block or in early 
mitosis (T/N) after double thymidine block followed by 
nocodazole arrest. Furthermore, the cells were 
released from nocodazole arrest during 720 minutes, 
being the cells harvested at different time periods (30, 
60, 90, and 180, 360 and 720 minutes). 
Unsynchronized cells (10%) were maintained in 
normal conditions during the time of the experiment. 
Next, the extracts were immunoprecipitated with a 
mouse monoclonal anti-VRK1 (1B5) antibody or with a mouse monoclonal anti-HA 
antibody as IP control (IgG). By immunoblot, AurKB was detected using a rabbit 
monoclonal anti-AurKB antibody and VRK1 was detected using a rabbit polyclonal anti-
VRK1 antibody. B) FACS analysis.  
 Next, we decided to study which population of VRK1 and AurKB was 
interacting. It is known that VRK1 is a chromatin-associated kinase involved in 
chromatin remodeling, affecting histone post-translational modifications, such as 
phosphorylation, acetylation and methylations. Still, VRK1 is also detected in the 
cytoplasm and in the nucleoplasm as we confirmed here (Figure 27A) (Salzano 
et al., 2015). In turn, AurKB was described to be associated with centromeric 
chromatin, in the early stages of mitosis, and was also identified in the cytoplasm 
(Murata-Hori and Wang, 2002; Wang et al., 2010). Therefore, we had executed 
a fractionation cytoplasm, nucleoplasm and chromatin with nocodazole arrested 
cells to analyze which kinases population participates in the complex formation. 
Nocodazole arrest cell cycle in early mitosis, more precisely at prometaphase. 
Since the nuclear membrane was disrupted in prophase and it is impossible to 
differentiate between cytoplasm and nucleoplasm, both fractions were taken into 
account together and named cytoplasm. After U2OS cell fractionation, each 
fraction was immunoprecipitated with a mouse monoclonal anti-VRK1 (1B5) 
antibody and AurKB was detected, by immunoblot, with a rabbit monoclonal anti-
AurKB antibody. It was observed that VRK1 and AurKB interacted independently 
of their localization, in nocodazole arrested cells (Figure 27B). Unsynchronized 
















































1 720 min.001 FL2-H 25,60 256,00 308 5,62 165,50 153,18 34,37
1 720 min.001 FL2-H 268,80 366,93 816 14,89 326,00 323,65 7,69
1 720 min.001 FL2-H 366,93 426,67 643 11,74 398,00 397,59 4,32




















cells were used as control of synchronization and α-tubulin and histone H3 as 
cytoplasm and chromatin markers, respectively.  
 
Figure 27. VRK1 and AurKB interaction is independent of their localization. A) 
VRK1 was detected in the cytoplasm, nucleoplasm and chromatin fractions in A549, 
HeLa and MCF7 cell line after cell fractionation. B) U2OS cells were fractionated and 
VRK1 was immunoprecipitated, from unsynchronized and nocodazole arrested cells, 
with a mouse monoclonal anti-VRK1 (1B5) antibody or with a mouse monoclonal anti-
HA antibody (IgG) as control. AurKB was detected, by immunoblot, using a rabbit 
monoclonal anti-AurKB antibody. Α-tubulin and histone H3 were used as cytoplasm and 
chromatin controls, respectively. Uns. = Unsynchronized. Noc. = Nocodazole arrest. 
Cyto. = Cytoplasm and nucleoplasm fractions. Chr. = Chromatin fraction.   
 Besides the phosphorylation of histone H3 on Thr3 and Ser10, we decided 
to analyze additional histone H3 modifications, such as H3K4me3, H3K9me3, 
H3K9ac and H3K14ac in the context of cell cycle. So, HeLa cells were arrested 
at G0/G1 through 72 hours of serum starvation, in S-phase through double 
thymidine block and in early mitosis after double thymidine block, followed by 13 































































































of mitosis, the cells were nocodazole-released and harvested 30, 60, 90, 180, 
360 and 720 minutes after the release. Histone H3 was detected using a rabbit 
polyclonal anti-histone H3 antibody, H3K4me3 was detected using a rabbit 
polyclonal anti-H3K4me3, H3K9me3 was detected using a rabbit polyclonal anti-
H3K9me3 antibody, H3K9ac was detected using a rabbit polyclonal anti-H3K9ac 
antibody and H3K14ac was detected using a rabbit polyclonal anti-H3K14ac 
antibody. VRK1 and AurKB were detected with a mouse monoclonal anti-VRK1 
(1F6) antibody and a rabbit monoclonal anti-AurKB antibody, respectively. 
Nevertheless, it was not perceived any extraordinary result, besides the fact that 
H3K9me3 seems to vary inversely to H3S10ph (histone crosstalk) as previous 
described (Figure 28) (Bannister and Kouzarides, 2011). 
 
Figure 28. Histone H3 post-translational modifications during cell cycle. H3K9me3 
seems to fluctuate inversely to H3S10ph. Histones were extracted using an acid 
extraction protocol, from HeLa cells synchronized at different stages of cell cycle, as 
explained in Figure 21.  
1.3 VRK1 co-localization with AurKB during cell cycle 
 Afterward, VRK1 and AurKB co-localization was analyzed in U2OS and 
HeLa cell line, by IF. Since both the kinases interacted during mitosis (Figure 26), 
it was expected that VRK1 and AurKB co-localize during any mitotic stage. 
Concerning U2OS cell line, the cells were arrested at G0/G1 by serum starvation 
during 72 hours, in S-phase with double thymidine block and in early mitosis after 
double thymidine block, followed by 13 hours of nocodazole treatment. Moreover 

















nocodazole arrest and harvested 30, 60, 90, 180, 360 and 720 minutes post the 
release. VRK1 was detected using two different antibodies recognizing different 
kinase populations. It was used a mouse monoclonal anti-VRK1 (1B5), which 
recognizes specifically the nuclear VRK1 population (Figure 29A) and a mouse 
monoclonal anti-VRK1 (1F6) that recognizes specifically the cytoplasmic VRK1 
population (Figure 29B). AurKB was detected using a rabbit monoclonal anti-
AurKB antibody and the chromatin was stained with DAPI. The co-localization 
studies were performed in a Leica TCS SP5 inverted fluorescence microscope 
connected to a digital video camera used to obtain the confocal microscopy 
images, which were analysed using the LAS AF Lite. In both cases, it was not 
observed any co-localization between VRK1 and AurKB at any stage of cell 
division cycle in U2OS (Figure 29). 
 Similar results were obtained in HeLa cell line. Once again, HeLa cells 
were arrested at G0-early G1 through serum starvation during 72 hours, in S-
phase after double thymidine block and in early mitosis after double thymidine 
block, followed by 13 hours of nocodazole treatment. Then and to attain cells at 
different stages of mitosis, the cells were released from nocodazole arrest and 
harvested 30, 60, 90, 180, 360 and 720 minutes after being released. VRK1 was 
detected using the same two mouse monoclonal anti-VRK1 (1B5) and anti-VRK1 
(1F6) antibodies, AurKB was detected with a rabbit monoclonal anti-AurKB 
antibody and chromatin was stained with DAPI (Figure 30). The representation 
of Figure 30 was elaborated distinctly from Figure 29, due to the fact that HeLa 
cell line showed a larger cell cycle comparing with U2OS cell line. So, in HeLa 
cells, each experimental point represented mostly a cell cycle stage, whereas in 
U2OS cells each experimental point included various mitotic stages, which made 
it impossible to attribute to each experimental point a stage of mitosis. Co-
localization analysis was executed drawing a straight line on the more likely co-
localization site, and evaluated directly with the specific tool provided by LAS AF 





























































































































Figure 29. VRK1 and AurKB don’t co-localize in U2OS cell line. U2OS cells, arrested 
at each point of cell cycle, were analyzed by IF. The protocol used was the same of 
Figure 26. VRK1 was detected with a mouse monoclonal anti-VRK1 (1B5) antibody (A) 
or with a mouse monoclonal anti-VRK1 (1F6) antibody (B). AurKB was detected using a 

































































































































































































































































































Figure 30. VRK1 and AurKB don’t co-localize in HeLa cell line. HeLa cells were 
analyzed, by IF, after being arrested at different stages of cell cycle. The protocol used 
was the same of Figure 26. VRK1 was detected with a mouse monoclonal anti-VRK1 
(1B5) antibody (A and C) or with a mouse monoclonal anti-VRK1 (1F6) antibody (B). 
AurKB was detected using a rabbit monoclonal anti-AurKB antibody. Chromatin was 
stained with DAPI. Co-localization studies were performed drawing a straight line on the 
potential co-localization site, and analyzed directly with the specific tool provided by LAS 
AF Lite software (C).   
 Moreover, it is known that phosphorylation of histone H3 on the Thr3 
residue is critical for the localization of CPC/ AurKB in centromeres, in the early 
stages of mitosis, and that during metaphase to anaphase transition, AurKB re-
locates to the midzone spindle, in line with a decrease in H3T3ph (Carmena and 
Earnshaw, 2003; Wang et al., 2010; Wang et al., 2011). Therefore we intended 
to verify, by IF, such behavior of H3T3ph in U2OS and HeLa cell lines and confirm 
that the in fact AurKB re-location and H3T3ph decrease may be related. Besides, 
immunoblot data showed a quick decline in H3T3ph, after nocodazole release, 
which is consistent with the loss of VRK1-AurKB interaction (Figure 26A). So, it 
could be important to analyze H3T3ph in the context of cell cycle, to limit the 
stages of mitosis in which both the kinases interact. H3S10ph, which is a 
phosphorylation AurKB-dependent and occurs mostly during mitosis, was used 
as control of antibody specificity. The protocol used to arrest cells at distinct 
points of mitosis was the same as previous described in this chapter and VRK1 
was detected using a mouse monoclonal anti-VRK1 (1B5) antibody, H3T3ph was 
detected using a rabbit polyclonal anti-H3T3ph and H3S10ph was detected using 
a rabbit monoclonal anti-H3S10ph antibody. DAPI was used to stain chromatin. 
Indeed, it was observed that H3T3ph appeared early in mitosis and lasted until 
anaphase (Figure 31A and Figure 31C), and this correlates with the change 
observed in AurKB localization (Figure 29 and Figure 30). In turn, H3S10ph 
decreased continuously during cell cycle, but histone phosphorylation was still 
detectable in the late phases of mitosis, in U2OS cell line (Figure 31B). Yet, in 
HeLa cell line maybe due the slighter stain of H3S10ph, it seemed to disappear 
during the anaphase to telophase transition (Figure 31D). Unfortunately, H3T3ph, 





localization studies were limited. Due to the same motive previously mentioned, 
























































































































































































































































































































Figure 31. H3T3ph and H3S10ph levels during cell cycle. U2OS (A and B) and HeLa 
(C and D) cell lines were analyzed, by IF, after being arrested at different stages of cell 
cycle. The protocol used was the same of Figure 26. VRK1 was detected with a mouse 
monoclonal anti-VRK1 (1B5) antibody, H3T3ph was detected using a rabbit polyclonal 
anti-H3T3ph antibody (A and C) and H3S10ph was detected using a rabbit monoclonal 
anti-H3S10ph antibody (B and D). Chromatin was stained with DAPI.  
1.4 Regulation of kinase activity by phosphorylation  
 At this point we knew that VRK1 and AurKB formed a stable complex 
during mitosis, which affected the kinase activity of one another. Furthermore, it 
is recognized that VRK1 is a highly active kinase that phosphorylates numerous 
substrates such as p53, histone H3, coilin, histone H2A.X or CREB (Cantarero et 
al., 2015; Kang et al., 2007b; Salzano et al., 2015; Vega et al., 2004a). Also, 
AurKB is very active during mitosis, and phosphorylates various protein 
substrates such as histone H3 and MCAK or even other protein kinases like 
Haspin and ATM (Hirota et al., 2005; Wang et al., 2011; Yang et al., 2011; Zhang 
et al., 2007). Thus, it is likely that these two kinase may be regulating one another 
by direct phosphorylation. Accordingly, there were performed two separated 
kinase assays with radiolabeled ATP to verify whether VRK1 phosphorylates 
AurKB or if AurKB phosphorylates VRK1. Similar experiment was performed 
initially, to the Figure 16, but we expected to discard that the presence of histone 
H3 on the mix, in combination with VRK1 and AurKB recombinant proteins, could 
weight on the result obtained.  
 First, GST-AurKB-K106R was incubated with GST-VRK1 and GST-p53 
was used as positive control. We observed that AurKB was not a direct substrate 
of VRK1 (Figure 32A) in such conditions. Secondly, inactive GST-VRK1-K179E 
was incubated with GST-AurKB and purified human histone H3 was used as 
positive control. Again, the result was negative, meaning that VRK1 was not an 
AurKB-direct substrate in these conditions (Figure 32B). Both kinase assays were 
performed in the presence of cold ATP and radiolabeled ATP [γ-32P] and were 
incubated in a thermomixer at 30ºC during 30 minutes.   
 Once again, we detected a slight decrease in the autophosphorylation of 




combined. This observation confirmed that the interaction between the two 
kinases affected the kinase capability of one another.  
 
Figure 32. A) AurKB is not a direct substrate of VRK1. B) VRK1 is not a direct 
substrate of AurKB. A) A) Inactive GST-AurKB-K106R (pGEX-GST-AurKB-K106R) 
was incubated with GST-VRK1 (pGEX-GST-VRK1) and with GST-p53 (pGEX-GST-p53) 
as positive control. B) Inactive GST-VRK1-K179E (pGEX-GST-VRK1-K179E) was 
incubated with GST-AurKB (pGEX-GST-AurKB) and purified human histone H3 was 
used as positive control. Both kinase assays were performed in the presence of cold 
ATP and radiolabeled [γ-32P] ATP, in a thermomixer at 30ºC during 30 minutes. The 
incorporated radioactivity was detected exposing the ray-x film to the membranes. 
1.5 VRK1 effect on the ubiquitination and stability of AurKB  
 Furthermore, we had also analyzed the potential role of VRK1 on the 
ubiquitination and stability of AurKB, since both kinases are peculiarly connected 
through the mitotic process. It is known that ubiquitination of AurKB regulates the 
CPC/ AurKB localization in the central spindle during anaphase or the kinase 
degradation (Maerki et al., 2009; Teng et al., 2012). In turn, VRK1 had been 
demonstrated to protect coilin from ubiquitination and degradation in the 
proteasome (Cantarero et al., 2015). Accordingly, VRK1 may also be relevant in 
the stabilization of AurKB levels, regulating the ubiquitination of the kinase. 
Initially, the effect of VRK1 downregulation on the AurKB ubiquitination was 
performed in HEK293T cells, in the presence or absence of MG132, a specific, 
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with a siRNA targeting VRK1 (siVRK1-02), or with a siRNA (siControl) lacking a 
specific target. Next day, the same cells were transfected with V5-AurKB and HA-
Ubiquitin, and 36 hours later they were treated ON with 20µM MG132. MG132 
non-treated cells were maintained as part of experiment as control of drug 
efficiency. Then, from cells extracts treated or not-treated with MG132, V5-AurKB 
was immunoprecipitated with a mouse monoclonal anti-V5 antibody or HA-
Ubiquitin was immunoprecipitated with a rabbit polyclonal anti-HA antibody. V5-
AurKB was detected, by immunoblot, with a mouse monoclonal anti-V5 antibody 
or with a rabbit polyclonal anti-V5 antibody. HA-Ubiquitin was detected, by 
immunoblot, with a mouse monoclonal anti-HA antibody or with a rabbit 
polyclonal anti-HA antibody. The choice of antibody used in the immunoblot 
depended of the antibody used in the IP, to minimize cross-reactivity between 
antibodies from the same species. It was observed that VRK1 knockdown led to 
a decrease in AurKB polyubiquitination (over 70 kDa), independently of MG132 
treatment, after HA-Ubiquitin IP. The same result is observed after IP of V5-
AurKB, in MG132 treated cells, but is not perceptible in MG132 non-treated cells. 
Nevertheless, it was observed that VRK1 knockdown induced an overall protein 





Figure 33. VRK1 knockdown interferes with AurKB ubiquitination. VRK1 was 
downregulated, in HEK293T cells, using a specific VRK1-siRNA (siVRK1-02 = siV-02) 
and a siRNA lacking a specific target (siControl = siC) was used as control. Then, V5-
AurKB (pcDNA3.1/nV5-DEST-AurKB) and HA-Ubiquitin (pSSK-HA-Ubiquitin) were 
transfected and later the cells were overnight treated with MG132. MG132 non-treated 
cells were also used as part of experiment. Next, V5-AurKB was immunoprecipitated 
with a mouse monoclonal anti-V5 and HA-Ubiquitin was immunoprecipitated with a rabbit 
polyclonal anti-HA antibody. V5-AurKB was detected, by immunoblot, with a mouse 
monoclonal anti-V5 antibody or with a rabbit polyclonal anti-V5 antibody. HA-Ubiquitin 
was detected, by immunoblot, with a mouse monoclonal anti-HA antibody or with a rabbit 
polyclonal anti-HA antibody. 
 Afterwards, AurKB stability was evaluated in VRK1 overexpression and 
knockdown conditions, by CHX chase assay. VRK1 was downregulated, during 







































































was used as control (siControl). On the other hand, HA-VRK1 was overexpressed 
alongside with V5-AurKB, during 48 hours. Empty vector was used as control and 
transfected together with V5-AurKB. Once CHX was added, the cells were 
harvest at different times (4, 8, 12 and 24 hours) and the extracts processed.  
 
Figure 34. VRK1 overexpression stabilizes transfected AurKB, but VRK1 
knockdown did not affect endogenous AurKB stability. A) In HEK293T cells, VRK1 
was downregulated, during 72 hours, using a specific VRK1-siRNA (siVRK1-02 = siV-
02) and a siRNA lacking a specific target (siControl = siC) was used as control. By 
immunoblot analysis, endogenous VRK1 was detected with a rabbit polyclonal anti-
VRK1 (VC) antibody, endogenous AurKB was detected using a rabbit monoclonal anti-
AurKB antibody. B) V5-AurKB (pcDNA3.1/nV5-DEST-AurKB) and HA-VRK1 (pCEFL-
HA-VRK1) or HA-ø (pCEFL-HA-ø) were transfected in HEK293T cells. By immunoblot 
analysis, V5-AurKB was detected with a mouse monoclonal anti-V5 antibody and HA-
VRK1 was detected with a rabbit polyclonal anti-HA antibody. In both experiments cells 
were harvest 4, 8, 12 and 24 hours after cycloheximide (CHX) treatment. Endogenous 
and transfected AurKB levels were quantified using ImageJ and represented in a graphic.  
 By immunoblot analysis, endogenous VRK1 was detected with a rabbit 
polyclonal anti-VRK1 (VC) antibody, endogenous AurKB was detected using a 
rabbit monoclonal anti-AurKB antibody, HA-VRK1 was detected using a rabbit 
polyclonal anti-HA antibody and V5-AurKB was detected using a mouse 
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ImageJ and represented in a graphic. It was observed that VRK1 knockdown did 
not changed endogenous AurKB stability (Figure 34A), but VRK1 overexpression 
seemed to increase V5-AurKB stability, comparing to the control (Figure 34B).   
1.6 Regulation of AurKB localization during mitosis by VRK1 
 CPC, and therefore AurKB, locates and accumulates during the early 
stages of mitosis on chromatin, more precisely, on centromeres. A localization 
that has been described to depend on the phosphorylation of histone H3 on Thr3 
by Haspin, and on the phosphorylation of histone H2A on Thr120 by Bub1. 
H3T3ph serves as a docking site for Survivin and the H2AT120ph as a docking 
site for Borealin via Sgo1. Accordingly, loss of H3T3ph leads to CPC-AurKB 
missed localization on the centromeres and increased AurKB dispersion on the 
chromatin (Wang et al., 2010; Wang et al., 2011; Watanabe, 2010). Thus and 
since H3T3 is a direct phosphorylation target of VRK1, it seems likely that AurKB 
centromeric localization, may depend on VRK1 activity. Thereby, we began to 
analyze, by IF, the effect of VRK1 downregulation on AurKB localization in 
nocodazole arrested cells. In U2OS cell line, VRK1 was downregulated using a 
specific VRK1-siRNA (siVRK1-02), and a siRNA lacking a precise target was 
used as control (siControl). 60 hours later the cells were treated with nocodazole 
for 13 hours. Unsynchronized cells, transfected with siControl, were used as 
control of drug efficiency. By IF, AurKB was detected using a rabbit monoclonal 
anti-AurKB antibody and VRK1 was detected using a mouse monoclonal anti-
VRK1 (1B5) antibody. Chromatin was stained with DAPI. As expected, was 
observed that AurKB localization seemed to change from a centromeric state to 






Figure 35. VRK1 downregulation re-locates AurKB from centromeres. In U2OS 
cells, VRK1 was downregulated using a specific VRK1-siRNA (siVRK1-02 = siV-02) and 
a non-specific siRNA (siControl = siC) was used as control. 60 hours later cells were 
treated with nocodazole, during 13 hours. Unsynchronized cells, transfected with siC, 
were used as control of drug efficiency. By IF, VRK1 was detected with a mouse 
monoclonal anti-VRK1 (1B5) antibody and AurKB was detected using a rabbit 
monoclonal anti-AurKB antibody. Chromatin was stained with DAPI. 
 At the same time, and using the same VRK1-knockdown protocol used in 
Figure 34, the effect of VRK1 downregulation on H3T3ph levels was confirmed, 
by IF, in nocodazole-arrested U2OS cells. Once again, unsynchronized cells 
transfected with siControl were used as control of drug efficiency. By IF, H3T3ph 
was detected using a rabbit polyclonal anti-H3T3ph antibody and VRK1 was 
detected using a mouse monoclonal anti-VRK1 (1B5) antibody. Chromatin was 
stained with DAPI. As previous determined, VRK1 downregulation led to a 

















































Figure 36. H3T3ph is negatively affect by VRK1 downregulation. In U2OS cells, 
VRK1 was downregulated using a specific VRK1-siRNA (siVRK1-02 = siV-02) and a non-
specific siRNA (siControl = siC) was used as control. 60 hours later cells were treated 
with nocodazole, during 13 hours. Unsynchronized cells, transfected with siC, were used 
as control of drug efficiency. By IF, VRK1 was detected with a mouse monoclonal anti-
VRK1 (1B5) antibody and H3T3ph was detected using a rabbit polyclonal anti-H3T3ph 
antibody. Chromatin was stained with DAPI. 
 Next, we aimed to analyze the co-localization of AurKB with centromeres, 
under VRK1 downregulation conditions. Again, U2OS cells were treated with a 
siRNA targeting VRK1 (siVRK1-02) or with a siRNA control (siControl), and 60 
hours later the cells were incubated with nocodazole during 13 hours. 
Unsynchronized cells, transfected with siControl, were used as control of drug 
efficiency. By IF, AurKB was detected using a rabbit monoclonal anti-AurKB 
antibody and centromeres were detected using a human anti-centromere 

















































Figure 37. AurKB fails to locate in the centromeres in the absence of VRK1. A) In 
U2OS cells, VRK1 was downregulated using a specific VRK1-siRNA (siVRK1-02 = siV-
02) and a non-specific siRNA (siControl = siC) was used as control. 60 hours later cells 
were treated with nocodazole, during 13 hours. Unsynchronized cells, transfected with 
siC, were used as control of drug efficiency. By IF, centromeres were detected with a 
human anti-centromere antibody (ACA) and AurKB was detected using a rabbit 
monoclonal anti-AurKB antibody. Chromatin was stained with DAPI. B) A total of 100 
cells were counted concerning the distribution of AurKB on centromeres and 
chromosome arm or diffused on the chromatin (Chi-square statistic is significant at 
p<0.01). Pearson’s correlation coefficient value was calculated separately for each cell, 
giving us the value of overlapping red and green pixels in each nucleus. (Student’s Test: 
















































































































 Co-localization studies were performed by two distinct methods: the first 
by analyzing the images and the distribution of AurKB on centromeres and 
chromosome arms, or diffused on the chromatin, and the second calculating the 
Pearson’s correlation coefficient value separately for each cell. This coefficient 
gave us the value of overlapped red and green pixels in each nucleus (Figure 
37B). This experiment confirmed that VRK1 downregulation re-located AurKB 
from centromeres to a more diffused state on the chromatin. The result is 
sustained by the decreased number of cells with yellow dots, consequence of 
diminished ACA and AurKB co-localization, and by the reduced overlapping 
pixels calculated by Pearson’s correlation coefficient (Figure 37).  
 Besides AurKB co-localization with ACA, also a potential co-localization 
between VRK1 and ACA was analyzed in unsynchronized and nocodazole 
arrested cells. By IF, VRK1 was detected using a rabbit polyclonal anti-VRK1 
antibody and centromeres were detected using a human anti-centromere 
antibody (ACA). Chromatin was stained with DAPI. We did not observe any co-
localization between VRK1 and centromeres. Neither during G1 (unsynchronized 
cells) nor during prometaphase (nocodazole arrested cells) (Figure 38).  
 
Figure 38. VRK1 is not located at centromeres in early stages of mitosis. U2OS 
cells were treated with nocodazole, during 13 hours and unsynchronized cells were used 
as control of drug efficiency. By IF, centromeres were detected with a human anti-
centromere antibody (ACA) and VRK1 was detected using a rabbit polyclonal anti-VRK1 



































 VRK1 knockdown led to the re-location of AurKB from centromeres to a 
more diffuse state on the chromatin. An observation that may be related to the 
loss of H3T3ph and consequently to the disruption of CPC/ AurKB interaction with 
histone H3. Therefore, we aimed to verify whether the change on AurKB mitotic 
localization, observed after the knockdown of VRK1, is related to the loss of 
interaction between histone H3 and AurKB. For that reason, U2OS cells were 
transfected with a siRNA targeting VRK1 (siVRK1-02) or a siRNA control 
(siControl), lacking a specific target, and 60 hours later they were treated with 
nocodazole during 13 hours. Unsynchronized cells, transfected with siControl, 
were used as control of drug efficiency. Afterwards, AurKB was 
immunoprecipitated with a rabbit polyclonal anti-AurKB antibody and histone H3 
was detected, by immunoblot, with a rabbit polyclonal anti-histone H3 antibody. 
Additionally, histones were extracted using an acid extraction protocol and 
H3T3ph was detected, by immunoblot, with a rabbit polyclonal anti-H3T3ph 
antibody. We confirmed that AurKB and histone H3 interacted in nocodazole 
arrested cells, and that the downregulation of VRK1 led to a decrease on this 
interaction. The loss of histone H3 and AurKB interaction occurs in line with the 
decline observed in H3T3ph levels in VRK1-knockdown conditions. The loss of 







Figure 39. Histone H3 and AurKB interaction is loss when VRK1 is downregulated. 
VRK1 was downregulated using a specific VRK1-siRNA (siVRK1-02 = siV-02) and a non-
specific siRNA (siControl = siC) was used as control. 60 hours later cells were treated 
with nocodazole, during 13 hours. Unsynchronized cells, transfected with siC, were used 
as control of drug efficiency. Afterward, AurKB was immunoprecipitated with a rabbit 
polyclonal anti-AurKB antibody and histone H3 was detected, by immunoblot, with a 
rabbit polyclonal anti-histone H3 antibody. Furthermore, histones were extracted by acid 
extraction and H3T3ph was detected, by immunoblot, with a rabbit polyclonal anti-
H3T3ph antibody. 






































Part 2. Regulation of VRK1 by Sox2 during cell 
proliferation and differentiation 
1.1 VRK1 and Sox2 co-localization 
 The implication of both Sox2 and VRK1 in cell proliferation led us to 
determine whether there is a relationship between these two proteins (Basu-Roy 
et al., 2012; Santos et al., 2006; Tompkins et al., 2011; Valbuena et al., 2008b). 
Firstly, we intended to verify the pattern of VRK1 and Sox2 protein expression in 
a stratified squamous epithelium of a normal human tonsil. Sox2 was detected 
using a mouse monoclonal anti-Sox2 antibody and VRK1 was detected using a 
rabbit polyclonal anti-VRK1 antibody. We observed that VRK1 and Sox2 showed 
a similar localization, overlapping consistently within the proliferative amplification 
compartment and decreasing their protein expression as epithelial cells were 
terminally differentiated. Moreover, VRK1 was also detected in normal and 
tumoral lymphoid follicles, while Sox2 was only detected in tumoral lymphoid 





Figure 40. VRK1 and Sox2 co-localize in a stratified squamous epithelium of a 
normal human tonsil. A and B) Normal human tonsil. C) Tumoral human tonsil. By IHC 
and fluorescent IHC Sox2 was detected using a mouse monoclonal anti-Sox2 antibody 
and VRK1 was detected using a rabbit polyclonal anti-VRK1 antibody. Chromatin was 
stained with DAPI. F = Follicular tissue. The images were amplified 400x. 
 Next, we examined the VRK1 and Sox2 potential relationship in several 
cancer cell lines: MCF7 and MDA-MB-231 breast cancer cell lines, and NT2, a 
















localize in a stratified squamous epithelium of a normal human tonsil, it was 
expected similar result among cell lines.  
 
Figure 41. VRK1 and Sox2 co-localize in NTERA-2, MCF7 and MDA-MB-231 cell 
lines. A) Sox2 was detected using a mouse monoclonal anti-Sox2 antibody and VRK1 
was detected using a rabbit polyclonal anti-VRK1 antibody. Chromatin was stained with 
DAPI. B) Endogenous levels of Sox2 were detected, by immunoblot, with a rabbit 
monoclonal anti-Sox2 antibody. C) Sox2 protein levels were immunoprecipitated with a 
mouse monoclonal anti-Sox2 antibody and detected, by immunoblot, using a goat 
monoclonal anti-Sox2 antibody.  
 Besides, the protein levels of reprogramming factor Sox2 were evaluated, 
by immunoblot, since they had been reported to be residual and imperceptible in 













































































anti-Sox2 antibody and VRK1 was detected using a rabbit polyclonal anti-VRK1 
antibody. Chromatin was stained with DAPI. By immunoblot, Sox2 was detected 
using a rabbit monoclonal anti-Sox2 antibody. We observed that NT2 cells have 
high levels of both Sox2 and VRK1 proteins (Figure 41B) and that MDA-MB-231 
low endogenous levels of Sox2 became detectable, by immunoblot, after IP 
(Figure 41C). Although Sox2 expression levels varied among cell lines, nuclear 
co-localization of Sox2 and VRK1 was confirmed by IF in NT2, MDA-MB-231 and 
MCF7 cell lines (Figure 41A).  
1.2 VRK1 interaction with reprogramming factor Sox2 
 VRK1 is a chromatin kinase that establishes stable complexes with several 
transcription factors such as p53, ATF2 and c-Jun (Lopez-Sanchez et al., 2014a; 
Sevilla et al., 2004a; Sevilla et al., 2004b). Therefore and since VRK1 and Sox2 
co-localize in human cancer cell lines and in a stratified squamous epithelium of 
a normal human tonsil, it is likely that both proteins interact, forming a stable 
protein complex. So, we performed reciprocal IPs of endogenous VRK1 and Sox2 
proteins from extracts of MDA-MB-231, NT2 and HEK293T cells. The extracts 
were immunoprecipitated or with a mouse monoclonal anti-VRK1 (1B5) antibody 
or with a mouse monoclonal anti-Sox2 antibody. By immunoblot, Sox2 was 
detected using a goat polyclonal anti-Sox2 antibody and VRK1 was detected 
using a rabbit polyclonal anti-VRK1 antibody (VC). In the three cell lines, Sox2 
was detected in the VRK1 immunoprecipitate, and reciprocally VRK1 was also 













Figure 42. VRK1 and Sox2 interact in NTERA-2, MCF7 and MDA-MB-231 cell lines. 
A) Sox2 was immunoprecipitated with a mouse monoclonal anti-Sox2 antibody and 
VRK1 was detected with a rabbit polyclonal anti-VRK1 (VC) antibody.  A mouse 
monoclonal anti-HA (IgG) antibody was used as control of IP. B) VRK1 was 
immunoprecipitated with a mouse monoclonal anti-VRK1 (1B5) antibody and Sox2 was 
detected a goat polyclonal anti-Sox2 antibody (HEK293T and MDA-MB-231) or with a 
rabbit polyclonal anti-Sox2 antibody (NT2). A mouse monoclonal anti-HA (IgG) antibody 
was used as control of IP.  
 Moreover, the stable VRK1-Sox2 protein interaction was confirmed by IP 
of transfected tagged-proteins. Therefore, myc-FLAG-Sox2 was transfected 
alone or alongside with HA-VRK1 in HEK293T cells. Then, protein extracts were 
immunoprecipitated with a rabbit polyclonal anti-FLAG antibody, or with a rabbit 
polyclonal anti-HA antibody or with a rabbit polyclonal anti-VRK1 (VC) antibody. 
VRK1 was detected in Sox2 immunoprecipitate with a mouse monoclonal anti-
HA antibody or with a mouse monoclonal anti-VRK1 (1B5) antibody. Sox2 was 
detected in VRK1 immunoprecipitate with a mouse monoclonal anti-FLAG 
antibody. In all the experiments VRK1 interacted with Sox2, confirming the results 
obtained previously (Figure 43A-D). Additionally, a stable concentration of HA-
VRK1 was transfected with increased doses of myc-FLAG-Sox2. Then, Sox2 was 
immunoprecipitated, from protein extracts, with a rabbit polyclonal anti-FLAG 
antibody and VRK1 was detected with a mouse monoclonal anti-HA antibody. 
Again, we observed that VRK1 and Sox2 interacted, being the interaction, in this 
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Figure 43. VRK1 and Sox2 transfected proteins interact. The interaction depends 
on Sox2 levels. A) HEK293T cells were transfected with pCMV6-myc-FLAG-Sox2 and 
pCEFL-HA-VRK1. Sox2 was immunoprecipitated with a rabbit polyclonal anti-FLAG 
antibody and VRK1 was detected, by immunoblot, with a mouse monoclonal anti-HA 
antibody. B) HEK293T cells were transfected with pCEFL-HA-VRK1 and pCMV6-myc-
FLAG-Sox2. VRK1 was immunoprecipitated with a rabbit polyclonal anti-HA antibody 
and Sox2 was detected, by immunoblot, with a mouse monoclonal anti-FLAG antibody. 
C) FLAG-Tagged Sox2 (pCMV6-myc-FLAG-Sox2) was transfected in HEK293T cells 
and Sox2 was immunoprecipitated with a rabbit polyclonal anti-FLAG antibody. VRK1 
was detected with a mouse monoclonal anti-VRK1 (1B5) antibody.  D) FLAG-Tagged 
Sox2 (pCMV6-myc-FLAG-Sox2) was transfected in HEK293T cells and VRK1 was 
immunoprecipitated with a rabbit polyclonal anti-VRK1 (VC) antibody. A rabbit polyclonal 
anti-HA (IgG) antibody was used as control of IP. Sox2 was detected with a mouse 
monoclonal anti-FLAG antibody. E) HEK293T cells were transfected with a stable 
concentration of pCEFL-HA-VRK1 and increased doses of pCMV6-myc-FLAG-Sox2. 
Sox2 was immunoprecipitated with a rabbit polyclonal anti-FLAG antibody and VRK1 
was detected, by immunoblot, with a mouse monoclonal anti-HA antibody. 
 Also, we intended to analyze the VRK1 region with which Sox2 interacted. 
Firstly, HEK293T cells were transfected with myc-FLAG-Sox2 (pCMV6-myc-


























































GST-VRK1), VRK1 carboxy terminal (pCEFL-GST-VRK1-C (267-396)) or VRK1 
truncated kinase (pCEFL-GST-VRK1-R358X). Sox2 was immunoprecipitated 
with a rabbit polyclonal anti-FLAG antibody and VRK1 plasmids were detected, 
by immunoblot, with a mouse monoclonal anti-GST-antibody. Secondly, 
HEK293T cells were transfected with VRK1 wild type (pCDNA3.1-VRK1-myc (1-
396)) or with VRK1 large amino terminal (pCDNA3.1-VRK1-myc-LA (1-332)). 
Endogenous Sox2 was immunoprecipitated with a mouse monoclonal anti-Sox2 
antibody and VRK1 plasmids were detected, by immunoblot with a rabbit 
polyclonal anti-myc antibody. We observed that VRK1 interacted with Sox2 
through both amino and carboxy terminals (Figure 44). 
 
Figure 44. VRK1 interacts trough both amino and carboxy terminal with Sox2. A) 
myc-FLAG-Sox2 (pCMV6-myc-FLAG-Sox2) and GST-tagged VRK1 plasmids (VRK1 
wild type (pCEFL-GST-VRK1), VRK1 carboxy terminal (pCEFL-GST-VRK1-C (267-396)) 
or VRK1 truncated kinase (pCEFL-GST-VRK1-R358X)) were transfected in HEK293T 
cells. Sox2 was immunoprecipitated with a rabbit polyclonal anti-FLAG antibody and 
VRK1 plasmids were detected, by immunoblot, with a mouse monoclonal anti-GST-
antibody. B) HEK293T cells were transfected with myc-VRK1 wild type (pCDNA3.1-
VRK1-myc (1-396)) or with myc-VRK1 large amino terminal (pCDNA3.1-VRK1-myc-LA 
(1-332)). Endogenous Sox2 was immunoprecipitated with a mouse monoclonal anti-
Sox2 antibody and VRK1 plasmids were detected, by immunoblot, with a rabbit 
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1.3 Sox2 is a phosphorylation target of VRK1 
 The chromatin associated VRK1 phosphorylates several transcriptional 
factors, such as p53, ATF2 and c-Jun, with which the kinase interact (Lopez-
Sanchez et al., 2014b; Sevilla et al., 2004a; Sevilla et al., 2004b). Therefore, it is 
possible that Sox2 may be phosphorylated by VRK1. In order to analyze the 
potential phosphorylation of Sox2 by VRK1, HEK2293T cells were transfected 
with myc-FLAG-Sox2 (pCMV6-myc-FLAG-Sox2) or with myc-FLAG empty vector 
(pCMV6-myc-FLAG-ø). Then, the protein extracts were immunoprecipitated with 
a mouse monoclonal anti-myc antibody and incubated, in a thermomixer at 30ºC 
during 30 minutes, with recombinant proteins GST-VRK1 (pGEX-GST-VRK1) 
and GST-VRK1-K179E (pCEFL-GST-VRK1-K179E), in the presence of cold ATP 
and radiolabeled ATP [γ-32P]. It was observed that Sox2 was a phosphorylation 
target of VRK1 (Figure 45).  
 
Figure 45. VRK1 phosphorylates Sox2. HEK293T cells were transfected with myc-
FLAG-Sox2 (pCMV6-myc-FLAG-Sox2) or with myc-FLAG empty vector (pCMV6-myc-
FLAG-ø) and Sox2 was immunoprecipitated with a mouse monoclonal anti-myc 
antibody. Immunoprecipitated myc-Sox2 was incubated with recombinant proteins GST-
VRK1 (pGEX-GST-VRK1) and GST-VRK1-K179E (pCEFL-GST-VRK1-K179E) in the 
presence of cold ATP and radiolabeled [γ-32P] ATP, in a thermomixer at 30ºC during 30 
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1.4 Sox2 is implicated in the regulation of cell proliferation 
 The co-localization of Sox2 and VRK1 in the proliferation compartment, as 
well as their interaction, suggested that both proteins are likely to be involved in 
the regulation of cell proliferation. Indeed, it was reported that the loss of VRK1 
reduced WS1 fibroblasts cell proliferation (Valbuena et al., 2008b) and likewise, 
some data indicated that Sox2 may also be involved in the control of cell 
proliferation (Basu-Roy et al., 2012; Chen et al., 2008a). Therefore, in MDA-MB-
231 cells, we evaluated the effect of Sox2 or VRK1 depletion on cell proliferation 
(Figure 46).  
 
Figure 46. Depletion of Sox2 results in loss of proliferation. An equal number of 
MDA-MB-231 cells were transfected with siRNAs targeting specifically Sox2 (siSox2 = 
siS) and VRK1 (siVRK1-02 = siV) or with a siRNA lacking a precise target (siControl = 
siC). Lipofectamine-treated cells (mock) were used to exclude a possible effect of the 
reagent on cell proliferation. Then, the cells were harvested during 5 days and the cell 
number counted. The results show the mean of three experiments, in which each point 
was determined in triplicate (A). Proliferative markers were analyzed by immunoblot (B) 
and the mRNA levels of Sox2 determined by qRT-PCR (C). (Student’s Test: *<0.05; 
**<0.005; ***<0.0005). Confluence images were acquired on a microscope, at 100x 








































































 The cells were transfected with siRNAs targeting specifically Sox2 
(siSox2) and VRK1 (siVRK1-02) or with a siRNA lacking a precise target 
(siControl). Then, the cells were harvest at 24, 48, 72, 96 and 120 hours, and the 
living ones counted using a haemocytometer. The depletion of Sox2 was verified 
by qRT-PCR, since the protein levels were undetectable by immunoblot, and 
protein extracts were obtained to analyze cell cycle associated markers. We 
observed that Sox2 or VRK1 downregulation caused a similar reduction in the 
rate of cell duplication, and the loss of phospho-Rb, cyclins D1 and A, PCNA, all 
associated with active proliferation. Depletion of Sox2 or VRK1 also resulted in 
accumulation of p27, an inhibitor of cell cycle progression (Figure 46). 
1.5 Sox2-dependent activation of VRK1 gene expression 
 Sox2 is a transcriptional factor that executes its function mostly through 
the regulation of target gene promoters (Soufi, 2014). Besides, we demonstrated 
that Sox2 was implicated in the control of cell proliferation (Figure 46) and it is 
known that VRK1 is an important proliferation-associated kinase (Valbuena et al., 
2008b). Accordingly, we speculated whether Sox2 was regulating VRK1 gene 
expression. In order to verify such hypothesis, MDA-MB-231 were transduced 
with a retroviral construct overexpressing Sox2 (pBabe.puro-Sox2) and the effect 
on VRK1 protein levels was evaluated by immunoblot and IF. Additionally, the 
effect of Sox2 overexpression on VRK1 mRNA was also evaluated. We observed 
that Sox2 high levels induced an increase of endogenous VRK1 protein, which 
was detected by IF (Figure 47A) and by immunoblot analysis (Figure 47B). 
Moreover, the effect of Sox2 overexpression caused an increase in the 
expression of VRK1 mRNA levels, indicating that Sox2 is regulating the VRK1 
gene (Figure 47C). The same experiment was performed in MCF7 breast cancer 
line, obtaining similar results concerning the expression of VRK1 protein (Figure 
48). The VRK1 protein levels detected by immunoblot analysis were quantified 
with ImageJ and normalize to β-actin protein levels. The VRK1 and Sox2 






Figure 47. Sox2 overexpression upregulates VRK1 protein and mRNA levels in 
MDA-MB-231 cell line.  MDA-MB-231 cells were transfected with pBabe.puro-Sox2 or 
with pBabe-ø empty vector. A) VRK1 protein levels were detected, by IF, with a rabbit 
polyclonal anti-VRK1 antibody and the corrected total cell fluorescence was quantified 
with ImageJ (Student’s Test: *<0.05; **<0.005; ***<0.0005). B) VRK1 protein levels were 
detected, by immunoblot analysis, with a rabbit polyclonal anti-VRK1 antibody and 
quantified with ImageJ. Quantified VRK1 protein levels were normalize to quantified β-
actin protein levels. C) VRK1 and Sox2 mRNA levels were determined by qRT-PCR and 
normalized to GAPDH mRNA levels. The experiment was performed in triplicate, three 




























































































































































Figure 48. Sox2 overexpression upregulates VRK1 protein levels in MCF7 cell line. 
MCF7 cells were transfected with pBabe.puro-Sox2 or with pBabe-ø empty vector. A) 
VRK1 protein levels were detected, by IF, with a rabbit polyclonal anti-VRK1 antibody 
and the corrected total cell fluorescence was quantified with ImageJ (Student’s Test: 
*<0.05; **<0.005; ***<0.0005).  B) VRK1 protein levels were detected, by immunoblot 
analysis, with a rabbit polyclonal anti-VRK1 antibody and quantified with ImageJ. 
Quantified VRK1 protein levels were normalize to quantified β-actin protein levels.  
 Next and because Sox2 is a transcription factor, we tested whether the 
VRK1 (-1028 to +52) proximal gene promoter, cloned in a luciferase reporter 
plasmid, was directly regulated by Sox2. Therefore, MDA-MB-231 cells were 
transfected with different amounts of pCMV6-myc-FLAG-Sox2 and with a plasmid 
expressing the long proximal VRK1 promoter (-1028 to + 52) region, cloned in 
pGL2-b-luciferase vector. Renilla-luciferase was used as internal control. We 
observed that VRK1 proximal gene promoter was activated in a dose dependent 
manner by Sox2 overexpression (Figure 49). Similar result was obtained in 






































































Figure 49. Sox2 overexpression activates VRK1 proximal gene promoter in MDA-
MB-231 cells.  A) VRK1 (-1028+52) promoter relative luciferase activity. MDA-MB-231 
cells were transfected with increased doses (0.5, 1.0 and 2.0µg) of pCMV6-myc-FLAG-
Sox2, with pGL2-b-luciferase-VRK1 (-1028+52) vector and Renilla-luciferase as internal 
control. Besides, pGL2-Control plasmid expressing luciferase under the SV40 promoter 
was used as positive control and pGL2-basic, a promoter-less plasmid, was used as 
negative and background control. The experiment was performed in triplicate, three 
times (Student’s Test: *<0.05; **<0.005; ***<0.0005). B) Immunoblot analysis. 
 
Figure 50. Sox2 overexpression activates VRK1 proximal gene promoter in 
HEK293T cells.  A) VRK1 (-1028+52 promoter) absolute (up) and relative (down) 
luciferase activity. HEK293T cells were transfected with increased doses (0.1, 0.5 and 
1.0µg) of pCMV6-myc-FLAG-Sox2, with pGL2-b-luciferase-VRK1 (-1028+52) vector and 
Renilla-luciferase as internal control. Besides, pGL2-Control plasmid expressing 
luciferase under the SV40 promoter was used as positive control and pGL2-basic, a 
promoter-less plasmid, was used as negative and background control. The experiment 
was performed in triplicate, three times (Student’s Test: *<0.05; **<0.005; ***<0.0005). 
B) Immunoblot analysis.  
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 The proximal VRK1 (-1028 to +52) gene promoter contains four consensus 
target sequences for Sox2 (Bowles et al., 2000; Chambers and Tomlinson, 2009; 
Fang et al., 2011b). Nevertheless, the DNA motifs are restricted between -1028 
to -264 region (Figure 51).  
 
Figure 51.  Sox2 targets the proximal promoter (-1028+52) of the human VRK1 
gene. The DNA motifs that are Sox2 transcription factor targets are indicated in red. 
 Therefore, we intended to verify whether the activation of VRK1 promoter, 
by Sox2 overexpression, was loss when the consensus target sequences for 
Sox2 were absent. HEK293T cells were transfected with different amounts of 



























promoter (-264 to + 52) region, cloned in pGL2-b-luciferase vector. Renilla-
luciferase was used as internal control. It was demonstrated that Sox2 had no 
effect on the activation of VRK1 promoter comprised between residues -264 to 
+52. This shorter promoter region shows a higher level of expression, reflecting 
the lack of some regulatory elements (Figure 52).  
 Altogether, these results indicated that the effect of Sox2 on VRK1 
promoter is mediated by the region comprised between residues -1028 to -264 
that contains four consensus target sequences for Sox2. 
 
Figure 52. Sox2 overexpression has no effect on shorter VRK1 proximal gene 
promoter.  A) VRK1 (-264+52 promoter) absolute (up) and relative (down) luciferase 
activity. HEK293T cells were transfected with increased doses (0.1, 0.5 and 1.0µg) of 
pCMV6-myc-FLAG-Sox2, with pGL2-b-luciferase-VRK1 (-264+52) vector and Renilla-
luciferase as internal control. Besides, pGL2-Control plasmid expressing luciferase 
under the SV40 promoter was used as positive control and pGL2-basic, a promoter-less 
plasmid, was used as negative and background control. The experiment was performed 
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1.6 Sox2 and VRK1 co-operation in CCND1 gene activation 
 Neither Sox2 nor VRK1 are direct regulators of cell cycle initiation and 
progression. Accordingly, both proteins have to regulate key genes or proteins 
implicated in cell cycle, among which CCND1 is a major candidate. It is known 
that the transcriptional factor Sox2 initiates cell division in the stem cell 
compartment and regulates cell cycle G1/S transition, which is mediated by cyclin 
D1 (Boumahdi et al., 2014; Chen et al., 2008b). In turn, VRK1 also assists cell 
cycle progression and is able to activate the CCND1 gene promoter, through the 
direct phosphorylation of CREB1. VRK1 depletion causes cell cycle arrest in 
G0/G1 (Kang et al., 2008a; Santos et al., 2006; Valbuena et al., 2008b). 
Accordingly, we verified the potential co-operation between VRK1 and Sox2 in 
the activation of the proximal CCND1 gene promoter. Therefore, MDA-MB-231 
cells were transfected with Sox2 tagged with flag-myc and/or HA-VRK1, 
alongside with a plasmid expressing the long proximal CCND1 promotor (-1745 
to +134), which was clones in a pGL2-b-luciferase vector. Renilla-luciferase was 
used as internal control. We showed that Sox2 and VRK1 individually activated 
the CCND1 gene promoter, with a nearly fivefold stronger activation for Sox2 
(Figure 53A and Figure 53B). However, the combination of both Sox2 and VRK1 
resulted in a higher activation of CCND1 gene expression, indicating that Sox2 
and VRK1 proteins co-operate in the activation of CCND1 gene expression and 
thus, they can contribute together to cell cycle progression and proliferation 






Figure 53. Sox2 co-operates with VRK1 on the activation of CCND1 gene promoter.  
A) MDA-MB-231 cells were transfected with pA3-CycD1-Prom-Luc (-1745 +134) and 
increasing amounts of HA-VRK1 (pCEFL-HA-VRK1). B) MDA-MB-231 cells were 
transfected with pA3-CycD1-Prom-Luc (-1745 +134) and increasing concentrations of 
myc-FLAG-Sox2 (pCMV6-myc-FLAG-SOX2). C) MDA-MB-231 cells were transfected 
with pA3-CycD1-Prom-Luc (-1745 +134), with HA-VRK1 (pCEFL-HA-VRK1) and with 
myc-FLAG-Sox2 (pCMV6-myc-FLAG-SOX2). All the experiments were also transfected 
with Renilla-luciferase as internal control, with pGL2-Control plasmid expressing 
luciferase under the SV40 promoter as positive control and with pGL2-basic, a promoter-
less plasmid, as negative and background control. The experiment was performed in 
triplicate, three times (Student’s Test: *<0.05; **<0.005; ***<0.0005). 
1.7 VRK1 modulates SOX2 gene expression 
 The VRK1 activity is controlled by auto-regulatory loops with some of its 
targets, as has been described in the context of p53 (Valbuena et al., 2007b; 
Valbuena et al., 2006a). Therefore, we studied whether there is a cross regulation 
between VRK1 and Sox2 expression. First, the effect of VRK1 downregulation on 
the level of Sox2 protein and mRNA was determined, by IF and qRT-PCR, in 
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MDA-MB-231 cell line. VRK1 was depleted using two different siRNAs (siVRK1-
02 or siVRK1-09) and a non-targeting siRNA (siControl) was used as control. 
Moreover, serum-free cells were maintained to determine whether the potential 
effect of VRK1 depletion on Sox2 levels may be due cell cycle arrest. We 
observed that VRK1 downregulation resulted in an increased intracellular level of 
Sox2 protein and mRNA, in MDA-MB-231 cells. An effect not related with the 
consequent cell cycle arrest induced by VRK1 depletion (Figure 54). Similar result 
was attained in MCF7 (Figure 55) and NT2 (Figure 56).  
 
Figure 54. VRK1 depletion upregulates Sox2 in MDA-MB-231 cell line.  MDA-MB-
231 cells were transfected with siRNAs targeting VRK1 (siVRK1-02 = siV-02; siVRK1-
09 = siV-09) and a non-targeting siRNA (siControl = siC) was used as control. Serum-
free cells (0%) were used as control of cell cycle arrest. By IF, Sox2 was detected using 
a mouse monoclonal anti-Sox2 antibody and VRK1 was detected using a rabbit 
polyclonal anti-VRK1 antibody. Chromatin was stained with DAPI. Corrected total cell 
fluorescence was calculated using ImageJ (A). VRK1 knockdown was confirmed by 
immunoblot analysis (B). SOX2 mRNA levels were quantified by real-time qRT-PCR and 
normalize with GAPDH mRNA levels. The experiment was performed in triplicate, three 



















































































































Figure 55. VRK1 depletion upregulates Sox2 in MCF7 cell line.  MCF7 cells were 
transfected with siRNAs targeting VRK1 (siVRK1-02 = siV-02; siVRK1-03 = siV-03) and 
a non-targeting siRNA (siControl = siC) was used as control. Serum-free cells (0%) were 
used as control of cell cycle arrest. By immunofluorescence, Sox2 was detected using a 
mouse monoclonal anti-Sox2 antibody and VRK1 was detected using a rabbit polyclonal 
anti-VRK1 antibody. Chromatin was stained with DAPI. Corrected total cell fluorescence 
was calculated using ImageJ (A). VRK1 knockdown was confirmed by immunoblot 
analysis (B). Sox2 mRNA levels were quantified by real-time qRT-PCR and normalize 
with GAPDH mRNA levels. The experiment was performed in triplicate, three times (C). 
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Figure 56. VRK1 depletion upregulates Sox2 in NT2 cell line.  NT2 cells were 
transfected with siRNAs targeting VRK1 (siVRK1-02 = siV-02; siVRK1-03 = siV-03) and 
a non-targeting siRNA (siControl = siC) was used as control. By immunofluorescence, 
Sox2 was detected using a mouse monoclonal anti-Sox2 antibody and VRK1 was 
detected using a rabbit polyclonal anti-VRK1 antibody. Chromatin was stained with DAPI. 
Corrected total cell fluorescence was calculated using ImageJ (A). The effect of VRK1 
knockdown on Sox2 protein levels was confirmed by immunoblot analysis. Sox2 was 
detected using a rabbit monoclonal anti-Sox2 antibody (B). (Student’s Test: *<0.05; 
**<0.005; ***<0.0005). 
 Moreover and to further confirm the regulation of SOX2 gene expression 
by VRK1, it was performed an opposed experiment. Therefore, VRK1 was 
overexpressed in MDA-MB-231 cell line with a retroviral plasmid vector 
overexpressing VRK1 (pQCXIP-VRK1) and the effect on Sox2 protein levels was 
evaluated by immunoblot and IF. Additionally, the effect of VRK1 overexpression 
on SOX2 mRNA levels was evaluated by qRT-PCR. We observed that VRK1 
overexpression led to the loss of Sox2 nuclear fluorescence, in comparison to the 
control. The effect was a consequence of a decrease in the level of SOX2 mRNA 
(Figure 57). The result observed upon Sox2 protein levels was verified in stable 
a HeLa cell line overexpressing VRK1, but no effect was observed on the level of 
SOX2 mRNA (Figure 58). Due to difficulties to transfect or transduce 




























































Figure 57. VRK1 overexpression downregulates Sox2 in MDA-MB-231 cell line.  
MDA-MB-231 cells were transduced with pQCXIP-VRK1 and pQCXIP empty vector was 
used as control. By immunofluorescence Sox2 was detected using a mouse monoclonal 
anti-Sox2 antibody and VRK1 was detected using a rabbit polyclonal anti-VRK1 
antibody. Chromatin was stained with DAPI. Corrected total cell fluorescence was 
calculated using ImageJ (A). VRK1 overexpression was confirmed by immunoblot 
analysis (B). SOX2 mRNA levels were quantified by real-time qRT-PCR and normalize 
with GAPDH mRNA levels. The experiment was performed in triplicate, three times (C). 

























































































































































Figure 58. Stable VRK1-overexpressing HeLa cell line does not show alterations 
on Sox2 levels. HeLa cells were transduced with pQCXIP-VRK1 and pQCXIP empty 
vector was used as control. Then, the cells were selected with puromycin and a HeLa-
VRK1-overexpressing pool was created. By immunofluorescence, Sox2 was detected 
using a mouse monoclonal anti-Sox2 antibody and VRK1 was detected using a rabbit 
polyclonal anti-VRK1 antibody. Chromatin was stained with DAPI. Corrected total cell 
fluorescence was calculated using ImageJ (A). SOX2 mRNA levels were quantified by 
real-time qRT-PCR and normalize with GAPDH mRNA levels. The experiment was 
performed in triplicate, twice (B). (Student’s Test: *<0.05; **<0.005; ***<0.0005). 
1.8 Effect of cell differentiation on VRK1 and Sox2 levels 
 Sox2 plays an important role in the early decision of stem cells and VRK1 
was reported to have a significant role in the initiation of cell proliferation 













































































































































Valbuena et al., 2011c). Therefore and since the initiation of cell lineage 
differentiation requires an asymmetric cell division, we decided to study the fate 
of Sox2 and VRK1 along the NT2 cell differentiation process induced with RA. 
The retinoid induces the rapid differentiation of NT2 cells into neurons (Pleasure 
and Lee, 1993). NT2 differentiation was performed during 14 days, changing the 
medium three times a week. Simultaneously, the cells were harvested every 48 
hours, extracting mRNA for qRT-PCR and protein for immunoblot analysis. IF 
was done in the day 14.  
 We observed that the induction of cell differentiation resulted in a 
significant loss of reprogramming factor Sox2, Oct4, Nanog, alongside with a 
decrease in the proliferation markers VRK1, cyclins D1 and B1 proteins (Figure 
59A and Figure 60B). The reduction of Sox2, VRK1, cyclin D1 Oct4 and Nanog 
protein levels, induced by RA, was also confirmed by the loss of their nuclear 
fluorescence (Figure 59B, Figure 60A and Figure 61). The differentiation state of 
the cells was also confirmed by the RA-induced morphological reorganization of 
α-tubulin observed by IF (Figure 60A), and through the detection of the 
corresponding increase in N-cadherin, βII-tubulin, PAX6 and CREB 
phosphorylated in Ser133, by immunoblot (Figure 59A) or by IF (Figure 61). 
Moreover, to determine whether these changes in protein levels were due to 
changes in gene expression we also determined, by qRT-PCR, the expression of 
SOX2, OCT4, VRK1 and H2AFY2 genes. H2AFY2 codes for the macroH2A2 
histone, an inhibitor of cell proliferation associated with terminal differentiation 
(Gaspar-Maia et al., 2013; Schnoder et al., 2015). RA induced a decrease of 
SOX2, OCT4 and VRK1 expression, while the macroH2A2 expression increases 





Figure 59. NT2 differentiation results in the loss of Sox2 and VRK1.  A) Time course 
of the expression of different proteins in NT2 cells induced to differentiate with retinoic 
acid (RA). Sox2 was detected with a rabbit monoclonal anti-Sox2 antibody and VRK1, 
was detected with a rabbit polyclonal anti-VRK1 (VC) antibody. B) The expression of 
Sox2 and VRK1 proteins in NT2 cells was detected by immunofluorescence before and 
after induction of differentiation with retinoic acid (RA). Sox2 was detected using a mouse 
monoclonal anti-SOX2 antibody and VRK1 was detected using a rabbit polyclonal anti-
VRK1antibody. Chromatin was stained with DAPI. C) Effect of RA-induced differentiation 
of NT2 cells on the gene expression levels SOX2, OCT4, VRK1 and H2AFY2. Total RNA 
































































































































































































































Figure 60. NT2 differentiation results in the loss of Sox2, Oct4, Nanog and VRK1, 
alongside with morphological reorganization of α-tubulin. A) The expression of 
VRK1 and reprogramming factors Sox2, Oct4 and Nanog, was detected by 
immunofluorescence before and after induction of NT2 differentiation with retinoic acid 
(RA). The morphological organization of α-Tubulin was also evaluated. Sox2 was 
detected using a mouse monoclonal anti-SOX2 antibody, Oct4 was detected using a 
rabbit monoclonal anti-Oct4 antibody, Nanog was detected with a rabbit monoclonal anti-
Nanog antibody and VRK1 was detected using a mouse monoclonal anti-VRK1 (1B5) 
antibody. Α-tubulin was detected with a rabbit polyclonal anti-α-tubulin antibody. 
Chromatin was stained with DAPI. B) The effect of RA-induced differentiation of NT2 
cells on the expression of VRK1, Sox2, Oct4 and Nanog was confirmed by immunoblot.  











































































































































Figure 61. Cyclin D1 and vimentin protein levels decrease during cell 
differentiation, while N-cadherin protein levels increase. NT2 were differentiated 
with retinoic acid (RA) during 14 days and cyclin D1, Vimentin and N-cadherin levels 
were analyzed by IF. Cyclin D1 was detected with a rabbit polyclonal anti-cyclin D1 
antibody, Vimentin was detected with a mouse monoclonal anti-Vimentin antibody and 
N-cadherin was detected with a rabbit polyclonal anti-N-cadherin antibody. Chromatin 
was stained with DAPI. 
 Furthermore, NT2 cells were maintained under RA-differentiation 
conditions during 4 weeks, to verify whether proliferative proteins, such as VRK1 
or cyclins, increase subsequently to the initial decrease observed during the initial 
14 days. We observed that the protein levels of VRK1 and cyclins B1 and D1 
remained low during the differentiation process (Figure 62). 
 
Figure 62. VRK1 levels remain low after 4 weeks of NT2 RA-differentiation. NT2 
were differentiated with retinoic acid (RA) during 4 weeks and the protein expression of 
VRK1 was analyzed, by immunoblot, with a rabbit polyclonal anti-VRK1 (VC) antibody.  
 VRK1 is regulated directly by Sox2. Thus, we aimed to confirm that VRK1 
is regulated by Sox2 in partially differentiated NT2 cells, where the levels of VRK1 
already started to decline. Important to mention that differentiated NT2 are easily 
transfected, contrarily to undifferentiated NT2. Therefore, differentiated NT2 were 
transduced with a retroviral vector overexpressing Sox2 (pBabe.puro-Sox2) and 





















that the re-introduction of Sox2 into the cells, led to an increase in VRK1 protein 
levels (Figure 63). 
 
Figure 63. VRK1 levels are restored in RA-differentiated NT2 cells after Sox2 
expression. NT2 cells were transfected with pBabe.puro-Sox2 and pBabe.puro empty 
vector, after 7 days of retinoic acid (RA) treatment. The protein expression of VRK1 was 
analyzed, by immunoblot, with a rabbit polyclonal anti-VRK1 (VC) antibody. The 
quantification of VRK1 protein levels was executed with ImageJ and its protein levels 
were normalize to the β-actin protein levels. 
 Furthermore, it is known that the downregulation of stem genes 
concomitant with differentiation is mediated by the exchange of histones variants 
in the chromatin. An example is the replacement of histone H2A by the macroH2A 
histones that have a larger C-terminal region (Buschbeck and Di Croce, 2010; 
Buschbeck et al., 2009). MacroH2A are histone variants that are associated with 
gene transcription inhibition and differentiation (Creppe et al., 2012b; Creppe et 
al., 2012c), as we showed for macroH2A2 (Figure 59C). Besides, macroH2A1.2 
histone is known to inhibit the activity of VRK1 by their direct physical interaction 
(Kim et al., 2012b). Therefore, we tested the potential role of macroH2A histone 
variants in the regulation of VRK1 and CCND1 gene promoters. First, HEK293T 
cells were transfected with macroH2A variants, together with the long proximal 
VRK1 promoter (-1028 to + 52) region expressing plasmid, cloned in pGL2-b-
luciferase vector. Renilla-luciferase was used as internal control. We observed 
that macroH2A1.2 and macroH2A2, but not macroH2A1.1 inhibited the promoter 
of VRK1 (Figure 64A). Similar results was obtained using increased doses of 
macroH2A histone isoforms instead of a single concentration (Figure 64B). 
Additionally, we determined if macroH2A histone variants were also capable to 
inhibit the effect of Sox2 on the VRK1 gene promoter. Therefore, HEK293T cells 
were transfected with a plasmid expressing the long proximal VRK1 promoter (-










concentrations of the macroH2A histone variants. It was observed that 
macroH2A1.2 and macroH2A2 proteins, but not macroH2A1.1 histone, were able 
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Figure 64. Inhibition of VRK1 and CCND1 expression by macroH2A histones. A) 
The cells were transfected with macroH2A histone variants (pCMV-Tag2A-FLAG-
mH2A1.1; pCMV-Tag2A-FLAG-mH2A1.2; pCMV-Tag2A-FLAG-mH2A2) and with pGL2-
b-luciferase-VRK1 (-1028+52) vector. B) Cells were transfected with increased 
concentrations (0.1, 0.5 and 1.0µg) of macroH2A histone variants (pCMV-Tag2A-FLAG-
mH2A1.1; pCMV-Tag2A-FLAG-mH2A1.2; pCMV-Tag2A-FLAG-mH2A2) and with pGL2-
b-luciferase-VRK1 (-1028+52) vector. C) The cells were transfected with increased 
concentrations (0.1, 0.5 and 1.0µg) of macroH2A histone variants (pCMV-Tag2A-FLAG-
mH2A1.1; pCMV-Tag2A-FLAG-mH2A1.2; pCMV-Tag2A-FLAG-mH2A2), together with 
myc-FLAG-Sox2 (pCMV6-myc-FLAG-SOX2) and with pGL2-b-luciferase-VRK1 (-
1028+52) vector. D) The cells were transfected with increased concentrations (0.1, 0.5 
and 1.0µg) of macroH2A histone variants (pCMV-Tag2A-FLAG-mH2A1.1; pCMV-
Tag2A-FLAG-mH2A1.2; pCMV-Tag2A-FLAG-mH2A2) and with pA3-CycD1-Prom-Luc (-
1745+134). All the experiments were performed in HEK293T and used Renilla-luciferase 
as internal control. Besides, pGL2-Control plasmid expressing luciferase under the SV40 
promoter was used as positive control and pGL2-basic, a promoter-less plasmid, was 
used as negative and background control. The experiment was performed in triplicate, 
three times (Student’s Test: *<0.05; **<0.005; ***<0.0005). 
 Finally, the potential regulatory effect of macroH2A histone variants on 
CCND1 gene promoter was also studied. Thus, HEK293T cells were transfected 
with increased concentrations of macroH2A proteins and with the long proximal 
CCND1 gene promotor (-1745 to +134), which was cloned in a pGL2-b-luciferase 
vector. Renilla-luciferase was used as internal control. Once again, we observed 
that both macroH2A1.2 and macroH2A2 were able to inhibit CCND1 gene 
promoter, while macroH2A1.1 had no effect (Figure 64D).  
1.9 VRK1 effect on Sox2 protein stability  
 Lately, we decided to study whether VRK1 had an effect on Sox2 stability. 
Therefore, NT2 cells were transfected with a siRNA targeting VRK1 (siVRK1-02) 
and a non-targeting siRNA (siControl) during 72 hours. Then, the cells were 
treated with CHX and harvest at distinct time periods. We observed that VRK1 
depletion did not affected the stability of endogenous Sox2 in NT2 (Figure 65A). 
Moreover, we tested if Sox2 overexpression affected VRK1 stability in HEK293T 




treated with CHX during 24 hours. We did not observe any effect of Sox2 on 
VRK1 stability (Figure 65B).  
 
Figure 65. Sox2 stability is unaffected by VRK1, while VRK1 stability is not affected 
by Sox2. A) NT2 cells were transfected with a specific siRNA targeting VRK1 (siVRK1-
02 = siV-02) and with a non-targeting siRNA (siControl = siC). 72 hours later cells were 
treated with cycloheximide (CHX) and the experimental points harvest at distinct times. 
Sox2 was detected with a rabbit monoclonal anti-Sox2 antibody. B) HEK293T cells were 
transfected with myc-FLAG-Sox2 (pCMV6-myc-FLAG-Sox2) or with an empty vector 
(pCMV6-myc-FLAG) and 48 hours later treated with CHX. The experimental points were 
harvest at different times during 24 hours.  
2.1 VRK1 interaction with Oct4, Klf4 and Nanog 
 Besides Sox2, we decided to test whether VRK1 interacted with other 
reprogramming factors such as Oct4, Nanog, Klf4 and c-Myc. Concerning Oct4, 
we studied first the potential interaction between transfected VRK1 and Oct4 in 
HEK293T cells. Therefore, the cells were transfected with myc-FLAG-Oct4 alone 
or alongside with HA-VRK1. Then, protein extracts were immunoprecipitated with 
a rabbit polyclonal anti-FLAG antibody, or with a rabbit polyclonal anti-HA 
antibody or with a mouse monoclonal anti-VRK1 (1B5) antibody. VRK1 was 
detected in Oct4 immunoprecipitate with a mouse monoclonal anti-HA antibody 
or with a mouse monoclonal anti-VRK1 (1B5) antibody. Oct4 was detected in 
VRK1 immunoprecipitate with a mouse monoclonal anti-FLAG antibody or with a 
rabbit polyclonal anti-FLAG antibody. In all the experiments we observed that 



















Figure 66. Reprogramming factor Oct4 interacts with VRK1. A) HEK293T cells were 
transfected with pCMV6-myc-FLAG-Oct4 and pCEFL-HA-VRK1. Oct4 was 
immunoprecipitated with a rabbit polyclonal anti-FLAG antibody and VRK1 was detected, 
by immunoblot, with a mouse monoclonal anti-HA antibody. B) HEK293T cells were 
transfected with pCEFL-HA-VRK1 and pCMV6-myc-FLAG-Oct4. VRK1 was 
immunoprecipitated with a rabbit polyclonal anti-HA antibody and Oct4 was detected, by 
immunoblot, with a mouse monoclonal anti-FLAG antibody. C) FLAG-Tagged Oct4 
(pCMV6-myc-FLAG-Oct4) was transfected in HEK293T cells and Oct4 was 
immunoprecipitated with a rabbit polyclonal anti-FLAG antibody. VRK1 was detected 
with a mouse monoclonal anti-VRK1 (1B5) antibody.  D) FLAG-Tagged oct4 (pCMV6-
myc-FLAG-Oct4) was transfected in HEK293T cells and VRK1 was immunoprecipitated 
with a mouse monoclonal anti-VRK1 (1B5) antibody. A mouse monoclonal anti-HA (IgG) 
antibody was used as control of IP. Oct4 was detected with a rabbit polyclonal anti-FLAG 
antibody. E) HEK293T cells were transfected with a stable concentration of pCEFL-HA-
VRK1 and increased doses of pCMV6-myc-FLAG-Oct4. Oct4 was immunoprecipitated 
with a rabbit polyclonal anti-FLAG antibody and VRK1 was detected, by immunoblot, 
with a mouse monoclonal anti-HA antibody. F) VRK1 was immunoprecipitated, from NT2 
extracts, with a mouse monoclonal anti-VRK1 (1B5) antibody and Oct4 was detected 
with a rabbit monoclonal anti-Oct4 antibody. A mouse monoclonal anti-HA (IgG) antibody 





























































 Also, a stable concentration of HA-VRK1 was transfected with increased 
doses of myc-FLAG-Oct4. Next, Oct4 was immunoprecipitated with a rabbit 
polyclonal anti-FLAG antibody and VRK1 was detected with a mouse monoclonal 
anti-HA antibody. Again, we observed that VRK1 and Oct4 interacted, being the 
interaction, in this case, dependent on Oct4 concentration (Figure 66E). Finally, 
we verified the interaction between endogenous VRK1 and Oct4 proteins. NT2 
extracts were immunoprecipitated with a mouse monoclonal anti-VRK1 (1B5) 
antibody and Oct4 was detected using a rabbit monoclonal anti-Oct4 antibody. 
Again, VRK1 interacted with Oct4 (Figure 66F). 
 Subsequently, we analyzed the potential interaction between VRK1 and 
the transcriptional factor Nanog. Thus, NT2 extracts were immunoprecipitated 
with a mouse monoclonal anti-VRK1 (1B5) antibody and Nanog was detected 
using a rabbit monoclonal anti-Nanog antibody. We observed that VRK1 
interacted with Nanog (Figure 67). 
 
Figure 67. VRK1 interacts with reprogramming factor Nanog. VRK1 was 
immunoprecipitated, from NT2 extracts, with a mouse monoclonal anti-VRK1 (1B5) 
antibody and Nanog was detected with a rabbit monoclonal anti-Nanog antibody. A 
mouse monoclonal anti-HA (IgG) antibody was used as control of IP. 
 Next, we focused our attention on the potential interaction between VRK1 
and Klf4. Therefore, HEk293T cells were transfected with myc-FLAG-Klf4 alone 
or together with HA-VRK1. Afterward, protein extracts were immunoprecipitated 
with a rabbit polyclonal anti-FLAG antibody, or with a rabbit polyclonal anti-HA 
antibody or with a mouse monoclonal anti-VRK1 (1B5) antibody. VRK1 was 
detected in Klf4 immunoprecipitate with a mouse monoclonal anti-HA antibody or 
with a mouse monoclonal anti-VRK1 (1B5) antibody. Klf4 was detected in VRK1 
immunoprecipitate with a mouse monoclonal anti-FLAG antibody or with a rabbit 
polyclonal anti-FLAG antibody. We observed that VRK1 interacts with Klf4 












Figure 68. Reprogramming factor Klf4 interacts with VRK1. A) HEK293T cells were 
transfected with pCMV6-myc-FLAG-Klf4 and pCEFL-HA-VRK1. Klf4 was 
immunoprecipitated with a rabbit polyclonal anti-FLAG antibody and VRK1 was detected, 
by immunoblot, with a mouse monoclonal anti-HA antibody. B) HEK293T cells were 
transfected with pCEFL-HA-VRK1 and pCMV6-myc-FLAG-Klf4. VRK1 was 
immunoprecipitated with a rabbit polyclonal anti-HA antibody and Klf4 was detected, by 
immunoblot, with a mouse monoclonal anti-FLAG antibody. C) FLAG-Tagged Klf4 
(pCMV6-myc-FLAG-Klf4) was transfected in HEK293T cells and Klf4 was 
immunoprecipitated with a rabbit polyclonal anti-FLAG antibody. VRK1 was detected 
with a mouse monoclonal anti-VRK1 (1B5) antibody.  D) FLAG-Tagged Klf4 (pCMV6-
myc-FLAG-Klf4) was transfected in HEK293T cells and VRK1 was immunoprecipitated 
with a mouse monoclonal anti-VRK1 (1B5) antibody. A mouse monoclonal anti-HA (IgG) 
antibody was used as control of IP. Klf4 was detected with a rabbit polyclonal anti-FLAG 
antibody. 
 Finally, we verified if VRK1 interacted with the transcriptional factor c-Myc. 
Therefore, NT2 extracts were immunoprecipitated with a mouse monoclonal anti-
VRK1 (1B5) antibody and c-Myc was detected using a rabbit polyclonal anti-c-
Myc antibody. We did not observe any interaction between VRK1 and c-Myc 
(Figure 69). 
 
Figure 69. VRK1 and c-Myc do not interact. VRK1 was immunoprecipitated, from NT2 
extracts, with a mouse monoclonal anti-VRK1 (1B5) antibody and c-Myc was detected 
with a rabbit polyclonal anti-c-Myc antibody. A mouse monoclonal anti-HA (IgG) antibody 














































3.1 Effect of Sox2-Oct4 complex on VRK1 gene promoter  
 Sox2 was described to be in some cases a weak/ moderate modulator of 
gene transcription, during embryonic development, pairing with several partner 
factors to potentiate its transcriptional activity. In fact, the transcriptional factors 
Sox2 and Oct4 had been reported to form a stable complex that is important in 
the regulation of NANOG gene promoter activity (Kamachi et al., 2000; Rodda et 
al., 2005). Attending to the fact that VRK1 gene promoter was average activated 
by Sox2, we studied the potential co-operation between Sox2 and Oct4 on the 
activation of this gene promoter. Initially, we decided to verify that in fact Sox2 
forms a stable complex with Oct4. Therefore, NT2 cells were immunoprecipitated 
with a mouse monoclonal anti-Sox2 antibody and Oct4 was detected, by 
immunoblot, in Sox2 immunoprecipitate with a rabbit monoclonal anti-Oct4 
antibody. Indeed, it was observed that Sox2 interacts with Oct4 (Figure 70A). 
Similar result was obtained between transfected proteins (Figure 70B). Next, we 
tested if the long proximal VRK1 gene promoter was modulated by Oct4, by itself. 
HEK293T cells were transfected with myc-FLAG-Oct4, alongside with the long 
proximal VRK1 promoter (-1028 to + 52) region expressing plasmid, cloned in 
pGL2-b-luciferase vector. Renilla-luciferase was used as internal control. Oct4 
did not activated or repressed the VRK1 gene promoter (Figure 70C). Finally, we 
analyzed the potential co-operation between both transcriptional factors Sox2 
and Oct4 on the activation of VRK1 gene promoter. Therefore, HEK293T cells 
were transfected with both myc-FLAG-Sox2 and myc-FLAG-Oct4, together with 
the long proximal VRK1 promoter (-1028 to + 52) region expressing plasmid, 
cloned in pGL2-b-luciferase vector. Once again, Renilla-luciferase was used as 
internal control. We confirmed that Sox2 activated VRK1 gene promoter, but Oct4 
did not potentiate Sox2 effect (Figure 70D). The analysis of proximal VRK1 (-
1028 to +52) gene promoter sequence confirmed the absence of consensus 
target sequences for Oct4 (Zhou and Liu, 2008), which could explain the lack of 






Figure 70. Sox2 and Oct4 did not co-operate on the activation of VRK1 promoter. 
A) NT2 cells were immunoprecipitated with a mouse monoclonal anti-Sox2 antibody and 
Oct4 was detected, by immunoblot, with a rabbit monoclonal anti-Oct4 antibody. B) 
HEK293T cells were transfected with pCMV6-myc-FLAG-Sox2 and pCMV6-myc-FLAG-
Oct4. Sox2-myc-FLAG tagged protein was immunoprecipitated with a mouse 
monoclonal anti-Sox2 antibody and Oct4-myc-FLAG tagged protein was detected with a 
rabbit polyclonal anti-FLAG antibody. C) HEK293T cells were transfected with increased 
concentrations (0.1, 0.5 and 1.0µg) of Oct4 (pCMV6-myc-FLAG-Oct4) and with pGL2-b-
luciferase-VRK1 (-1028+52) vector. D) HEK293T cells were transfected with both 
transcriptional factors Sox2 (pCMV6-myc-FLAG-Sox2) and Oct4 (pCMV6-myc-FLAG-
Oct4), together with pGL2-b-luciferase-VRK1 (-1028+52) vector. All the luciferase 
assays used Renilla-luciferase as internal control. Besides, pGL2-Control plasmid 
expressing luciferase under the SV40 promoter was used as positive control and pGL2-
basic, a promoter-less plasmid, was used as negative and background control. The 
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Figure 71.  Oct4 consensus target sequences on the proximal promoter (-1028+52) 







































































































Part 1. Implication of VRK1 in the regulation of 
AurKB mitotic localization and activity 
1.1 Role of VRK1 on the regulation of AurKB activity during mitosis 
 Human VRK1 is implicated in the correct progression of cell cycle. This 
observation derives mainly from VRK1 gene expression knockdown assays, 
where induction of G0/G1 cell cycle arrest is observed, as a result of a reduction 
on the levels of cyclin A, cyclin D1, PCDNA, among other proliferation markers 
(Lee et al., 2015; Valbuena et al., 2008b; Valbuena et al., 2011b). Nevertheless, 
VRK1 regulates also numerous mechanisms during mitosis, more precisely, in 
the G2/M phase transition, indicating a role not only in interphase but also later, 
during the mitotic phases. Indeed, VRK1 regulates the nuclear envelope 
assembly and disassembly, as well as the mitotic Golgi fragmentation and, plays 
a major role on the chromatin condensation during the G2/M transition, 
phosphorylating the Thr3 and Ser10 residues on the histone H3, as previously 
described (Gorjanacz et al., 2008; Lopez-Sanchez et al., 2009; Nichols et al., 
2006a). Indeed, our results undeniably show that the depletion of VRK1 causes 
a decrease in both H3T3ph and H3S10ph, as previously reported (Kang et al., 
2007b). Nonetheless, using specific antibodies against histone H3 
phosphorylation and through a kinase assay with cold ATP, we show that only 
the Thr3 residue is a direct phosphorylating target of VRK1, in contrast to 
previously described results. This difference could be related to distinct 
experimental conditions, but we mostly emphasize the fact that in some kinase 
assays, performed by Kang and colleagues, GST protein by itself showed 
H3S10ph, quite similar to recombinant protein GST-VRK1 (Kang et al., 2007b). 
The condensation of chromatin begins in prophase and is vital to ensure that the 
chromosomes are highly compacted in the following phases of the cell cycle. 
Compacted chromatin facilitates the correct bi-orientation of sister chromatids 
and the segregation of the chromosomes (Kang et al., 2007b; Salzano et al., 
2015; Thadani and Uhlmann, 2015; Wilkins et al., 2014). In turn, human AurKB 




an important element of CPC, along with Survivin, Borealin and INCENP. AurKB 
activity is fulfilled during mitosis, and it regulates centromere function, chromatin 
condensation, spindle assembly, chromosome alignment and segregation and, 
cytokinesis (Bolanos-Garcia, 2005; Carmena and Earnshaw, 2003). AurKB 
activity is particularly interesting for our work given that this kinase participates in 
chromatin condensation, via H3S10 phosphorylation (Crosio et al., 2002). 
Besides, AurKB seems to regulate H3T3ph, through the direct phosphorylation 
of Haspin, which turns active and phosphorylates H3T3. This phosphorylation 
targets CPC/ AurKB to centromeric chromatin were this kinase executes its 
functions (Wang et al., 2010; Wang et al., 2011). Besides histone H3, also 
transcriptional factor p53 is a common phosphorylation target of VRK1 and AurKB 
(Gully et al., 2012; Lopez-Sanchez et al., 2014b; Valbuena et al., 2011a; Vega et 
al., 2004a). Altogether, it seems likely that both VRK1 and AurKB jointly 
participate in the regulation of specific mitotic mechanisms. 
 Initially, we studied the hypothetical co-regulation of a known common 
substrate, histone H3, by VRK1 and AurKB, through kinase assays with 
radiolabeled [γ-32P] ATP (Cantarero et al., 2015; Crosio et al., 2002; Kang et al., 
2007b; Salzano et al., 2015). Our results showed that the ability of AurKB and 
VRK1 to phosphorylate histone H3 was inhibited, since recombinant proteins 
incubated alone with the substrate, showed higher levels of histone H3 
phosphorylation in comparison to the phosphorylation levels observed when 
these recombinant proteins were incubated together. A decrease on the 
autophosphorylation levels of AurKB and VRK1 was also detected, when kinases 
were incubated with the respective kinase dead partner, indicating that each WT 
kinase was unable to self-activate by phosphorylation. Therefore, the lack of 
catalytic activity of both VRK1 and AurKB towards histone H3, could be due to 
the inability of these kinases to self-activate. Indeed, autophosphorylation of 
AurKB was previously reported to be essential for its kinase activity towards 
histone H3 and Vimentin, during cytokinesis (Yasui et al., 2004). On the other 
hand, VRK1 was described to have a strong autophosphorylation activity, 
apparently critical to its kinase activity on the transcriptional factor p53 (Lopez-
Borges and Lazo, 2000; Nichols and Traktman, 2004). Similar results were 





histone H3 phosphorylations and p53 phosphorylation. AurKB negatively affected 
the phosphorylation of histone H3 and p53, by VRK1, being this effect 
independent of AurKB kinase activity and dependent on the kinase levels. In turn, 
VRK1 negatively affected the phosphorylation of histone H3, by AurKB, 
independently of it kinase activity and dependent on kinase levels. Accordingly, 
AurKB and VRK1 seemed to be regulating the kinase activity of one another, 
independently of their kinase activity and dependently on their levels. This is 
attributed to an unknown mechanism that probably targets the 
autophosphorylation activity of each kinase. Moreover, the fact that AurKB 
regulates VRK1 activity is quite fascinating, since the first kinase seems to be 
regulating both protein kinases that target H3T3 for phosphorylation. The first, 
through the phosphorylation of Haspin, which is able to phosphorylate H3T3 
when activated by AurKB and the second, through the regulation of VRK1, by an 
unknown mechanism (Wang et al., 2010; Wang et al., 2011). Moreover, it seemed 
that this regulatory effect was independent of their kinase activity, since no 
phosphorylation was observed on VRK1 by AurKB or on AurKB by VRK1. 
Nevertheless, the fact that histone H3 is present in the mix with the recombinant 
proteins VRK1 and AurKB, might had induced a miss-observation and further 
experiments were necessary to test whether at least one of the kinases is a 
phosphorylation target of the other.   
 Afterwards, we studied the potential formation of a complex between 
VRK1 and AurKB that could explain the catalytic inhibitory effect detected when 
kinases were combined together in kinase assays. Physical interaction between 
human kinases had been previously reported (i.e. VRK1 and Plk3) and therefore 
it seemed probable that this could also occur between VRK1 and AurKB (Lopez-
Sanchez et al., 2009). Indeed, our results showed a clear interaction between 
exogenous VRK1 and AurKB. Moreover, this interaction occurred independently 
of VRK1 activity, since VRK1 dead kinase (K179) also interacted with AurKB. 
Surprisingly, AurKB formed a stronger complex with inactive VRK1, which is 
compatible with the fact that inactive VRK1 is unable to complete the potential 
catalytic cycle. Similar results have also been described concerning VRK1 and 
p53 stable complex (Lopez-Sanchez et al., 2014b). At this point, it would also be 




(K106R), to verify if this interaction is also independent of AurKB activity. 
Additionally, we observed that VRK1 interacted with AurKB, through both amino 
and carboxy terminals, perhaps due to the tertiary structure of the protein. 
Nonetheless, it was expected that VRK1 interacted with AurKB mainly through 
the carboxy terminal region. Evidence showed that VRK1 interacts with several 
other proteins through the carboxy terminal region, characterized by its low 
complexity and high flexibility. Besides, the amino terminal kinase domain don’t 
form stable protein complexes, to allow the rapid release of ADP and 
phosphorylated target proteins (Kim et al., 2012c; Lopez-Sanchez et al., 2014b; 
Sanz-Garcia et al., 2012).  
 The interaction between VRK1 and AurKB exogenous proteins was quite 
consistent in all the performed experiments. Nevertheless, it was crucial to 
confirm the formation of a stable complex between endogenous VRK1 and AurKB 
protein kinases. Our results showed that both endogenous VRK1 and AurKB 
proteins, interacted and that this interaction occurred in mitosis, when AurKB 
activity and levels are higher. Unfortunately, it was impossible to ensure the 
precise mitotic phase in which the stable complex between VRK1 and AurKB was 
formed. In fact, co-localization was not observed between the two mitotic kinases 
at any stage of mitosis. In early mitotic stages, nearly all VRK1 is located in the 
cytoplasm, not associated with chromatin, whereas AurKB was linked to 
centromeric chromatin or chromosomal arms. These distinct localizations agree 
with previous reports (Cantarero et al., 2015; Carmena and Earnshaw, 2003; 
Wang et al., 2010) and could mean that the stable complex only involved a small 
subpopulation of each mitotic kinase. Actually, it has also been showed that a 
small dynamic pool of cytoplasmic AurKB, continuously exchanged with the 
centromeric pool of AurKB, before the onset of anaphase (Murata-Hori and 
Wang, 2002). These AurKB cytoplasmic location resembles more with the VRK1 
observed localization and therefore, it could mean that the stable kinase complex 
was formed between the two protein cytoplasmic subpopulations. In our work, we 
observe no differences in the formation of VRK1 and AurKB protein complex, 
when comparing the chromatin associated fraction with the cytoplasmic fraction, 
in prometaphase arrested cells. Yet, it could be important to repeat this assay, to 
be sure that the low VRK1 levels observed in the chromatin, in the cell lysate of 





separation of cytoplasmic and chromatin fractions. Even facing the impossibility 
to define a specific stage or stages of mitosis, in which AurKB interacted with 
VRK1, we can speculate and abridge these stages. Taking into account the fact 
that nocodazole arrested cells into prometaphase (Pagan et al., 2015) and that 
the VRK1-AurKB interaction decreased and disappeared in parallel with the 
H3T3ph, which is dephosphorylated at the onset of anaphase (Qian et al., 2011), 
we can assume that the mitotic complex formed between the two kinases is most 
likely to occur during prometaphase and/or metaphase (Figure 72). However we 
cannot exclude that at the beginning of chromosome segregation, both kinases 
are still interacting nor that VRK1 and AurKB interaction is formed before 
prometaphase, during G2 or at prophase.  
 
Figure 72. Mitotic stages when AurKB and VRK1 are more likely to interact. The 
interaction occurs after nocodazole arrest in prometaphase and lasts until the loss of 
H3T3ph. The dephosphorylation of histone H3 phosphorylation happens in anaphase.  
 Until the moment, we knew that VRK1 interacted with AurKB, during 
mitosis and that this interaction interfered with the kinase activity of each member 
of the complex. Yet, the most expected event would be when a protein kinase 
interacts with another protein, that the kinase phosphorylates the protein 

















including VRK1 and AurKB. For example, it was reported that VRK1 
phosphorylates p53, histone H3, coilin, histone H2A.X or CREB (Cantarero et al., 
2015; Kang et al., 2007b; Salzano et al., 2015; Vega et al., 2004a) and it is 
phosphorylated by Plk3 (Lopez-Sanchez et al., 2009). In turn, AurKB 
phosphorylates proteins such as histone H3 and MCAK, and protein kinases like 
Haspin, and ATM (Hirota et al., 2005; Wang et al., 2011; Yang et al., 2011; Zhang 
et al., 2007) and it is phosphorylated by Chk1 (Petsalaki et al., 2011). However, 
in our work, even if our results showed that both kinases interacted, VRK1 was 
not a phosphorylation target of AurKB and vice versa. Yet, we cannot discard that 
at least one of the two protein kinases is a substrate for phosphorylation by the 
other. In fact, using a tool to predict kinase-specific phosphorylation sites, the 
GPS software, VRK1 was determined as a high-score potential substrate for 
AurKB phosphorylation. At this point, it is curious to observe that VRK1 could be 
a phosphorylation substrate of AurKB, alike the mitotic protein kinase Haspin 
(Wang et al., 2011). Both VRK1 and Haspin phosphorylate H3T3 and therefore  
the existence of a regulatory feedback mechanism is highly probable, in which 
AurKB regulates the phosphorylation of histone H3, through the phosphorylation 
of Haspin (Qian et al., 2013; Wang et al., 2010; Wang et al., 2011) and maybe by 
phosphorylating VRK1. Less likely to occur is the phosphorylation of AurKB by 
VRK1, since the phosphorylating scores and thresholds, given by the GPS 
analysis, were very low. Accordingly, it could be important to repeat the kinase 
assay, in order to verify the potential phosphorylation of VRK1 by AurKB, using 
immunoprecipitated AurKB from nocodazole arrested cells, instead of 
recombinant GST-AurKB protein. AurKB immunoprecipitated from prometaphase 
arrested cells, could have a distinct activation status and/ or different tertiary 
conformation and therefore, it could be able to phosphorylate VRK1. Moreover, it 
is important to notice that AurKB is the enzymatic core of the CPC, but depends 
on other members of the complex (notably INCENP) for its localization and 
activity (Floyd et al., 2013). So, it could be necessary to use the CPC complex, 
instead of AurKB alone, in order to prove that VRK1 is a phosphorylation target 
of the CPC enzymatic member, AurKB.  
 At this point, it seemed that the formation of a stable complex between 
VRK1 and AurKB, was directly involved in the regulation of their 





regulation that seems regardless of phosphorylation on one another and that 
occurs during mitosis (Figure 73).    
 
Figure 73. Schematically representation of AurKB and VRK1 inhibitory complex. 
The formation of a stable complex between VRK1 and AurKB inhibits their kinase activity, 
probably due to repressed autophosphorylation activity. The examples are potential 
targets of regulation, when the kinases interact. Non-interacting AurKB is able to 
phosphorylate MCAK and histone H3, while non-interacting VRK1 is able to 
phosphorylate p53 and histone H3. The phosphorylation of p53, by VRK1, was not 
demonstrated to occur during mitosis, but it was used as an example of VRK1 substrate. 
However, we cannot exclude that VRK1 phosphorylates p53 in response to DNA damage 
during mitosis. 
 Nonetheless, it’s unclear the phosphorylation targets that may be affected 
by the AurKB and VRK1 mitotic inhibition, due to their interaction. The 
phosphorylation of histone H3, is an obvious candidate as the main final target of 
this regulation, but our results showed that the levels of H3T3ph (VRK1-
dependent) and H3S10ph (AurKB-dependent) were on top, during the mitotic 
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the histone H3 phosphorylation is a dynamic process, involving numerous protein 
kinases and phosphatases, which are responsible for the modulation of histone 
H3 phosphorylation, in a given location at a given time. (Baek, 2011; Jeong et al., 
2013; Sugiyama et al., 2002). Accordingly, interacting VRK1 and AurKB could be 
inhibiting the phosphorylation in one precise chromatin location, while non-
interacting VRK1 and AurKB are phosphorylating the histone at a different point 
of the chromatin. Besides, it is important to confirm the exact time or stage within 
the VRK1 and AurKB complex is formed and whether it occurs before or after 
histone H3 phosphorylation. Therefore, it could be important to release cells from 
thymidine arrest and analyze whether this interaction appears before or after 
mitotic phosphorylation of histone H3.  
 Furthermore, it could be interesting to test other of the most likely targets 
to be regulated by this complex, during the early stages of mitosis, the MCAK. 
This protein form dimers that assemble at the end of microtubules to form an 
ATP-hydrolyzing complex that processively depolymerizes microtubules. 
Moreover, MCAK is phosphorylated by AurKB in three different sites (Thr95, 
Ser110, Ser196), creating a two-site phosphoregulatory mechanisms, which 
targets kinesin to chromosomal arms or centromeres. The binding of MCAK to 
chromatin precedes its centromeric localization and creates a dynamic pool of 
MCAK protein set to load on the centromeres. Thr95ph associates MCAK with 
the chromosome arms, whereas Ser196ph promotes de disassociation of the 
chromosome arms. Se196ph also inhibits the microtubule depolymerizing activity 
of MCAK. In turn, MCAK centromere targeting is accomplished by a balance 
between Ser110ph and dephosphorylation of Thr95. MCAK located in the 
centromeres is relevant to correct mal-attachments of kinetochores to 
microtubules, and so for proper chromosomal alignment and segregation. 
Centromeric MCAK is hyper-phosphorylated on Ser110 and hypo-
phosphorylated on Ser196 at mal-attached kinetochores (Andrews et al., 2004; 
Zhang et al., 2007). Altogether, it could be relevant to analyze the effect of VRK1 
knockdown on the regulation of MCAK activity and localization, by AurKB 
phosphorylation. For example, uncontrolled phosphorylation of MCAK on T95 
could affect its centromeric localization and consequently mal-attachment 
correction. Moreover, continuous phosphorylation of S196 could inhibit MCAK 





mal-attachment could lead to improper chromosomal alignment and segregation 
and culminate in cell cycle arrest. Indeed, unpublished microscopic video data 
from our lab, revealed that VRK1 knockdown induces incomplete segregation, 
associated with the formation of chromosomal bridges during segregation. 
Besides, it could be fascinating to study whether VRK1 could also phosphorylate 
and regulate MCAK activity and localization or if VRK1 could participate in the 
mitotic spindle formation, through an independent pathway. In fact, it is known 
that RCC1 generates a highly local concentration of Ran-GTP around the 
chromatin which in turn induces the local nucleation of microtubules and mitotic 
spindle formation. Moreover, inactive RanGDP interacts with VRK1 and inhibits 
its kinase activity, whereas VRK1 activity is recovered if it is free, or bound to Ran 
in its active conformation (RanGTP), or to Ran activated by RCC1 (Carazo-Salas 
et al., 1999; Sanz-Garcia et al., 2008). Accordingly, VRK1 could be regulating the 
mitotic spindle formation in co-operation with a Ran-dependent pathway and with 
an AurKB-dependent pathway. 
 Finally, it could be important to analyze the effect of AurKB and VRK1 
double depletion, especially on cell proliferation. Either by using specific siRNAs 
targeting VRK1 and AurKB, or by using specific kinase inhibitors, even if the 
actual panorama on VRK1 inhibitors is not encouraging (Kim et al., 2015; Kim et 
al., 2014; Vazquez-Cedeira et al., 2011). Knowing that both kinase proteins are 
implicated in cell cycle division and that their kinase activity seems strictly 
regulated by one another, a double depletion could induce a higher effective cell 
arrest and lower cell proliferation, with potential promising results for the 
therapeutics. 
 1.2 Implication of VRK1 on the control of AurKB localization during 
mitosis 
 The centromeric localization and accumulation of CPC, and consequently 
of AurKB, during the early stages of mitosis, has been reported to depend on the 
phosphorylation of histone H3 on Thr3 by Haspin, and on the phosphorylation of 
histone H2A on Thr120 by Bub1. Moreover, it is known that H3T3ph serves as a 
docking site for Survivin and the H2AT120ph is a binding site for Borealin via 
Sgo1. Therefore, loss of H3T3ph leads to CPC-AurKB mislocalization at the 




et al., 2008; Wang et al., 2010; Wang et al., 2011; Watanabe, 2010). Altogether 
and since H3T3 is a direct phosphorylation target of VRK1 (Kang et al., 2007b; 
Salzano et al., 2015), it is likely that AurKB centromeric localization, may depend 
also on VRK1 kinase activity, as much as it depends on Haspin kinase activity. 
Indeed, our results show that VRK1 depletion led to a re-location of AurKB from 
centromeres and chromosomal arms to a more diffuse state on the chromatin, in 
prometaphase arrested cells. This result is sustained by the decreased number 
of cells with yellow dots, consequence of diminished ACA and AurKB co-
localization, and by the reduced overlapping pixels calculated by Pearson’s 
correlation coefficient. Furthermore, our results showed that VRK1 depletion led 
to a decrease in the interaction between the mitotic kinase AurKB and histone 
H3, potentially due to the loss of H3T3ph. Altogether, these results fundamentally 
demonstrate that VRK1 downregulation induced a loss of H3T3ph, which affected 
the direct binding of Survivin to the phosphorylated histone. Since AurKB is 
associated with histone H3 phosphorylated via Survivin, the loss of interaction 
with the histone protein led to an alteration on its localization, since the kinase is 
unable to accumulate on the centromeres (Figure 74).  
 Nevertheless, it is always important to notice that interaction between 
histone H3 and AurKB, during early stages of mitosis, depends constantly on 
Survivin, since this protein binds directly to the phosphorylated histone H3 (Wang 
et al., 2010). Therefore, it could be also important to analyze the interaction of 
histone H3 and Survivin, when VRK1 is depleted. We should observe an equal 
decrease on the interaction between histone H3 and Survivin, similarly to what 
was observed between AurKB and histone H3. Besides, it could be also important 
to confirm the direct association of Survivin and AurKB with H3T3ph, apart from 
their association with histone H3 (Figure 73).  
 Moreover, the centromeric localization of AurKB, depends also on the 
binding of Borealin via Shugoshin-1 to phosphorylated H2AT120 (Kawashima et 
al., 2010; Watanabe, 2010). This phosphorylation was associated with Bub1 in 
humans, but in Drosophila the phosphorylation of H2AT119, which corresponds 
to human H2AT120, was attributed to NHK-1, a Drosophila orthologous gene to 
human VRK1 (Aihara et al., 2004; Brittle et al., 2007). Therefore, it could be 
important to study whether human VRK1 phosphorylates H2AT120 and if so, 





CPC and consequently of AurKB. Human VRK1 could be regulating AurKB 
localization and accumulation on centromeric chromatin through both H3T3ph 
and H2AT120ph. Likewise, it could be stimulating to assess the potential 
relationship between both the human mitotic Ser/ Thr kinases VRK1 and Haspin. 
These kinases may act synergistically or synchronously on the regulation of 
mitotic H3T3ph, and consequently one could be regulating the other or both could 
be regulated upstream by some unknown mechanism.     
 
Figure 74. Role of VRK1 on AurKB localization and accumulation on centromeres. 
VRK1 phosphorylates the histone H3 on the residue Thr3 (H3T3ph), which is critical for 
the binding to the centromeric chromatin of CPC and therefore of AurKB, via Survivin. 
The potential implication of VRK1 on the phosphorylation of histone H2A on the Thr120 
and on the regulation of AurKB localization and accumulation through this 
phosphorylation residue remains unexplored. This figure has been updated from Figure 
12.   
 Additionally, the potential regulation of AurKB ubiquitination, by VRK1 was 
also explored. It is known that VRK1 protects Coilin of ubiquitination and 
degradation, in the proteasome (Cantarero et al., 2015) and has been reported 
that AurKB ubiquitination regulates the kinase degradation and the CPC/ AurKB 
















2013; Maerki et al., 2009; Sumara et al., 2007; Teng et al., 2012). So, AurKB 
ubiquitination, and therefore its degradation or localization, could be regulated in 
some way by VRK1. Our results showed that ubiquitination of AurKB seemed 
diminished when VRK1 was depleted, but an overall decrease in the 
ubiquitination on the cell lysate was also observed. Such remark may indicate 
that VRK1 plays an important role on global protein ubiquitination instead of a 
specific and limited part on the ubiquitination of AurKB. Nevertheless, if in fact 
VRK1 is required for the ubiquitination of AurKB, it could indicate that VRK1 is 
essential for the degradation of AurKB or that VRK1 is important for the re-
location of AurKB. Since our results showed that the overexpression of VRK1 
stabilizes overexpressed AurKB, we are more inclined to rule out the potential 
role of VRK1 on the AurKB degradation, through the UPP. However, it is 
necessary to confirm the implication of VRK1 on AurKB ubiquitination and re-
localization. 
Summarizing this section, our work showed a well-organized biological 
link between both AurKB and VRK1. VRK1 regulates the localization of AurKB on 
the centromeres, at least by phosphorylating the H3T3, which is a relevant 
binding site for CPC via Survivin. Then, VRK1 regulates the activity of AurKB 
through the physical interaction with the kinase, during the early stages of mitosis. 
The two kinases form a stable complex that inhibits not only the kinase activity of 
AurKB, but also VRK1. This regulatory mechanism affects the phosphorylation of 







Part 2. Regulation of VRK1 by Sox2 during cell 
proliferation and differentiation 
2.1 Implication of VRK1 and Sox2 on the regulation of cell 
proliferation 
The reprogramming factor Sox2 regulates the self-renewal of stem cells 
as well as cellular differentiation, which culminates into a specific tissue after 
several rounds of cell division. Recently, Sox2 was also associated with cancer 
development, including in the regulation of cell proliferation, wherein the role of 
the transcriptional factor is lightly explored (Basu-Roy et al., 2012; Tompkins et 
al., 2011). On the other hand, the role of VRK1 on cell proliferation is better 
documented. VRK1 participates in G0 exit and G1 entry, chromatin compaction 
in G2/M or in the regulation of nuclear envelope assembly and disassembly, in 
addition to mitotic Golgi complex fragmentation. VRK1 knockdown causes cell 
cycle arrest and decreased cell proliferation (Kang et al., 2007b; Lopez-Sanchez 
et al., 2009; Nichols et al., 2006b; Vega et al., 2004a). Thus, all the results pointed 
for a potential connection between VRK1 and Sox2 on the regulation of cell 
proliferation. Accordingly, our results showed that VRK1 and Sox2 were 
expressed in a cellular subpopulation of the highly proliferative epithelial basal 
layer, in normal tonsil stratified epithelium, while it is lost in cells terminally 
differentiated. VRK1 pattern conform the previous results obtained from our 
group, where it was also observed that the kinase co-localize with Ki67 and p63 
in dividing cells, but not in differentiated cells. This suggests a role for VRK1 in 
cell proliferation and in cell differentiation, when the levels of the kinase need to 
be lower (Valbuena et al., 2008b). In turn, Sox2 was also demonstrated to have 
a similar expression in the pituitary gland and esophagus epithelium (DeWard et 
al., 2014; Fauquier et al., 2008), in which Sox2 has a role within the amplification 
compartment, more precisely on the regulation of self-renewal. Also interesting 
was the fact that Sox2 was expressed in the lymphoid follicles of tumoral tissue, 
whereas it was not detected in normal tissue. Therefore, the detection of 




for cancer development and/ or maintenance. Indeed, self-renewal genes, 
including Sox2 were reported to be significantly expressed in several tumor 
samples and in cancer cell lines, showing a significant relationship with tumor 
grade (Amini et al., 2014). Likewise, Sox2 was also demonstrated to be 
overexpressed in breast tumor cells, displaying even higher levels in a 
subpopulation of tamoxifen resistant cells (Piva et al., 2014). This results indicate 
that Sox2 might be a potential tumor marker in the diagnosis and/or prognosis of 
cancer. 
Moreover, our results showed that VRK1 and Sox2 co-localized and 
formed a stable complex in the nuclei of various cancer cell lines, such as 
HEK293T, breast cancer cell lines MCF7 and MDA-MB-231 or NT2. This is 
consistent with all known interactions of VRK1, as chromatin kinase, with 
transcription factors such as p53, ATF2, c-Jun or CREB, as well as the p300 
acetyltransferase transcriptional coactivator (Guermah et al., 2006; Kang et al., 
2008a; Lopez-Sanchez et al., 2014a; Sevilla et al., 2004a; Sevilla et al., 2004b). 
Also, VRK1 was described as part of Oct4 interactome in addition to the one of 
Nanog, which could indicate a straight relationship between the kinase with the 
regulatory network for self-renewal and pluripotency (Ding et al., 2012). In fact, 
could be interesting to study, during embryonic development, the relationship 
between VRK1 and self-renewal genes and the implication of this connection in 
early cell faith decision. Undeniably, VRK1 had been confirmed to be 
overexpressed at the time of massive cellular expansion during murine 
hematopoietic embryo development, as well as in murine developing retina, 
which validates a potential role of importance for the kinase during 
embryogenesis (Dorrell et al., 2004; Vega et al., 2003). Furthermore, our results 
showed that VRK1 was also able to phosphorylate the transcriptional factor Sox2 
in in vitro kinase assays. The interaction with and the phosphorylation of many 
others transcriptional factors, by VRK1, was previous described (Guermah et al., 
2006; Kang et al., 2008a; Lopez-Sanchez et al., 2014a; Sevilla et al., 2004a; 
Sevilla et al., 2004b). Nevertheless, it is important further studies to dissect which 
Sox2 residues are phosphorylation targets of VRK1 and to explain the relevance 
of this phosphorylation(s). The analysis of Sox2 sequence with GPS software 
tool, which predicts kinase-specific phosphorylation sites indicated that VRK1 





Seri and Thr residues: Thr85, Thr118, Thr211, Ser212, Thr256, Ser257 and 
Ser258. Except Thr85, which is located in the HMG domain, all the other residues 
are part of the transactivation domain, Therefore, it seem probable that Sox2 
phosphorylation, by VRK1, is essential for the modulation of the transcriptional 
factor activity. Actually, Sox2 has been demonstrated to be phosphorylated on 
the Thr118, by AKT, in ESCs. This phosphorylation stabilizes Sox2, enhancing 
its transcriptional activity and its cooperation in the reprogramming of mouse 
embryonic fibroblasts by making the induction of iPSCs more efficient. (Jeong et 
al., 2010).  
The co-localization of VRK1 and Sox2 in the proliferation compartment, as 
well as their interaction, pointed that both are likely to contribute to the control of 
cell proliferation. Indeed, our results showed that depletion of either Sox2 or 
VRK1 caused a similar reduction in the rate of cell duplication, alongside with the 
loss of phospho-Rb, cyclins D1 and A, PCNA, all associated to active 
proliferation. Depletion of Sox2 or VRK1 also resulted in accumulation of p27, an 
inhibitor of cell cycle progression. These results come in line with previous reports 
in human WS1 fibroblasts, when VRK1 was depleted, and in MCF7, when Sox2 
was downregulated (Chen et al., 2008a; Valbuena et al., 2008b).  
When cells initiate their first self-renewal asymmetric division it is 
necessary the cooperation of Sox2 with other proliferation associated proteins, 
among which VRK1 stands out as a potential candidate. At this point the 
transcriptional factor Sox2 associates with the chromatin kinase VRK1 that is 
connected to several aspect of cell proliferation (Valbuena et al., 2011c) as well 
to chromatin remodeling (Salzano et al., 2015). Our results showed that Sox2 
increases VRK1 gene expression, by targeting Sox2 response elements in VRK1 
proximal promoter that has several Sox2 target sequences approximately one 
kilobase upstream of the transcription initiation site, a position consistent with that 
identified in other Sox2 targets (Fang et al., 2011b; Lodato et al., 2013). Thus, 
the regulation of VRK1 gene by Sox2 is fully consistent with a role for VRK1 as 
an initiator of cell proliferation (Valbuena et al., 2008b). Moreover, it is important 
to notice that the activation of VRK1 gene promoter, by Sox2, even though 
relatively low, is enough to increase the levels of one of the most abundant 




taking into account that Sox2 could be considered a modest activator of VRK1 
gene transcription, by itself, it could important to further explore potential partners 
to Sox2 for the co-activation of VRK1 gene promoter. Our results demonstrated 
that Oct4, one of the most common Sox2 associated partners, was not able to 
increase VRK1 gene promoter, by itself or alongside with Sox2. A results 
consistent to the fact that VRK1 proximal promoter lack Oct4 target sequences 
(Zhou and Liu, 2008). However, another potential candidate to explore could be 
PAX6, a transcriptional regulator in the early development of the ocular system, 
central nervous system, and gastrointestinal system (Chien et al., 2009). PAX6 
was also described to form with Sox2 a co-DNA-binding partner complex that 
regulates the initiation of lens development and eye morphogenesis (Kamachi et 
al., 2001; Kondoh et al., 2004; Smith et al., 2009). On VRK1 gene promoter, PAX-
6 has one response element immediately upstream of one Sox2 target sequence, 
as analyzed through the Transfac database (Figure 75). Yet, the possible 
association between Sox2 and PAX6 on the regulation of VRK1 gene promoter, 
might be better tested during the early stages of embryonic development, where 
VRK1 plays also a role (Dorrell et al., 2004; Vega et al., 2003).   
 
Figure 75.  Sox2 and PAX6 target sequences on the proximal promoter (-1028+52) 
of the human VRK1 gene. Sox2 and PAX6 response elements are indicated in red and 
green, respectively.  
However, neither Sox2 nor VRK1 are direct regulators of the cell cycle 
initiation and progression. This indicates that they have to regulate key genes or 
proteins implicated in cell cycle, among which CCND1 is a major candidate 
(Malumbres and Barbacid, 2009). Thus, Sox2 and VRK1 as proliferation 
regulators, have to co-operate in the control of cell cycle specific genes, as 
CCND1, which is regulated by both Sox2 (Chen et al., 2008a) and VRK1 (Kang 
et al., 2008b) by themselves. Moreover, Sox2 depending on its levels and 
therefore on its affinity for its target sequence can also function as an inhibitor of 





and Sox2 individually activated the CCND1 gene promoter, and that this effect 
was potentiated when both proteins were combined. Therefore, it is clear that 
both proteins are necessary to and co-operate on the regulation of cell cycle 
progression and proliferation, at least through the modulation of CCND1 gene 
promoter. Likewise, CCND1 gene expression is in part controlled by the CREB 
transcription factor (Kang et al., 2008b). In this context, it is important to notice 
that CREB gene expression is regulated by Sox2 (Iida et al., 2012) and CREB 
protein is a phosphorylation target of VRK1 (Kang et al., 2008b). Consequently, 
it is likely that depending on CREBSer133 phosphorylation levels, there are 
different threshold of responses. In dividing cells low levels of phospho-CREB are 
required for cell cycle progression and in cells that are differentiated, and in which 
a different set of genes is required to fulfill their specific function, a higher level of 
phosphorylation may be necessary. According to our results, it is noteworthy that 
the highest phosphorylation level of CREB in Ser133 was detected in RA-
differentiated NT2 cells, at a time when Sox2 and VRK1 levels had already 
declined. Accordingly, it is possible that in differentiated cells, CREBSer133 
phosphorylation is mediated by different kinases, not VRK1, among which lie the 
calcium/calmodulin-dependent protein kinase types II and IV (Matthews et al., 
1994). This might indicate that CREB phosphorylation might have different roles 
depending on whether it is participating in cell cycle progression or in cellular 
differentiation. 
Furthermore, the activity of VRK1 is regulated by an auto-regulatory loop 
with some of its targets, as has been described in the context of p53 (Valbuena 
et al., 2007b; Valbuena et al., 2006a) and now in the context of Sox2. In fact, our 
results displayed that the accumulation of VRK1 protein, negatively down-
regulated the Sox2 protein and its mRNA levels. A result that is complemented 
by VRK1 depletion assays, in which Sox2 levels were upregulated. This could 
indicate that even if cell fate is already determined and ongoing, VRK1 is still 
necessary to maintain proliferation, whereas Sox2 levels are almost undetectable 
and probably dispensable to cell proliferation. In line, with the role of VRK1 on 
the phosphorylation of Sox2, it could be interesting to analyze whether the 
changes observed on Sox2 levels, when VRK1 varies, are related to its 




by which VRK1 affects Sox2. VRK1 is not a transcriptional factor and so, it must 
be an active part of a larger transcriptional complex that regulates Sox2. 
The cells already differentiated do not divide and this implies that 
proliferative proteins must to be downregulated. In fact, our results showed a 
significant loss on proliferative associated proteins such as the reprogramming 
factors Sox2, Oct4 and Nanog, both Cyclins B1 and D1 and VRK1, during NT2 
cell differentiation with RA (Figure 76). The lower and slower rate of VRK1 
downregulation is likely to be a consequence of the high stability of this protein 
(Valbuena et al., 2008b). As originally stipulated, the RA-differentiation state of 
the cells was confirmed by the morphological reorganization of α-tubulin and by 
detecting the corresponding increase in macroH2A2 isoform, N-cadherin, βIII-
tubulin, PAX6 and CREB phosphorylated in Ser133, and the decrease in 
Vimentin (Buschbeck et al., 2009; Creppe et al., 2012a; Fang et al., 2003; Kakhki 
et al., 2013; Megiorni et al., 2005; Pleasure and Lee, 1993; Pleasure et al., 1992; 
Podrygajlo et al., 2009; Spinella et al., 1999).  
 
Figure 76 – VRK1 is downregulated during cell differentiation. NT2 cells were 
differentiated in neurons-like with upon retinoic acid (RA). In turn, macroH2A2 isoform 
increases during cell differentiation. This figure has been updated from Figure 15. 
Contextualizing, it is likely that when VRK1 accumulates, it is able to 
activate CCND1 by itself and also downregulate SOX2 by an unknown 
mechanism. This latter outcome is consistent with the upregulation of 
pluripotency transcription factors, Sox2, Oct4 and c-myc, observed upon luteolin 
treatment, an inhibitor of VRK1 (Kim et al., 2014; Liu et al., 2015). Moreover, high 
expression of VRK1 can stabilize p53 and consequently contribute to the 
necessary cell cycle arrest to permit differentiation. Besides, inhibition of 






















which can be induced by the incorporation of histone variants. In this context the 
role of macroH2A isoforms is relevant as our results demonstrated. MacroH2A 
variants 1.2 and 2 can inhibit the VRK1 promoter by themselves, and also prevent 
the activating effect of Sox2 on the VRK1 and CCND1 promoters, which facilitates 
cell differentiation. 
All told, our work has identified a functional biological connection between 
the reprogramming transcriptional factor Sox2 and the human VRK1 protein 
kinase. At first Sox2 directly activates VRK1 gene expression and both proteins 
cooperate in activation of the CCND1 expression, which consequently promotes 
cell proliferation. Moreover, VRK1 contributes, by an unknown mechanism, to the 
downregulation of SOX2, reducing cell proliferation and facilitating cell 
differentiation. Meanwhile, macroH2A2 variant contributes to cell differentiation 
by completely shutting down VRK1 in terminally differentiated cells. Therefore, 
both VRK1 and Sox2 are downregulated in the process of final differentiation. 
Our data shows a coordinated role for these proteins in the transition from cell 
division to cell differentiation (Figure 77). 
 
Figure 77 – Diagram of Sox2 and VRK1 roles in the regulation of cell proliferation 


















The role of human VRK1 within the tumor phenotype appears to be 
complex, since it may have roles of both oncogene and tumor suppressor 
gene. VRK1 is a strong facilitator of cell cycle progression and proliferation 
(Kang et al., 2007a; Molitor and Traktman, 2013; Valbuena et al., 2008b), through 
various mechanisms, to which we add two new. One by regulating the 
localization and activity of the mitotic AurKB and the other through a 
regulatory feedback loop with the reprogramming transcriptional factor Sox2, 
which facilitates also cell differentiation. Besides, many tumors feature very high 
levels of VRK1 protein which is consistent with an oncogenic role of wild-type 
VRK1. In turn, VRK1 is also a positive regulator of p53, as well as an important 
player of the genomic stability network, which is important to maintain cell 
homeostasis. In this context the role of VRK1 is similar to that of other tumor 
suppressor genes or tumor predisposition genes (Lopez-Borges and Lazo, 2000; 
Lopez-Sanchez et al., 2014a; Salzano et al., 2015; Salzano et al., 2014; Sanz-
Garcia et al., 2012; Valbuena et al., 2011a; Vega et al., 2004b). In any case, 
VRK1 is not mutated in human cancer, and the very rare mutations described are 
associated with neurodegenerative diseases (Gonzaga-Jauregui et al., 2013b; 
Nguyen et al., 2015; Renbaum et al., 2009a; Vinograd-Byk et al., 2015). Thus, 
the complexity of VRK1 functions might be a reflection of its late appearance in 
evolution as organisms become more complex, and where VRK1 appears to play 





































































This work led to the following conclusions: 
1a)  VRK1 regulates AurKB localization and activity. VRK1 positions AurKB at the 
centromeres, during mitosis, at least through the phosphorylation of histone H3 
on its Thr3 residue. VRK1 depletion causes the displacement of AurKB from the 
centromeres to a more diffuse state on the chromatin.  
1b) VRK1 and AurKB form a stable complex, in early mitosis, which inhibits the 
catalytic activity of each kinase. This effect seems independent of their kinase 
activity and seems to aim kinase specific phosphorylation targets such as the 
histone H3 and the transcriptional factor p53.   
2a) VRK1 is regulated by, and cooperates coordinately with the transcriptional 
factor Sox2 on the regulation of cell cycle progression, activating the CCND1 
gene expression. Depletion of either VRK1 or Sox2, reduces the rate of cell 
duplication, alongside with decreased levels of proliferation-associated proteins, 
including cyclin D1. 
2b) VRK1 contributes to SOX2 downregulation, creating a regulatory feedback 
loop, which promotes cell differentiation over proliferation. As the cells are 
terminally differentiating, the macroH2A2 variant completely shuts down VRK1. 
Proliferative proteins such as Sox2 and VRK1, as well as cyclin D1, are 
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enorme para ti. Tuas palavras seguem-me fazendo feliz e sempre que estou em 
casa sinto-me como uma criança amada. Toda a minha vida estiveste ao meu 
lado, ouvindo meus problemas e alegrias e aconselhando-me o melhor que 
podias e sabias. Nunca esquecei teus sacrifícios e teu amor. Obrigado! Mica, faz 
29 anos que tenho que aturar-te. És o melhor irmão que algum dia poderia ter 
tido. Somos como água e vinho, mas nas horas da verdade estás presente e se 
necessário sacrificando-te por mim e pelos demais. Nunca percas tua 
capacidade de dar vida até aos mortos. Luta sempre pelos teus objetivos, porque 
foi esse teu espírito lutador que me contagiou e fez de mim melhor. Que o diga 
o meu ombro, que ainda sente dor de tanta pancada que ali levava. Bons velhos 
tempos, em que andar a ‘’porrada’’ era um modo de demonstrar afeto e de 
aprendizagem entre irmão. Obrigado também a minha avó. Gostaria que 
pudesses assistir a tudo o que alcance. Ficarias orgulhosa de mim, depois de 
tudo que me ensinaste e sacrificaste. Onde quer que estejas avô, amo-te e 
obrigado!  
E apenas falta-me agradecer a duas pessoas mais. E que pessoas. As duas que 
dão mais cor e muita alegria há minha vida. Obrigado Ana e Vasco! Amo-vos! 
Ana, no dia que te conheci, senti que irias revolucionar o meu pequeno mundo, 
de uma forma ou da outra. E não é que acertei. Nunca vivi momentos de alegria, 
de afeto e emotivos como os que vivi contigo ao meu lado. Tu dás-me 
tranquilidade, concentração, amor, inteligência, bondade, vida, entre muitas 
outras coisas e por isso nunca te poderei pagar devidamente. Obrigado por me 
aturares, o que não é fácil para o deixar claro, por seres a minha melhor amiga, 
por me ajudares em todos os meus projetos, por dares tudo de ti por aqueles 
que tu amas e por todos os teus pormenores do dia-a-dia, que de alguma forma 
dão sempre ritmo há minha vida. E que ritmo…diga-se de passagem. Espero 




bussola. E quanto a ti Vasquito, obrigado por estes 19 meses alucinantes e a 
alta velocidade. Espero que um dia estejas tu a escrever os agradecimentos na 
tua tese de doutoramento e que tudo o que eu te possa ensinar esteja na tua 
mente. Mas por favor, escreve qualquer coisa melhor do que isto que para aqui 
escrevi. Além disso, quando uma dia leres esta tese, já que será leitura 
obrigatória para ti durante a primária, espero que sintas orgulho no teu pai. Tudo 
isto é para ti!  
 
Obrigado 
 
 
 
 
